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GENERAL INTRODUCTION 
Today, nanoparticle-mediated drug delivery and drug targeting is intensively 
researched. Within the growing field of nanomedicine, drug delivery accounts for 
more 50 % of all publications and patent filings worldwide [Wagner et al., 2006], 
whereas nanoparticulate delivery is still mostly part of basic research. The need for 
nanoparticles as biodegradable and non toxic drug delivery system was firstly 
formulated in 1978 by Marty [Marty et al., 1978]. Since then, numerous synthetic 
and natural polymers were adopted for the production of biodegradable 
nanoparticles. Poly-ε-caprolactone (PCL), poly(lactic acid) (PLA), poly(glycolic 
acid) (PGA), and their co-polymers poly(lactide-co-glycolide) (PLGA) are the most 
widely used starting materials [Hans et al., 2006]. Applied natural polymers are 
proteins (albumin and gelatin) [Kaul et al., 2005] and polysaccharides (dextran, 
alginate, and chitosan) [Chorny et al., 2004]. Scholes summarized the requirements 
for an ideal targeting system as follows: i) biocompatibility, biodegradability, and 
low antigenicity, ii) protection of the drug, iii) maintenance of the integrity till the 
target is reached, iv) avoidance of side effects, v) membrane passage, vi) target 
recognition and association, vii) controlled drug release, and viii) elimination upon 
drug release [Scholes et al., 1997]. 
Among natural polymers gelatin offers some advantageous material properties. 
Due to its proteinaceous nature it is readily accessible for chemical modifications 
either of the bulk material or the finished nanoparticles via the functionalities of the 
amino acid residues [Djagny et al., 2001]. And, beside these technological aspects 
gelatin is known for its good biodegradability and biocompatibility [Yamamoto et 
al., 2001; Stevens et al., 2002] accompanied with low immunogenicity [Schwick et 
al., 1969; Kuijpers et al., 2000]. These beneficial characteristics are not only 
expressed in long clinical usage of gelatin as plasma expander [Tabata et al., 1998] 
and as sealant for vascular prosthesis [Kuijpers et al., 2000] but also led to the 
acceptance of gelatin as “Generally Recognized as Safe” (GRAS) substance in the 
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area of food additives by the U.S. Food and Drug Administration (FDA)*. The 
application of gelatin in controlled release devices for bioactive molecules like 
proteins or plasmid DNA was recently reviewed [Young et al., 2005] and the 
emerging interest in gelatin nanoparticles as drug delivery system can be drawn from 
the increasing number of scientific contributions published in last five years 
(Figure 1). 
Figure 1 Number of publications containing gelatin nanoparticles for drug delivery and drug 
targeting (source: Chemical Abstract Service; search criteria: „gelatin“ AND „nanoparticles“ AND 
„drug delivery“ OR „drug targeting“) 
 
 
 
 
 
 
 
 
 
 
The present work is based on the achievements in the preparation of stable 
gelatin nanoparticles exhibiting a homogenous size distribution described by Coester 
[Coester et al., 2000]. It was the objective of this thesis to technologically advance 
this colloidal drug carrier system in order to provide the basis for further in vitro and 
in vivo applications. 
In the end of the performed research work on gelatin nanoparticles the obtained 
results are here discussed in three discrete chapters covering analytical aspects, 
formulation development, and in vivo application. In CHAPTER I the introduction 
of asymmetrical flow field-flow fractionation (AF4) in the analysis of colloidal drug 
carrier systems is described. The impact of gelatin bulk material on the preparation 
of gelatin nanoparticles, the drug loading of gelatin nanoparticles with single- and 
double-stranded oligonucleotides, and the PEGylation of the nanoparticles were 
intensively studied. CHAPTER II explores the applicability of freeze-drying for the 
stabilization of gelatin nanoparticles. Different common freeze-drying excipients
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were employed and assessed for their protection of empty and oligonucleotide-
loaded nanoparticles during lyophilization and short term stability stress testing. The 
investigation of the role that NF-κB, released from Kupffer cells, plays during 
hepatic ischemia reperfusion (I/R) injury, was subject of the work summarized in 
CHAPTER III. Conducted in cooperation, together with the chair of Pharmaceutical 
Biology of the Ludwig-Maximilians-University Munich the interruption of NF-κB 
activation within Kupffer cells was addressed in an animal model. Thereby a drug 
targeting approach with NF-κB decoy oligonucleotide-loaded gelatin nanoparticles 
was utilized. The selective Kupffer cell uptake of the nanoparticles, the correlation 
between their biodistribution and corresponding plasma protein adsorption patterns, 
and the NF-κB decoy efficacy are reviewed. 
The NF-κB decoy oligonucleotide forms the brace that thematically links the 
work. It is applied during AF4 studies; it is part of the freeze-drying formulation 
development; and it is the center of the ischemia reperfusion injury cooperation 
project. 
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CHAPTER I 
Asymmetrical Flow Field-Flow Fractionation (AF4) in the 
Analytical Description of Gelatin Nanoparticles 
Abstract 
Asymmetrical flow field-flow fractionation (AF4) offers unique separation 
properties for macromolecules, colloids, particles, and even cells from human or 
animal origin. At the same time the characterization of non viral colloidal drug 
delivery systems by means of AF4 is barely described in literature. Here, three 
different analytical tasks investigating gelatin nanoparticles as drug delivery system 
were executed utilizing AF4 coupled with multi-angle light scattering (MALS), UV, 
and refractive index (RI) detection respectively. In a comparative study, several 
batches of gelatin bulk material were characterized for their molecular weight 
distribution. Based on these data the exact requirements on gelatin for the realized 
development of a one-step desolvation process for gelatin nanoparticle synthesis 
could be described. Following the loading of surface-modified gelatin nanoparticles 
with a double-stranded oligonucleotide revealed systematical limits of the analytical 
approach. And finally, the quantification of the PEGylation of gelatin nanoparticles 
could successfully be completed. In sum, the presented results demonstrate the 
versatile applicability of asymmetrical flow field-flow fractionation also in the field 
of colloidal drug delivery systems. 
 
Keywords: field-flow fractionation, multi-angle light scattering, gelatin, 
nanoparticulate drug delivery systems, PEGylation 
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1.1 Introduction 
Field-flow fractionation (FFF) was proposed in 1966 as separation concept 
especially exhibiting advantages in separating macromolecules and colloids 
[Giddings, 1966]. Since then FFF was developed to one of the most versatile families 
of separation techniques known [Giddings, 2000] and its potential in the analysis of 
high molecular weight specimen even up to human and animal cells was 
demonstrated [Reschiglian et al., 2005; Kowalkowski et al., 2006; 
Ratanathanawongs-Williams et al., 2006]. The theory behind and the basic 
mechanisms of AF4 are discussed elsewhere [Wahlund et al., 1987; Litzen et al., 
1991; Colfen et al., 2000; Schimpf et al., 2000] and are thus in the following only 
summarized in brief. During an FFF sample run a liquid carrier is transported 
through a hollow separation channel forming a parabolic flow profile with layers of 
different velocities. Perpendicular to this laminar carrier flow a field of separation is 
applied. With respect to the source of this field (symmetrical, asymmetrical, and 
hollow fiber) flow (F)FFF, thermal (Th)FFF, sedimentation (Sd)FFF, electrical and 
dielectric (E/DI)FFF, as well as magnetic (Mg)FFF are differentiated. During 
asymmetrical flow field-flow fractionation (AF4) the separation field is erected by 
another liquid flow, called cross-flow, which contributes to the distribution of the 
analytes in the different areas of velocity of the laminar channel flow, finally leading 
to their fractionated elution. The cross-flow leaves the channel through an 
ultrafiltration membrane covering the bottom (= accumulation) wall of the channel. 
The analyte’s diffusion coefficient is thereby the critical number the cross-flow has 
to compensate. The Stokes-Einstein equation expresses the relationship between the 
diffusion coefficient D of a spherical particle and its hydrodynamic radius Rh in a 
medium with a given viscosity η: 
 
   (1-1) 
 h
R
kTD πη6=
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where k is the Boltzmann constant and T is the absolute temperature. Together cross-
flow Vc and diffusion coefficient D determine the elution (retention) time tr of the 
analytes as it is shown in the following equation: 
 
   (1-2) 
 
where t0 is the retention time of an unretained solute, V0 is the volume of the 
separation channel, and w is the channel height. This means that larger particles with 
a smaller diffusion coefficient (eq. 1-1) are stronger influenced by the actual cross-
flow. Therefore they are concentrated in areas of the laminar flow closer to the 
accumulation wall exhibiting lower velocities, which finally leads to prolonged 
retention (eq. 1-2). Due to the open architecture of the separation channel species 
ranging from 1 nm up 100 µm are accessible for separation by field-flow 
fractionation [Giddings, 1993]. 
The described strengths in the fractionation of macromolecules, colloids, 
particles, and cells are thereby reflected in the applications of FFF ranging from 
industrial [Schimpf et al., 2000] and environmental [Gimbert et al., 2003] to 
biotechnological [Reschiglian et al., 2005] and (bio)pharmaceutical [Fraunhofer et 
al., 2004a] tasks. However, despite the growing implementation of the different field-
flow fractionation subtechniques over the last two decades [Kowalkowski et al., 
2006] and the general recognition of field-flow fractionation for the characterization 
of nanoparticles [Haskell, 2006] only little is reported about employing FFF for the 
characterization of non viral colloidal drug delivery systems. Investigation of size 
and size distribution via (flow) FFF of gelatin [Fraunhofer et al., 2004b], PLGA 
[Augsten et al., 2005] and solid lipid nanoparticles [Jores et al., 2004] as well as 
virus like particles [Lang et al., 2006] and lipid-DNA complexes [Lee et al., 2001] 
were just recently described. The characterization of liposomes via SdFFF and FFFF 
is in turn already known for more than 20 years [Caldwell et al., 1981; Moon et al., 
1993]. In addition, Andersson described the influence of several surface 
modifications on size distribution and mass of polystyrene nanoparticles utilizing 
SdFFF [Andersson et al., 2005]. 
In this context, it was the objective of the present work to illustrate how 
asymmetrical flow field-flow fractionation can be used as high resolution technique 
0
2
0
6DV
wVt
t cr =
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for the analytical description of nanoparticulate drug delivery systems. In 
continuation of the basic work accomplished by Wolfgang Fraunhofer at this chair 
[Fraunhofer, 2003] three different applications of AF4 in the work with gelatin 
nanoparticles are introduced. Gelatin bulk material used for the nanoparticle 
synthesis was investigated for its molecular weight distribution via the combination 
of AF4 and multi-angle light scattering (MALS) detection, drug loading of surface-
modified gelatin nanoparticles with a double-stranded oligonucleotide was followed 
with AF4 and UV-detection, and in the end PEGylation of gelatin nanoparticles was 
quantified after AF4 separation from refractive index (RI) detection signals. 
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1.2 Materials and Methods 
Reagents 
Reagent Description Supplier 
Acetone p.a. VWR International GmbH (Ismaning, Germany) 
Cholaminechloride 
hydrochloride 
(2-aminoethyl)-trimethyl- 
ammoniumchloride hydrochloride 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
ds NF-κB decoy ODN  5´-AGT TGA GGG GAC TTT CCC AGG C-3´ phophorothioate 
biomers.net GmbH 
(Ulm, Germany) 
EDC 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
Gelatin type A 175 Bloom Sigma-Aldrich GmbH (Taufkirchen, Germany) 
Gelatin PN307779 Portion of peptides with MW < 65 kDa below 40 % 
Gelita AG 
(Eberbach, Germany) 
Gelatin VP433 
Portion of peptides with MW < 65 kDa 
below 40 %; enriched portion of high 
molecular weight fractions > 104 kDa 
Gelita AG 
(Eberbach, Germany) 
Gelatin VP306/VP413-2 Portion of peptides with MW < 65 kDa below 20 % 
Gelita AG 
(Eberbach, Germany) 
Glutaraldehyde 25 % aqueous solution  Sigma-Aldrich GmbH (Taufkirchen, Germany) 
HCl 2 N VWR International GmbH (Ismaning, Germany) 
PEG 5000 (mPEG-NH2) 
Methoxy-poly(ethyleneglycol)-amine 
MW 5,884 Da 
Nektar Therapeutics 
(Huntsville, AL, USA) 
ss ODN 5´-TCG-CTC-GAT-AGC-TCG-ATC-3´ MWG-Biotech AG (Ebersberg, Germany) 
AF4 Running buffers 
Solution Components* Concentration 
Dulbecco’s PBS pH 7.3 
KCl 
KH2PO4 
NaCl 
Na2HPO4 X 7H2O 
2.67 mM 
1.47  mM 
137.93  mM 
8.06  mM 
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Solution Components* Concentration 
PBS pH 6.0 
NaCl 
Na2HPO4 x 2H2O 
NaOH/HCl 
14 mM 
2 mM 
q.s. 
PBS pH 7.0 
NaCl 
Na2HPO4 x 2H2O 
NaH2PO4 x 2H2O 
NaOH/HCl 
150 mM 
30 mM 
20 mM 
q.s. 
PBS pH 7.4 
NaCl 
Na2HPO4 x 2H2O 
NaOH/HCl 
140 mM 
2 mM 
q.s. 
 
*All buffer salts were purchased from Sigma-Aldrich GmbH (Taufkirchen, Germany) 
Preparation and surface modification of gelatin nanoparticles 
Gelatin nanoparticles were prepared by the two-step desolvation method 
[Coester et al., 2000]: 1.25 g gelatin were dissolved in water (5% [w/w]) under 
stirring (500 rpm) and heating up to 50°C. The resulting solution was fractionated in 
a first desolvation step by quickly adding 25 mL of acetone. The supernatant was 
discarded and the remaining sediment –containing the high molecular weight fraction 
of gelatin – was dissolved in another 25 mL of water. After adjusting the pH with 
110 µL hydrochloric acid nanoparticles emerged in a second desolvation step by 
dropwise adding 50 mL of acetone under constant stirring (500 rpm). After 5 min of 
stirring, the in situ formed particles were stabilized by crosslinking with 43.8 µg 
glutaraldehyde. Nanoparticles were 4 times purified by centrifugation for 20 min at 
20.000 g (SIGMA 4K15, SIGMA Laborzentrifugen GmbH, Osterode, Germany) and 
redispersion in highly purified water. Finally, the concentration of the nanoparticle 
dispersions was determined gravimetrically by drying three aliquots of 100 µL each 
to weight constancy. 
Surface modification (cationization) of gelatin nanoparticles was performed with 
the quaternary amine cholamine in a modified procedure based on the method 
previously described by Coester [Coester, 2003]: after preparation and purification, 
the nanoparticles were suspended in highly purified water to a volume of 25 mL 
followed by adjusting the pH to 4.20 and dissolving 50 mg cholamine in the resulting 
suspension. After 5 minutes of stirring, 50 mg EDC were added to the reaction vessel 
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in order to activate the free carboxyl groups on the surface of the unmodified 
nanoparticles for the coupling with cholamine. Beside the activated carboxyl groups 
cholamin reacts with aldehyde groups of mono-functionally bound glutaraldehyde 
derived from crosslinking. After 3 h the reaction was abandoned and the 
nanoparticles were purified as described above. 
PEGylation of gelatin nanoparticles 
For PEGylation 50 µL of an aqueous nanoparticle dispersion (20 mg/mL) were 
incubated for 2 h under constant shaking (800 rpm; 25°C; Thermomixer comfort, 
Eppendorf, Hamburg, Germany) with various amounts of an mPEG-NH2 solution in 
borate buffer pH 8.4 (20 mg/mL). Thereby, mPEG-NH2 reacts with residual 
aldehyde groups on the surface of the gelatin nanoparticles (Figure 1.2.1). After 
incubation the total volume was completed with highly purified water to 1 mL 
resulting in a nanoparticle concentration of 1 mg/mL. An aliquot was transferred to 
AF4 analysis and the remaining particles were washed by 3-fold centrifugation and 
redispersion in PBS pH 7.4. PEGylation of gelatin nanoparticles is described and was 
conducted by Klaus Zwiorek [Zwiorek, 2006]. 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.1 PEGylation reaction scheme of gelatin nanoparticles 
 
PEGylated nanoparticles used in atomic force microscopy (AFM) experiments 
demanded furthermore a cationic surface charge to enable fixation on the anionic 
sample grid and were surface-modified as described above subsequent to 
PEGylation. 
N
H
NH
pH 8.4
mPEG-NH2:     CH3O    (CH2CH2O)n CH2CH2 NH2
mPEG-NH2
mPEG
+        H2O
N
O
H
H
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Characterization of nanoparticles 
Size and zetapotential of the applied gelatin nanoparticle batches were 
determined by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern 
Instruments, Worcestershire, UK). Zetapotential measurements were conducted 
under standardized ionic conditions in 10 mM NaCl at pH 7.0. 
Analysis of the gelatin bulk material 
Samples of different gelatin batches were dissolved under heating (50 °C) in 
highly purified water and diluted to a final concentration of 2.5 mg/mL, which is 
sufficient to avoid gelation upon cooling down to room temperature. In addition, 
gelatin sediment derived from the first desolvation step from the manufacturing 
process of the gelatin nanoparticles was diluted in highly purified water to an 
equivalent final concentration. Samples were transferred to AF4 analysis without 
further preparation. 
AF4 studies were performed using a HRFFF-10.000 AF4 system (Postnova 
Analytics GmbH, Landsberg a. L., Germany). The channel height was set at 350 µm; 
the applied ultrafiltration membrane was a regenerated cellulose membrane with 
5 kDa cut-off (Nadir Filtration, Wiesbaden, Germany). PBS pH 6.0 was chosen as 
running buffer. The channel flow rate accounted for 1 mL/min, the cross-flow was 
adjusted to 0.05 mL/min over 30 min (cp. Figure 1.2.2 for complete cross-flow 
profile), and the measurement period amounted to 40 min. 
 
 
 
 
 
 
 
 
 
Figure 1.2.2 Cross-flow profile applied for the AF4 analysis of aqueous gelatin solutions 
 
On-line detection was done UV-spectrophotometrically at a wavelength of 
220 nm (Spectra System UV 1000, Thermo Separation Products, Germany) coupled 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 5 10 15 20 25 30 35 40
time [min]
cr
os
s-
flo
w
 [m
L/
m
in
]
AF4 in the Analytical Description of Gelatin Nanoparticles 
17 
with multi-angle light scattering (MALS) detection using a miniDAWNTM light 
scattering detector (Wyatt Technology Europe GmbH, Dernbach, Germany). For 
molar mass determination of gelatin the refractive index increment was set to 
0.174 mL/g and the second virial coefficient was set to 0. The whole study was 
repeated three times. 
Quantification of oligonucleotide-loading onto the surface of gelatin nanoparticles 
Single-stranded oligonucleotide loading: 185 µL of an aqueous nanoparticle 
dispersion containing 1.0 mg surface-modified gelatin nanoparticles were incubated 
with 10 µL of an aqueous oligonucleotide (ODN) solution containing 0.1 mg single-
stranded ODN (i.e., 10 % [w/w]) in PBS pH 7.4 adjusted to a final volume of 1.0 mL 
for 2 h at 22 °C and 800 rpm under constant shaking (Thermomixer Comfort, 
Eppendorf AG, Hamburg, Germany). The amount of loaded oligonucleotide was 
calculated from unbound oligonucleotide determined UV-spectrophotometrically at a 
wavelength of 260nm (UV1, Thermo Spectronic, Dreieich, Germany) in the 
supernatant of the reaction media after separating the nanoparticles by centrifugation 
for 50 min at 14000g (neo lab 16/18, Hermle Labortechnik GmbH, Wehingen, 
Germany). In addition blanks of oligonucleotide and gelatin nanoparticles at their 
own were accordingly prepared in PBS pH 7.4. All samples were afterwards directly 
transferred to AF4 analysis. AF4 studies were performed using a HRFFF-10.000 
AF4 system (Postnova Analytics GmbH, Landsberg a. L., Germany). The channel 
height was set at 500 µm; the applied ultrafiltration membrane was a regenerated 
cellulose membrane with 1 kDa cut-off (Nadir Filtration, Wiesbaden, Germany). 
PBS pH 7.4 was chosen as running buffer. The channel flow rate accounted for 
1 mL/min and the cross-flow was initially adjusted to 1.86 mL/min and gradually 
decreased down to 0 mL/min after 13 min (cp. Figure 1.2.3 for complete cross-flow 
profile). The measurement period amounted to 40 min. On-line detection was done 
UV-spectrophotometrically at a wavelength of 260 nm (Spectra System UV 1000, 
Thermo Separation Products, Germany). ODN loading was quantified by comparing 
the AUCs of oligonucleotide and nanoparticles from their respective peaks in the 
resulting fractograms before and after the loading process. The results from UV-
spectroscopy were thereby used as positive control for the AF4 experiments. The 
whole study was repeated three times. 
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Figure 1.2.3 AF4 cross-flow profile applied for the quantification of the loading of gelatin 
nanoparticles with single-stranded oligonucleotide 
 
Experiments were conducted together with Wolfgang Fraunhofer. According 
data are as well described in his thesis and have already been published elsewhere 
[Fraunhofer, 2003; Zillies et al., 2003; Fraunhofer et al., 2004b]. 
Double-stranded oligonucleotide loading: 95 µL of an aqueous nanoparticle 
dispersion containing 1.4 mg surface-modified gelatin nanoparticles were incubated 
with 100 µL of an aqueous oligonucleotide solution containing 0.07 µg double-
stranded ODN (i.e., 5 % [w/w]) in highly purified water adjusted to a final volume of 
1.0 mL for 2 h at 22 °C and 800 rpm under constant shaking (Thermomixer Comfort, 
Eppendorf AG, Hamburg, Germany). The oligonucleotide-loading was 
UV-spectrophotometrically assessed as already described for the single-stranded 
oligonucleotide-loaded gelatin nanoparticles. Again blanks from oligonucleotide and 
gelatin nanoparticles at their own were accordingly prepared in highly purified water 
and all samples were then directly transferred to AF4 analysis. AF4 studies were 
performed using a Wyatt Eclipse2 AF4 system (Wyatt Technology Europe GmbH, 
Dernbach, Germany). The channel height was set at 350 µm; the applied 
ultrafiltration membranes were a regenerated cellulose membrane and a 
polyethersulfone (PES) membrane each with 5 kDa cut-off. Isocratic HPLC pump, 
autosampler, degasser, and UV-detector are parts of the Agilent 1100 series (Agilent 
Technologies, Palo Alto, CA, United States). Dulbecco’s PBS pH 7.3 was chosen as 
running buffer. The channel flow rate accounted for 1 mL/min, the cross-flow was 
adjusted to 2.5 mL/min over 10 min (cp. Figure 1.2.4 for complete cross-flow 
profile), and the measurement period amounted to 51 min. On-line detection was 
done UV-spectrophotometrically at a wavelength of 260 nm.  
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Figure 1.2.4 AF4 cross-flow profile applied for the quantification of the loading of gelatin 
nanoparticles with double-stranded oligonucleotide 
Quantification of gelatin nanoparticle PEGylation 
The study was performed using a Wyatt Eclipse2 AF4 system (Wyatt 
Technology Europe GmbH, Dernbach, Germany). The channel height was set at 
350 µm; the applied ultrafiltration membrane was a regenerated cellulose membrane 
with 5 kDa cut-off. Isocratic HPLC pump, autosampler, degasser, refractive index 
(RI) -, and UV-detector are parts of the Agilent 1100 series (Agilent Technologies, 
Palo Alto, CA, United States). PBS pH 7.0 was chosen as running buffer. The 
channel flow rate accounted for 1 mL/min, the cross-flow was adjusted to 3 mL/min 
over 10 min (cp. Figure 1.2.5 for complete cross-flow profile), and the measurement 
period amounted to 29 min.  
 
 
 
 
 
 
 
 
 
Figure 1.2.5 AF4 cross-flow profile applied for the quantification of the PEGylation of gelatin 
nanoparticles  
 
On-line detection was done UV-spectrophotometrically (gelatin nanoparticles) 
and via refractive index (PEG 5000). The amount of detected PEG was calculated 
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from the AUC of its respective peaks in the resulting fractograms via a calibration 
curve. The PEGylation was quantified by comparing the AUCs of PEG before and 
after the PEGylation process. The whole study was repeated three times. 
Atomic force microscopy analysis of plain and PEGylated gelatin nanoparticles 
Size and surface morphology of cationized plain and PEGylated gelatin 
nanoparticles were analyzed by atomic force microscopy (AFM) in cooperation with 
Christian Löbbe (JPK Instruments, Berlin, Germany). Thereby, a JPK 
NanoWizard™ Life science version (JPK Instruments) was used in intermittent 
contact (ic) mode with a super sharp silicon (SSS) cantilever (NanoWorld, 
Schaffhausen, Switzerland). These special cantilevers were chemically etched and 
end with a slim 200 nm long and 2 nm radius tip. The cantilevers had a spring 
constant of about 42 N/m. Measurements in water were utilized with softer 
cantilevers having spring constants of about 0.2 N/m (10-15 nm-radius tip). In both 
cases the cantilever was excited close to its resonance frequency (air: ~300 kHz; 
water: ~12 kHz). 
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1.3 Analysis of Gelatin Bulk Material Applied for the 
Manufacturing of Gelatin Nanoparticle Drug Delivery Systems 
Using Asymmetrical Flow Field-Flow Fractionation (AF4) and 
Multi-Angle Light Scattering (MALS) Detection 
1.3.1 Introduction 
Due to its unique gel-forming ability, gelatin has long been used in food and 
pharmaceutical industry [Djagny et al., 2001]. Thus, intensive research was rendered 
to elucidate the chemical composition and structure of gelatin to understand its 
functional properties. Basically, gelatin is derived from collagen, the chief structural 
protein of the body [Friess, 1998], extracted from animal sources. In the meantime 
there are 27 types of collagen described [Brinckmann, 2005], but only collagen type I 
originating from skin and bone, type II originating from hyaline vessels, and type III 
as well originating from skin are used as source for gelatin production [Babel, 1996]. 
Related to the manufacturing process two types of gelatin are differentiated. Gelatin 
type A (acid) is obtained by an acidic hydrolysis of pig skin collagen, whereas the 
amide groups of the amino acid residues asparagine and glutamine remain unaffected 
causing an isoelectric point (IEP) of the finished product comparable to that of 
collagen between pH 7.0 to 8.5. During the alkaline processing of ossein from bovine 
origin and cattle hide to gelatin type B these amide groups are hydrolyzed and the 
resulting acidic amino acids aspartate and glutamate squeeze the IEP down to values 
between pH 4.5 and 5.0 [Bauer et al., 2006]. The exact chemical composition of 
gelatin was already intensively investigated and accurately described in the 1950ies 
[Djagny et al., 2001] and revealed a composition of 33 % glycin, 22 % proline and 
4-hydroxyproline, and 45 % further 17 amino acids [Babel, 1996]. As seen for 
collagen the repetitive triplet Gly-X-Y can be assumed to form the primary structure 
of gelatin with proline almost exclusively occupying position X and 
4-hydroxyproline predominantly occupying position Y [Friess, 1998]. The secondary 
structure of gelatin consists of α-chains. Based on those, several fractions of different 
molecular weight exhibiting fragments and multimers are known to build up the bulk 
material of gelatin [Farrugia et al., 1999]. Thus, gelatin shows in contrast to soluble 
collagen a broad molar mass distribution in solution [Meyer et al., 2003]. Describing 
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this molecular heterogeneity, size exclusion chromatography (SE-HPLC) is the 
analytical method routinely used for process control and development in gelatin 
industry [Meyer et al., 2003]. Molecular weights ranging from 104 Da up to more 
than 106 Da are reported by several authors [Farrugia et al., 1999; Meyer et al., 2003; 
Fraunhofer et al., 2004b]. 
Besides the well established application in foods and pharmaceuticals, gelatin 
was firstly described as base material for the production of nanoparticles to be used 
as drug delivery system in the 1970s [Speiser et al., 1974; Marty et al., 1978]. During 
the manufacturing of nanoparticles from gelatin its high molecular weight fraction 
(hmw) plays a major role [Zwiorek, 2006; Ahlers et al., 2006]. This was already 
assumed by Farrugia [Farrugia et al., 1999], who systematically investigated the 
desolvation process described by Marty for the production of gelatin nanoparticles 
[Marty et al., 1978]. Their assumption was finally corroborated by the development 
of the two-step desolvation technique [Coester et al., 2000]. During two-step 
desolvation gelatin bulk material is fractionated, whereas the low molecular weight 
fraction (lmw) is discarded and nanoparticles can be manufactured from the hmw 
fraction with a remarkable homogenous size distribution. Former results derived 
from SE-HPLC and AF4 analysis provided detailed information about the molecular 
weight distribution of gelatin bulk material and gelatin sediment – comprising the 
high molecular weight fraction obtained from two-step desolvation – revealing up to 
~27 % [w/w] hmw protein molecules present in the sediment [Fraunhofer et al., 
2004b]. A number of 100 kDa marking the border line between low and high 
molecular weight fraction was determined and molecular weights ranging from 
20 kDa to 10,000 kDa were characterized to constitute gelatin bulk material. 
Followed from these findings it can be assumed that the application of gelatin 
possessing reduced amounts of its low molecular weight fraction should enable the 
production of homogenous nanoparticles by a one-step desolvation procedure i.e., the 
direct preparation of gelatin nanoparticles from gelatin bulk material omitting its 
initial fractionation. Accordingly, four customized gelatin batches developed from 
the Gelita AG (Eberbach, Germany), one of the world’s largest gelatin 
manufacturers, were provided to investigate their potential in terms of successful 
one-step desolvation. The four batches were prepared with reduced amounts of 
peptides < 65 kDa accounting for < 40 % [w/w] (batch PN307779 / VP433) and 
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< 20 % [w/w] (batches VP306 / VP413-2) respectively. Batch VP433 was 
additionally spiked with a high molecular weight fraction > 107 Da in order to 
estimate the impact of pronounced present hmw fractions in comparison to the 
further reduced peptide portions in batches VP306 and VP413-2. Due to its strengths 
in resolving samples of macromolecules and polymers [Giddings, 2000] and the 
possibility of absolute determination of molar masses [White, 1997] the analytical 
description of this material via AF4 coupled with multi-angle light scattering 
(MALS) detection was the aim of this study. 
The absolute molar mass determination derived from light scattering detection is 
based on the everyday phenomenon of static or classical light scattering emanating 
from analytes upon exposure to light as a function of size and molecular weight. 
Thereby, the ratio between the intensity of scattered light and the intensity of 
incident light of a certain wavelength is detected. The resulting excess Rayleigh ratio 
R(θ) defined by 
 
(1-3) 
 
where I0 is the incident light intensity, fgeom is a geometrical calibration constant that 
is a function of solvent and scattering cell’s refractive index and geometry, and I(θ) 
and Is(θ) are the normalized intensities of scattered light detected at angle θ with 
respect to the illuminated solution and solvent respectively. For generally assumed 
vanishing small concentrations and negligible interactions between sample and 
solvent the following proportionality can be described 
 
(1-4) 
 
where K is a constant representing the refractive index increment of the analyte, c is 
the sample concentration, Mw is the weight average molar mass, and P(θ) is the 
scattering function, which is 1 for sample molecules smaller than λ/20 (λ is the 
vacuum wavelength of the incident light = 690 nm for the applied miniDAWNTM 
detector). This proportionality reveals the relation between the samples’ light 
scattering properties and its molar mass providing the basis for molecular weight 
determination from light scattering data. It is important to note that the scattering 
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properties of samples exhibiting a bigger diameter than λ/20 e.g., nanoparticles are 
shifted from an isotropic to an anisotropic behavior (Figure 1.3.1). For accurate 
molar mass determination it is then necessary to detect light scattering at up to 18 
angles directed around the scattering cell; in this case 3 angles are employed at 45°, 
90°, and 135°, which is sufficient for polymer analysis. 
 
 
 
 
 
 
 
Figure 1.3.1 Dependence of light scattering from sample size; if the sample size exceeds λ/20 the 
pattern of the scattered light will change from an isotropic to a forwarded anisotropic manner 
 
It has to be confined that MALS is only able to provide exact data for the 
analysis of sample populations which consist of identical specimens. Consequently, 
the necessity of sample fractionation into distinct slices prior to detection becomes 
evident and is in this study achieved by AF4. 
Basic theoretical considerations to light scattering detection are summarized 
from according literature [Arndt et al., 1996; White, 1997; Wyatt, 1998]. 
Data from AF4/MALS analysis should help to understand failure or success of 
the respective gelatin batches while developing a one-step desolvation procedure for 
the synthesis of gelatin nanoparticles. Experiments were conducted in comparison to 
regularly applied gelatin bulk material purchased from Sigma-Aldrich and gelatin 
sediment obtained from two-step desolvation. Particle manufacturing via one-step 
desolvation was evaluated by Klaus Zwiorek; for a detailed description of the 
corresponding experimental conditions it is referred to his thesis [Zwiorek, 2006]. 
laser 
     isotropic scattering: d < λ/20                        anisotropic scattering: d > λ/20 
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1.3.2 Results and discussion 
At first gelatin bulk material purchased from Sigma-Aldrich was analyzed to 
gain a benchmark for the following investigations. The molar mass of the applied 
batch was determined to comprise sizes ranging from 10 kDa to above 10,000 kDa 
(Figure 1.3.2), which confirms the data reported by Fraunhofer [Fraunhofer et al., 
2004b] and exceeds the findings from SE-HPLC/MALS analysis [Meyer et al., 2003; 
Fraunhofer et al., 2004b] by more than one order of magnitude. The discrepancy 
between sizing data obtained from SE-HPLC and AF4 reflects the fundamental 
differences between these two separation techniques. While SE-HPLC separation 
takes place in a packed column AF4 utilizes an open channel leading to lower 
hydrostatic pressure and therewith lower shear forces the samples are encountered 
during analysis.  
 
 
 
 
 
 
 
 
 
Figure 1.3.2 UV signal (continuous line) and molecular weight (dots) calculated from respective 
UV and MALS data resulting from AF4 analysis of gelatin bulk material purchased from 
Sigma-Aldrich; the circle marks the low molecular weight fraction 
 
Particularly high molecular weight specimens suffer from degradation by 
increased shear forces and are thus preserved and can be detected during AF4 
analysis [Myers, 1997]. The displayed diagram showing the high molecular weight 
fraction of gelatin almost eluting over the whole experimental period, expresses the 
chosen cross-flow conditions displayed in Figure 1.2.2. Due to the broad variety of 
molecules all possessing different molar masses present in gelatin bulk material a 
baseline separation of particular portions is excluded. Thus it was decided to only 
apply a weak separation force in order to expand the elution of the blend of 
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molecules over a prolonged period and thereby visualizing the heterogeneous nature 
of gelatin. 
Gelatin from Sigma-Aldrich is characterized by a broad molecular weight 
distribution as displayed in Figure 1.3.2. As solely its high molecular weight fraction 
can be used for the preparation of homogenous nanoparticles (cp. chapter 1.3.1) it 
generally has to be processed by two-step desolvation. Manufacturing experiments in 
turn, conducted with two of the four customized Gelita batches (VP306 / VP413-2) 
that possessed less than 20 % [w/w] peptides < 65 kDa resulted in successful one-
step desolvation synthesis of gelatin nanoparticles exhibiting equivalent size and size 
distribution [Zwiorek, 2006]. Batch PN307779 that exhibited peptides < 65 kDa only 
reduced to amounts < 40 % [w/w] failed in this context as well as batch VP433 
containing an identically reduced peptide fraction but at the same time an expanded 
amount of hmw components > 104 kDa. These findings reveal the restriction that has 
especially to be made for the presence of low molecular weight portions in gelatin 
batches designated to one-step desolvation. 
Compared to gelatin from Sigma-Aldrich the molar mass distribution of the 
Gelita batches is altered, which can be followed during AF4/MALS analysis. In 
Figure 1.3.3 results are exemplarily displayed for batch VP413-2.  
 
 
 
 
 
 
 
 
 
Figure 1.3.3 UV signal (continuous line) and molecular weight (dots) calculated from respective 
UV and MALS data resulting from AF4 analysis of gelatin bulk material VP413-2 developed and 
provided from Gelita; the circle marks the low molecular weight fraction 
 
Highlighted by the circle (cp. Figure 1.3.2) the successful depletion of the low 
molecular weight fraction of gelatin is demonstrated. In addition, gelatin sediment 
obtained from two-step desolvation after the first desolvation step – as the result 
from fractionation and used for the preparation of nanoparticles – was transferred to 
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AF4 analysis. Data from these experiments and from gelatin bulk material are 
displayed as function of their mean molecular weight and opposed in Figure 1.3.4. 
Interestingly the clear shift of the mean molecular weight of the gelatin sediment (4) 
by more than one order of magnitude compared to the bulk material (1) must not be 
stated as necessity in terms of successful one-step desolvation. Even a mean 
molecular weight between 400 and 500 kDa determined for the Gelita batches 
VP306 and VP413-2 was sufficient. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.4 Mean molecular weight fractions calculated from respective UV and MALS data 
resulting from AF4 analysis of gelatin bulk material purchased from Sigma-Aldrich (1), of gelatin 
bulk material VP306 (2) and VP413-2 (3) developed and provided from Gelita, and of gelatin 
sediment obtained after the first desolvation step from the manufacturing process of the gelatin 
nanoparticles (4) 
 
Thus, derived from these findings and the specification of the applied gelatin 
batches a mean molecular weight of ~500 kDa and a threshold of maximum 20 % 
[w/w] for the portion of low molecular weight fractions < 65 kDa could be defined as 
prerequisite for the successful manufacturing of gelatin nanoparticles by a one-step 
desolvation procedure. 
The mean molecular weight of gelatin sediment ranges clearly above the one of 
the Gelita batches, which may not only be attributed to even more reduced amounts 
of peptides < 65 kDa far below 20 % in the sediment. Thus, the fractionation of 
gelatin bulk material during two-step desolvation supposedly led to a depletion of 
molecular weight fractions bigger than 65 kDa. 
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1.3.3 Summary 
The analysis of gelatin bulk material by the combination of asymmetrical flow 
field-flow fractionation and multi-angle light scattering was accomplished in 
continuation of preliminary studies from Fraunhofer [Fraunhofer et al., 2004b]. At 
first, their basic results obtained for gelatin bulk material applied for the 
manufacturing of gelatin nanoparticles by two-step desolvation could be confirmed. 
Secondly, mean molecular weights of customized gelatin batches from the Gelita AG 
characterized by the depletion of low molecular weight fractions during production 
could be successfully classified in between the mean molecular weight determined 
for gelatin bulk material from Sigma-Aldrich and gelatin sediment obtained from 
two-step desolvation. These results demonstrated the impact of the low molecular 
weight fraction of gelatin for the manufacturing of gelatin nanoparticles and 
contributed to further understanding and description of gelatin nanoparticle synthesis 
by desolvation. This was at least feasible in a one-step attempt utilizing particular 
batches of the customized Gelita material [Zwiorek, 2006]. The one-step desolvation 
is not only straightforward in terms of technological aspects as it simplifies the 
manufacturing procedure but also especially interesting for regulatory considerations. 
One of the major drawbacks of the two-step desolvation is that gelatin nanoparticles 
are produced with not exactly defined bulk material obtained from the first 
desolvation step i.e., bulk material resulting from an indeed validated but “hand 
made” fractionation with varying outcome. The successful application of the one-
step desolvation for gelatin nanoparticle synthesis circumvents this problem. 
Finally, concerning the restrictions for certain molecular weight fractions of 
gelatin, necessary for the one-step desolvation, together with the Gelita AG a patent 
application could be filed to the authorities [Ahlers et al., 2006]. 
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1.4 Quantifying the Oligonucleotide-Loading of Gelatin 
Nanoparticle Drug Delivery Systems Using Asymmetrical Flow 
Field-Flow Fractionation (AF4) and UV Detection 
1.4.1 Introduction 
Basically, drug loading of nanoparticulate carrier system is either conducted 
during manufacturing or afterwards by binding the respective substances onto the 
surface of the finished product [Soppimath et al., 2001]. Thereby matrix systems 
exhibiting homogenously distributed drug molecules and core-shell like structures 
emerge. Subsequent conducted assessment of the drug loading efficiency has thus to 
be accordingly adapted. The preparation techniques of gelatin nanoparticles that are 
described in literature admit both the incorporation of drugs during manufacturing as 
well as a later binding onto the nanoparticles’ surface. Due to the various 
applications in drug delivery and drug targeting gelatin nanoparticles are developed 
for, there is a multiplicity of analytical approaches utilized for the quantification of 
their drug load. In the following these approaches revealing the current status of 
drug-loaded gelatin nanoparticle research are summarized in brief. 
Applying W/O emulsions nanoparticles are formed within the aqueous phase 
which optionally contains the drug substance at the same time. After purification 
drug loading can be UV spectrophotometrically determined from the remaining 
reaction medium [Gupta et al., 2004] or from dissolved nanoparticles [Cascone et al., 
2002]. Bajpai described a gravimetrical approach for gelatin nanoparticles drug-
loaded by swelling the dried particles till equilibrium in a freshly prepared drug 
solution, as he determined the weight of the same dried nanoparticle aliquot before 
and after drug loading [Bajpai et al., 2005]. Originally dating from the work of Marty 
[Marty et al., 1978] several desolvation procedures are described for the 
incorporation of drug substances in gelatin nanoparticles. To quantify the respective 
drug loading UV spectroscopy [Leo et al., 1997] and HPLC [Vandervoort et al., 
2004] are employed for the analysis of the supernatant after separating the 
nanoparticles. Labhasetwar reported a dialysis approach for the extraction of 
incorporated metronidazole [Labhasetwar et al., 1990] and the group of Amiji 
determined the amount of plasmid DNA after enzymatic digestion of gelatin 
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nanoparticles via a PicoGreen® assay [Kaul et al., 2005; Kommareddy et al., 2005]. 
Self-assembled nanoparticulate DNA-polycation i.e., gelatin systems were 
identically processed [Leong et al., 1998; Truong-Le et al., 1999] and Lu combined a 
HPLC protocol with preceding digestion of nanoparticles [Lu et al., 2004]. Gelatin 
nanoparticles prepared by two-step desolvation were drug-loaded by physical 
entrapment of a low molecular weight substance into the nanoparticles and after 
surface activation with reactive sulfhydryl groups by NeutrAvidinTM mediated 
coupling with biotinylated antibodies or peptide nucleic acids (PNAs). Drug loading 
was determined after centrifugation from the supernatant containing unbound drug 
by UV spectroscopy [Verma et al., 2005] as well as reversed phase HPLC and 
immunoblotting / fluorimetry respectively [Langer et al., 2000; Dinauer et al., 2005]. 
In the present study drug loading of gelatin nanoparticles obtained from two-step 
desolvation with single- and double-stranded DNA oligonucleotides was performed 
by electrostatic interactions comparable to the mechanism driving the self-
assembling synthesis of DNA-polycation complexes. To permit the adsorption of 
negatively charged oligonucleotide molecules onto gelatin nanoparticles a permanent 
positive surface charge is crucial. It can be achieved by the covalent introduction of 
cholamin, bearing a quaternary amino group, via the carboxyl residues present on the 
surface of gelatin nanoparticles, whereas a clear pH independent positive surface 
charge arises [Coester, 2003; Zwiorek et al., 2004]. This oligonucleotide-loading 
procedure is routinely quantified via UV spectroscopical detection of unbound 
oligonucleotide staying within the incubation medium after removing the 
nanoparticles [Zillies et al., 2004]. The verification of these data by utilizing 
asymmetrical flow field-flow fractionation (AF4) coupled with UV detection was 
aspired during this study. Based on the well known strengths of AF4 in resolving 
macromolecular and particulate matter [Giddings, 2000] its ability to separate gelatin 
nanoparticles from biopolymers i.e., proteins or oligonucleotides should be 
demonstrated. It was intended to develop a fractionation protocol that provides the in 
situ quantification of the oligonucleotide-loading of gelatin nanoparticles 
concurrently omitting further sample preparation. 
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1.4.2 Results and discussion 
Characterization of nanoparticles 
Both nanoparticle formulations applied during AF4 experiments exhibited the 
same homogenous size distribution with polydispersity indices (PDIs) clearly below 
0.050. The slightly varying sizes can be stated as negligible in the present analytical 
context. Zetapotential differences between the two batches utilized for 
oligonucleotide-loading are in accordance to the requirements for single and double-
stranded ODN loading. Equivalent amounts i.e., 5 % [w/w] can be loaded under 
identical conditions (in highly purified water) of the single-stranded oligonucleotide 
onto batch G-NPZW 03-121 pos and of the double-stranded oligonucleotide onto 
batch G-NP 06-027 pos. 
Table 1.4.1 Size, polydispersity, and surface charge of nanoparticle formulations applied for the 
quantification of single-stranded# and double-stranded§ oligonucleotide-loading  
 
 
#Surface-modified 
gelatin nanoparticles 
(G-NPZW 03-121 pos) 
§Surface-modified 
gelatin nanoparticles 
(G-NP 06-027 pos) 
size [nm] 255.7 365.0 
PDI 0.028 0.043 
ZP [mV] +2.3 +16.4 
 
Single-stranded oligonucleotide loading 
Before the single-stranded oligonucleotide-loading onto gelatin nanoparticles 
could be evaluated, adequate AF4 separation conditions for the oligonucleotide and 
the gelatin nanoparticles were developed and the linear relation of sample 
concentration and UV detection signal was proven. UV detection was chosen since 
the analytes were not accessible by refractive index (RI) detection. Initiatory 
experiments demonstrated the separation of gelatin nanoparticles from several 
macromolecules exhibiting declining molecular weights. An immunoglobulin (IgG1, 
147 kDa), human serum albumin (HSA, 66.4 kDa), granulocyte colony stimulating 
factor (G-CSF, 19.6 kDa), and insulin (5.8 kDa) were successfully fractionated from 
gelatin nanoparticles. Especially the separation from insulin was important as the 
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oligonucleotide exhibited a similar molecular weight of 5.5 kDa. Thus, the developed 
cross-flow profile (Figure 1.2.3) could also be applied for quantifying the 
oligonucleotide loading. All experiments were performed together with Wolfgang 
Fraunhofer. For a detailed description of the corresponding data it is referred to his 
thesis [Fraunhofer, 2003]. Here, the final results of these studies are shown in Figure 
1.4.1 as they illustrate the goal that was aimed at during the development of an AF4 
separation protocol for quantifying the double-stranded oligonucleotide-loading onto 
gelatin nanoparticles without previous sample preparation. 
 
 
 
 
 
 
 
 
 
Figure 1.4.1 UV signals resulting from AF4 analysis of the single-stranded oligonucleotide 
before loading (1) and after loading (3) onto gelatin nanoparticles as well displayed before (2) and 
after oligonucleotide-loading (4); originally published data from Fraunhofer [Fraunhofer, 2003] 
 
The graphs summarize the AF4 runs separately performed before 
oligonucleotide-loading with the oligonucleotide (1) and the nanoparticles (2) and at 
once performed after oligonucleotide-loading with both (3) / (4). The alterations 
thereby observed for the respective UV signals showed a clear downsizing of the 
ODN peak and concurrently a commensurate growth of the nanoparticle peak. 
Calculated from the corresponding AUCs an amount of ~50 % of the applied single-
stranded oligonucleotide could be determined to be bound representing a loading 
capacity of the gelatin nanoparticles of 5 % [w/w]. These findings met expectations 
as they were confirmed by data from centrifugation / UV-spectroscopy. Regarding 
the size of the oligonucleotide, it has to be mentioned that its molecular weight marks 
the lower limit of sample sizes which can be effectively handled during AF4 analysis 
[Giddings, 1993]. This is also expressed by the void peak merging the 
oligonucleotide peak (Figure 1.4.1). The void peak inherent in AF4 occurs after the 
time required to flush out the channel volume and contains non-retained parts of the 
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injected sample that did not interact with the separation field [Giddings et al., 1977; 
Klein et al., 1998]. 
Based on the completed quantification of single-stranded oligonucleotide 
loading, double-stranded oligonucleotide-loading onto gelatin nanoparticles was 
evaluated via AF4/UV in the next step. 
Double-stranded oligonucleotide loading 
Due to their size and molecular weight gelatin nanoparticles are affected by very 
low cross-flow intensities [Giddings, 1993; Colfen et al., 2000], which became 
obvious during the first AF4 experiments. Thus, to achieve sufficient separation 
during oligonucleotide-loading quantification studies it could be concentrated on the 
development of cross-flow conditions providing adequate elution of the respective 
oligonucleotide; whereas nanoparticles are retained within the separation channel 
until the cross flow was completely abandoned. For the experiments assessing the 
double-stranded ODN loading the cross-flow was slightly increased compared to the 
formerly applied profile (Figure 1.2.3) as a thinner channel was applied and kept 
constant over 10 min (Figure 1.2.4). The applied settings comprising cross-flow, 
ultrafiltration membrane, and running buffer provided reproducible detection signals 
of a symmetrical shape (Figure 1.4.2). Furthermore, due to its higher molecular 
weight of 14.1 kDa the double-stranded ODN could sufficiently be baseline-
separated from the void peak allowing a more precise determination of the resulting 
AUC.  
 
 
 
 
 
 
 
 
 
Figure 1.4.2 UV signals arising from the double-stranded oligonucleotide after AF4 analysis; 
identical concentrations were injected 3 times under the same conditions (Dulbecco’s PBS pH 7.3 / 
regenerated cellulose ultrafiltration membrane 5kDa cut-off) 
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Subsequently, gelatin nanoparticles were investigated for their elution behavior 
by applying the same instrumental set-up. The obtained fractograms are displayed in 
Figure 1.4.3 a). Despite repeated injection no congruent detection signals could be 
gained. The picture shows the nanoparticles’ UV signals arising from the first three 
injections. Along the stepwise appearance membrane saturation with nanoparticles 
was assumed that finally led to bouncing peak heights and excluded reproducible 
AUC calculation (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.3 UV signals arising from gelatin nanoparticles after AF4 analysis; identical 
concentrations of a) surface-modified nanoparticles and b) plain nanoparticles were injected 3 times 
each under the same conditions (Dulbecco’s PBS pH 7.3 / regenerated cellulose ultrafiltration 
membrane 5kDa cut-off) 
 
The applied surface-modified gelatin nanoparticles exhibited a clear positive 
surface charge necessary for loading the double-stranded oligonucleotide onto their 
surface. Presumably, electrostatic interactions emerging between the positively 
charged nanoparticles and the negatively charged cellulose residues of the 
ultrafiltration membrane delayed the elution of the nanoparticles from the separation 
channel and led to nanoparticles persisting on the membrane. This hypothesis could 
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be proven when not surface-modified gelatin nanoparticles were examined under 
identical conditions. These particles produced already after the first sample run 
congruent UV detection signals (Figure 1.4.3 b). The small peak appearing after 
27 min in both fractograms of Figure 1.4.3 originates from flushing the injection 
valve and will not disturb calculation of the AUCs, especially as it can be omitted or 
initiated later. Concerning the nanoparticles used for the single-stranded 
oligonucleotide-loading the observed discrepancy might be explained by their lower 
surface charge which seems to be in a way abolished by the ionic environment of the 
PBS running buffer that allows unaffected elution. The disappointing results from the 
surface-modified gelatin nanoparticles were in turn also obtained with 
oligonucleotide-loaded nanoparticles revealing the positive surface charge partially 
remaining after oligonucleotide-loading (cp. chapter 3.3.3, Table 3.3.1). And, as 
nanoparticles accumulating within the separation channel disturb propelling others 
by electrostatic interactions via the bound oligonucleotide, the quantification of the 
oligonucleotide-loading process only from the excellent oligonucleotide detection 
signal was not possible. 
Thus, in the following changes of the instrumental setup were implemented in 
order to achieve the aspired quantification of the double-stranded oligonucleotide 
loading. At first the material of the ultrafiltration membrane was changed from 
regenerated cellulose to polyethersulfone. Due to the missing negatively charged 
cellulose residues ionic interactions between the membrane material and the surface-
modified gelatin nanoparticles should therewith be excluded. However, this time the 
oligonucleotide exhibited certain membrane adsorption. This was expressed in 
stepwise appearing UV detection signals (Figure 1.4.4) comparable to those seen for 
the nanoparticles on the regenerated cellulose membrane (Figure 1.4.3 a). Again this 
problem could not be circumvented by repeated injections in order to obtain stable 
membrane saturation, whereas interactions with subsequent injected nanoparticles 
either empty or ODN loaded would corrupt this attempt. Intensive focusing or high 
initial cross-flow commonly known to evoke adsorption phenomena during AF4 
analysis [Wahlund, 2000] can be excluded as the cause of the problem as these 
parameters remained unchanged. But, in contrast to membranes made of regenerated 
cellulose polyethersulfone membranes do not exhibit negatively charged side chains 
of the applied polymer. 
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Figure 1.4.4 UV signals arising from the double-stranded oligonucleotide after AF4 analysis; 
identical concentrations were injected 3 times under the same conditions (Dulbecco’s PBS pH 7.3 / 
polythersulfone ultrafiltration membrane 5kDa cut-off) 
 
Thus electrostatic repulsion driven by equal charge of analyte and membrane 
material is missing and consequently hydrophilic interactions were assumed to be 
responsible for the observed irregular elution. Suggesting, that ionic shielding of the 
nanoparticles’ surface charge explains the good results from single-stranded ODN 
loading the augmentation of the ionic strength within the running buffer was obvious. 
Therefore the NaCl concentration was adjusted to 0.6 mol/L, phosphate content and 
pH were maintained unaltered, and the membrane material was changed back to 
regenerated cellulose. Corresponding results obtained for the double-stranded 
oligonucleotide and the gelatin nanoparticles are summarized in Figure 1.4.5. For 
both analytes the chosen combination of membrane material and running buffer 
evidently provided optimum separation conditions. Congruent detection signals were 
observed after triple injection and with respect to the corresponding elution times a 
sufficient separation could be expected analyzing oligonucleotide and gelatin 
nanoparticles together in one run subsequent to loading.  
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Figure 1.4.5 UV signals arising from a) the double-stranded oligonucleotide and b) surface-
modified gelatin nanoparticles after AF4 analysis; respective identical concentrations were injected 3 
times under the same conditions (Dulbecco’s PBS pH 7.3 containing 0.6 mol/L NaCl / regenerated 
cellulose ultrafiltration membrane 5kDa cut-off) 
 
In fact, a baseline separation was achieved (Figure 1.4.6) but with respect to the 
aim of the study these final sample runs failed. As nanoparticles were incubated with 
5 % [w/w] double-stranded oligonucleotide for what centrifugation / 
UV-spectroscopy data revealed complete loading, its UV signal should have been 
totally erased. In discussing this phenomenon, the ionic strength of the running 
buffer has to be taken into account. Utilizing electrostatic attractive forces loading 
will be more stable the stronger the electrostatic interactions are. Working in 
buffered media with its elevated ionic strength, net charges of the involved analytes 
are partially or even completely compensated. This is successfully used for the 
prevention of membrane adsorption during AF4 analysis as discussed above but 
abrogates at the same time also the attractive forces between nanoparticles and 
oligonucleotide. Thus, the raised NaCl concentration within the running buffer was 
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indeed able to prevent membrane adsorption but finally led to the release of the 
oligonucleotide-loading of gelatin nanoparticles. 
 
 
 
 
 
 
 
 
 
Figure 1.4.6 UV signals arising from the double-stranded oligonucleotide (1) and surface-
modified gelatin nanoparticles (2) – after incubating the nanoparticles for 2 h with the ODN – 
subsequent to AF4 analysis; identical concentrations were injected 3 times under the same conditions 
(Dulbecco’s PBS pH 7.3 containing 0.6 mol/L NaCl / regenerated cellulose ultrafiltration membrane 
5kDa cut-off) 
 
Similar observations were already made during former studies evaluating the 
siRNA loading of gelatin nanoparticles when the medium was changed upon 
incubation from highly purified water to PBS [Zillies et al., 2004]. Regarding the 
ODN release from gelatin nanoparticles in vivo, the same mechanism can be 
assumed, whereas an immediate release right after injection before reaching the 
respective target is not desirable. Here, a sodium chloride concentration of 0.6 mol/L 
was finally applied which is about four times higher than isotonic i.e., physiological 
values (~0.15 mol/L). In a comparable in vitro setup, Tondelli reported about almost 
complete release of electrostatically bound ODN from PMMA nanoparticles in the 
presence of 1 mol/L sodium chloride. 0.1 mol/L NaCl in turn governed a release up 
to 78 % over eight days depending on the total amount of bound oligonucleotide 
[Tondelli et al., 2003]. These data were further confirmed by our findings from 
biodistribution studies in rats with fluorescent-labeled NF-κB decoy oligonucleotide-
loaded gelatin nanoparticles that did not reveal a rapid release of the oligonucleotide 
(cp. chapter 3.4.2). Thus, a release of electrostatically bound oligonucleotide from 
nanoparticles by (partially) compensated attractive forces in buffered media can be 
stated, whereas the degree of release seems to be determined by the ionic strength of 
the particular medium. Derived from the present data it can be stated that sufficient 
AF4 separation settings can be described even for charged analytes. This is achieved 
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by compensating the involved charges by accordingly adjusting the ionic strength of 
the running buffer, which is in general recommended for samples exhibiting charged 
surfaces [Ratanathanawongs-Williams, 2000]. This in turn causes the dilemma: if 
there were conditions applied that provided stable oligonucleotide-loading membrane 
adsorption took place and if the chosen conditions inhibited this, oligonucleotide-
loading was destabilized. Nevertheless, the unique capability of AF4 to separate 
soluble specimens from suspended material was once more highlighted still leaving it 
attractive for the work with colloidal drug carriers in general and gelatin 
nanoparticles in special. 
1.4.3 Summary 
Followed from former studies demonstrating the potential of asymmetrical flow 
field-flow fractionation for the separation of dissolved biopolymers and gelatin 
nanoparticles the quantification of double-stranded oligonucleotide-loading onto 
gelatin nanoparticles via AF4 was assessed. The conducted experiments proved the 
known high resolution power but lastly failed in terms of a successful quantification. 
Neither replacing the ultrafiltration membrane nor varying the ionic strength of the 
running buffer could solve this problem. Due to the involved high surface charges of 
the analytes it was not possible to develop adequate separation conditions for the 
three investigated specimens double-stranded oligonucleotide, surface-modified 
gelatin nanoparticles, and oligonucleotide-loaded gelatin nanoparticles at once. High 
surface charges on the one hand require high ionic strength of the running buffer on 
the other hand. This methodical restriction lastly led to the ODN-loaded formulation 
eluting either in a non reproducible manner or releasing the oligonucleotide during 
AF4 analysis. Thus, direct quantification of the oligonucleotide-loading without 
previous sample preparation was not feasible. Thereby, the release mechanism of 
electrostatically bound oligonucleotide from nanoparticles was elucidated. Elevated 
concentrations of sodium chloride led to immediate oligonucleotide release, whereas 
as a sustained effect can be assumed under in vivo conditions with a roughly four 
times reduced ionic strength compared to the respective AF4 running buffer.  
In sum, the results describe the limits of this analytical approach but do not 
basically challenge the advantages of AF4 in colloidal analysis. 
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1.5 Quantifying the PEGylation of Gelatin Nanoparticle Drug 
Delivery Systems Using Asymmetrical Flow Field-Flow 
Fractionation (AF4) and Refractive Index (RI) Detection 
1.5.1 Introduction 
The growing experience with colloidal drug carrier systems led to a detailed 
understanding of their in vivo fate subsequent to intravenous application. Hence, it is 
nowadays well known that foreign material with a molecular weight higher than the 
renal threshold is sequestered in the mononuclear phagocytic system (MPS) organs 
[Owens et al., 2006]. The involved phagocytotic cells recognize colloidal structures 
like liposomes and nanoparticles due to the rapid opsonization immediately 
occurring after application [Yan et al., 2005; Owens et al., 2006]. The resulting low 
plasma half life minimizing most therapeutic effects led to an intensive research in 
order to overcome this problem. Ruling out the extensive plasma protein adsorption 
during opsonization should consequently provide a certain macrophage resistance 
expressed in a reduced MPS accumulation and a prolonged circulation time. 
Followed from this idea long circulating liposomes and nanoparticles have been 
developed [Peracchia, 2003; Yan et al., 2005; Owens et al., 2006]. These systems 
possess a “molecular cloud” of polymer chains esp. polyethylene glycol (PEG) 
chains grafted onto their surface, which sterically protect them from opsonization 
and enable prolonged circulation. Despite the long circulation properties 
opsonization even of these systems cannot be completely excluded and is meanwhile 
critically discussed [Moghimi et al., 2003; Yan et al., 2005]. Due to this successful 
approach the concept of PEG grafting is widely applied for drug carriers as 
liposomes [Yan et al., 2005], nanoparticles based on synthetic [Peracchia et al., 1999; 
Owens et al., 2006] and natural polymers [Lin et al., 1999; Kaul et al., 2002; Owens 
et al., 2006], and polyplexes [Ogris et al., 1999; Walker et al., 2005] as wells as for 
drug molecules at their own, namely proteins [Fee et al., 2005; Veronese et al., 2005] 
and in the field of transfusion medicine for red blood cells [Garratty, 2004]. 
Besides the grafting process the quantification of the introduced PEG is a matter 
of interest as the grade of PEGylation is decisive for a successful shielding 
[Veronese, 2001; Moghimi et al., 2003; Yan et al., 2005] and a homogenous product 
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is a necessary prerequisite during the regulatory process [Chamberlain et al., 2003]. 
Quantifying PEG is in general an analytical challenge. The lack of any chromophors 
and its transparent and non-fluorescent appearance excludes the direct 
spectrophotometrical detection. Indirect methods like the determination of unreacted 
functionalities of the reaction counterpart will not provide a precise evaluation of the 
number of polymer chains bound. So, due to the various PEGylated systems 
numerous analytical approaches have been proposed quantifying the PEGylation. 
The first successful attempts utilizing colorimetric assays by introducing an UV 
active staining into the PEG molecule, were described in the 1970s [Childs, 1975; 
Skoog, 1979]. The formed PEG barium iodide complex produces a band at 535nm 
which can be used for quantitative measurements. This complex formation was 
transferred to SDS-PAGE [Kurfurst, 1992] and is still in use for the evaluation of 
PEGylation efficiencies [Natarajan et al., 2005; Zhang et al., 2006]. Another 
colorimetric assay without initial extraction of PEG could be developed based on the 
partitioning of a chromophore present in aqueous ammonium ferrothiocyanate from 
an aqueous to an organic phase in the presence of PEG [Nag et al., 1996]. However, 
despite rapidness, accuracy, and sensitivity these methods suffer from the high values 
of the blanks. Finally, derivatization techniques have been used to produce UV active 
PEG species like PEG dibenzoates [Murphy et al., 1981]. Besides these PEG 
modifying assays, detecting PEG without any changes of the molecule is nowadays 
extensively described in literature: flame ionisation detection [Kwong et al., 1995], 
dynamic surface tension detection [Miller et al., 2000], nuclear magnetic resonance 
spectrometry [Leenheer et al., 1991; Mazarin et al., 2006], mass spectrometry [Fakt 
et al., 1997; Crescenzi et al., 1997; Nielen et al., 1999; Na et al., 2004b], and 
refractive index detection [Delahunty et al., 1986; Kirkland et al., 1992b; Oliva et al., 
1994; Benincasa et al., 2001] are applied for the quantitative (and qualitative) 
evaluation of PEG of different molecular weights. The separation of PEGylated from 
non-PEGylated compounds and PEG, required prior to any kind of detection, is 
feasible by different chromatographic techniques as well as flow field-flow 
fractionation (FFFF). Due to the amphiphilic properties of PEG, RP-HPLC [Oliva et 
al., 1994; Crescenzi et al., 1997] and organic FFFF [Kirkland et al., 1992a] are 
likewise applied as conventional SEC-HPLC [Delahunty et al., 1986; Miller et al., 
2000; Fee et al., 2005] and aqueous FFFF [Kirkland et al., 1992b; Benincasa et al., 
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2001]. Furthermore, capillary electrophoresis is applied for sample separation [Na et 
al., 2004a; Na et al., 2004b]. Working with PEGylated colloidal drug carrier systems 
the adoption of the field-flow fractionation combined with subsequent PEG 
determination appears especially interesting, as separation takes place in a hollow 
channel, allowing the concurrent fractionation of undissolved i.e. suspended colloidal 
structures and dissolved samples like PEG within a broad molecular weight range of 
~104-1018 Da = 1 nm – 100 µm (cp. chapter 1.1) [Giddings, 1993]. 
The present study describes an AF4 separation method for PEGylated gelatin 
nanoparticles and PEG as well as the determination of the PEGylation efficiency of 
gelatin nanoparticles via the concentration of non-reacted PEG residues in the 
reaction media. Beyond the quantitative description of this process we were 
interested in visualizing the successful PEGylation of the nanoparticles. Therefore 
plain and PEGylated gelatin nanoparticles were investigated in atomic force 
microscope (AFM) experiments. During AFM experiments samples are mechanically 
scanned with a special cantilever resulting in a resolution of nanometre sized 
structures like the helical morphology of DNA double strands [LaVan et al., 2002; 
Ravi Kumar, V et al., 2004], which makes AFM the method of choice in this context. 
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1.5.2 Results and discussion 
Characterization of nanoparticles 
Prior to AFM measurements, nanoparticles had to be fixed on the sample grid as 
scans performed with mobile analytes will not guarantee optimum resolution of 
subtle morphological changes like the investigated PEGylation of gelatin 
nanoparticles. Fixation was accomplished via electrostatic interactions comparable to 
the above investigated oligonucleotide-loading procedure (chapter 1.4). Since the 
sample grid had a negatively charged coating, the nanoparticles had to be cationized 
to ensure sufficient fixation. During AF4 analysis this additional surface 
modification was not necessary. Furthermore, the PEGylation is accomplished via 
the free aldehyde groups of mono-functionally bound glutaraldehyde derived from 
crosslinking present at the surface of the nanoparticles. As the aldehyde groups are 
beside free carboxyl groups as well reaction counterpart during cationization, the 
resulting competitive situation may lead to released PEG during subsequent 
conducted cationization. With respect to the aim of the AF4 study, to reproducibly 
quantify a maximum amount of PEG that can be bound onto the surface of gelatin 
nanoparticles, experiments were conducted without cationization. Thus, cationization 
differentiates nanoparticles applied during AFM studies from the nanoparticles 
analyzed via AF4. It was assumed that the modification with cholamine, a low 
molecular weight substance (Mw 175.10 Da) should not have a crucial impact on the 
particle’s morphology.  
Table 1.5.1 Size and polydispersity of nanoparticle formulations applied for AF4 and AFM 
analysis of the PEGylation  
 
 
non-PEGylated 
gelatin nanoparticles 
(G-NPZW AF) 
PEGylated 
gelatin nanoparticles 
(G-NPZW AF-PEG) 
 plain cationized plain cationized 
size [nm] 179.7 180.4 185.2 184.5 
PDI 0.041 0.064 0.072 0.097 
 
Otherwise, it was thereby exemplified, that both modifications (cationization and 
PEGylation) can be performed on one nanoparticle batch. Dynamic light scattering 
(DLS) revealed that neither cationization or PEGylation nor cationization and 
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PEGylation led to changes in the particle homogeneity as indicated by the 
polydispersity index; all batches still exhibited PDIs below 0.1. 
Quantification of the PEGylation reaction via AF4 
During the intended quantification of the PEGylation of gelatin nanoparticles 
there are two requirements to be met in order to succeed. First, the baseline 
separation of the analytes has to be guaranteed and second, the linear relation 
between PEG and its detection signal intensity has to be proven.  
Figure 1.5.1 shows the cross-flow profile of the separation procedure developed 
for the fractionation of PEG and gelatin nanoparticles and the resulting RI signal of 
PEG. Refractive index detection was chosen due to the poor spectrophotometric 
properties of PEG. The squares indicate the changes in the instrument’s running 
mode and in the cross-flow strength respectively.  
 
 
 
 
 
 
 
 
 
Figure 1.5.1 Cross-flow profile and resulting RI signal of PEG 5000 
 
Note that in comparison to cross flow-profiles displayed in Figure 1.2.3 and 
Figure 1.2.4 for the oligonucleotide-loading quantification experiments the cross 
flow is as well plotted for injection (0 - 3 min) and focusing (3 - 5 min) both taking 
place during AF4 analysis prior to separation, which starts after 8 min. This 
presentation was chosen to highlight the pressure sensitivity of the RI signal [Colfen 
et al., 2000]. It is reflected by a baseline shift at 3, 9, and 19 min as well as peaks at 
8 min and 25 min. The chosen cross-flow conditions provide a constant baseline in a 
time frame between 9 and 19 min, necessary for a reproducible calculation of the 
AUC and finally the quantification of PEG (Figure 1.5.2  a and b). 
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Figure 1.5.2 The fractogram section showing a) the peak of PEG 5000, c = 1 mg/mL and b) the 
respective baseline recorded with water 
 
Before terminating the cross-flow after the period of 10 min of a constant 
baseline the analyte is completely eluted. The graph exhibits a shoulder on the 
descending arm of the peak indicating the presence of higher molecular weight 
compounds than PEG 5000 and therefore certain heterogeneity of the PEG size 
distribution. These data are confirmed by the specification from the manufacturer. 
Due to its anionic polymerization PEG has a certain variance in the number of 
ethylene oxide units [Nektar Therapeutics, 2006]. Since the whole amount of 
unbound PEG present in the particular reaction medium should be quantified, there 
was no emphasis laid on a further separation of the PEG sample specimens. The 
separation of unbound PEG from its reaction partner, the gelatin nanoparticles, is 
especially important, as the nanoparticles show certain RI response and are therefore 
able to disturb the PEG quantification. After adjusting the cross-flow aiming at a 
good PEG peak symmetry the afterwards reduced cross-flow enables the controlled 
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elution of the nanoparticles sufficiently separated from PEG. Figure 1.5.3 shows the 
successful separation of PEG and gelatin nanoparticles. Since there is only a weak RI 
signal arising from the gelatin nanoparticles an overlay of UV and RI detection is 
shown. Compared with the basic method shown in Figure 1.2.5 it was now modified 
to the point of a prolonged elution step (plus 10 min) after abandoning the cross-
flow. This prolonged duration enables a more complete elution of the nanoparticles 
from the AF4 channel subsequent to separation.  
 
 
 
 
 
 
 
 
 
Figure 1.5.3 Separation of PEG 5000, c = 1 mg/mL and gelatin nanoparticles highlighted by the 
overlay of the concurrently recorded UV260 (gelatin nanoparticles) and RI (PEG 5000) signal. 
 
To achieve a calibration curve describing the correlation of the detection signal 
intensity with the PEG concentration a row of PEG containing solutions with rising 
concentrations was investigated. Figure 1.5.4 displays the stepwise appearance of the 
fractograms related to the increasing mass of PEG per sample.  
 
 
 
 
 
 
 
 
 
Figure 1.5.4 The fractogram section showing the peak of PEG 5000; peak hight and AUC are 
decreasing with injecting reduced amounts of PEG; concentrations of the injected samples were 
adjusted to 1 mg/mL (1), 0.5 mg/mL (2), 0.25 mg/mL (3), 0.125 mg/mL (4), and 0.0625 mg/mL (5) 
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Plotting the resulting AUC of each peak versus the according PEG concentration 
the expected linear relation could be proven and a straight calibration curve 
(R2 = 0.9992) was obtained (Figure 1.5.5). After establishing the analytical basis, the 
PEGylation reaction was conducted with four different initial PEG concentrations 
“offered” to a constant amount of gelatin nanoparticles. The idea behind was to 
determine a threshold of PEG above which a further PEGylation will not take place 
even with increasing amounts of PEG. 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.5 Calibration curve of PEG 5000 based on the AUCs calculated from the respective 
fractograms displayed in Figure 1.5.4 
 
To follow the course of the PEGylation reaction PEG was analyzed twice. A 
defined amount of PEG was first determined in the absence of gelatin nanoparticles 
and in a second step PEG was measured directly in the reaction media after 
separation from the now PEGylated gelatin nanoparticles. Based on the calibration 
curve the respective mass of PEG could be calculated from the obtained AUCs. 
The decrease of the AUC determined for PEG caused by its consumption during 
the PEGylation reaction is visualized in Figure 1.5.6. Exemplarily shown for two of 
the investigated concentrations, the comparison of the fractograms recorded before 
and after the PEGylation reveals this consumption. In contrast to the single-stranded 
oligonucleotide-loading studies the according detection signal of the nanoparticles 
could not be exploited in terms of a grown AUC in response to the PEGylation. On 
the one hand PEG is inaccessible for UV detection and on the other hand the RI 
detection signal of the nanoparticles arises only weakly direct upon to a baseline shift 
(Figure 1.5.3) caused by the cross-flow gradient (Figure 1.5.1), which negatively 
affects reproducibility. 
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Figure 1.5.6 Fractograms of PEG 5000 before (1b) / (2b) and after (1a) / (2a) the PEGylation of 
gelatin nanoparticles, the decrease of the particular AUC reflects the degree of the PEGylation; initial 
PEG concentrations were adjusted to 1 mg/mL (1b) and 0.25 mg/mL (2b) 
 
From the resulting AUCs the particular amounts of PEG bound onto the surface 
of the nanoparticles were determined. The amount of bound PEG was calculated by 
the following equation [Zwiorek, 2006]: 
 
m0 = initially administered mass of mPEG-NH2 
mX = mass of mPEG-NH2 being loaded onto the nanoparticles 
AUC0 = 
AUC of the RI signal being detected for the amount m0 of 
mPEG-NH2 before incubation 
AUCX = 
AUC of the RI signal being detected for the amount mX of 
residual free mPEG-NH2 after incubation 
 
Figure 1.5.7 shows the mass of bound PEG plotted against the initially 
administered PEG. From the hyperbolic shape of the resulting curve it is obvious that 
the amount of PEG bound onto the surface of a given number of gelatin 
nanoparticles is limited. We could determine a maximum mass of ~0.350 mg PEG 
per mg gelatin nanoparticles that can be completely bound. PEG administered in 
lower concentrations (0.125 mg and 0.25 mg per mg nanoparticles) is almost 
completely bound, whereas the application of higher amounts of PEG did not lead to 
a further PEGylation of the nanoparticles. In a comparable context Xu et al. 
determined an amount of 0.01 to 0.02 mg PEG 5000 monomethyl ether incorporated 
into 1 mg silica nanoparticles with a FT-IR based quantification method. But, due to 
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some technical considerations they did not chose optimum conditions that may lead 
to higher degrees of PEGylation [Xu et al., 2003]. 
 
 
 
 
 
 
 
 
 
Figure 1.5.7 Mass of PEG 5000 bound onto 1 mg nanoparticles in dependency of the initially 
applied amount of PEG 
 
Referred to the PEGylation mechanism as it is shown in Figure 1.2.1 a limited 
number of monofunctionally bound glutraraldehyde is accessible for PEGylation, 
thus leading to the assumed threshold. Applying a validated process for the 
manufacturing of the gelatin nanoparticles the number of free aldehyde groups is 
held constant for each nanoparticle batch.  
Finally, we could show the pH dependency of the PEGylation process. As the 
coupling of aldehydes with primary amino groups demands slightly alkaline 
conditions we could show a successful PEGylation in borate buffer pH 8.4. When 
changing the pH towards an acidic value of pH 3.0 the fractograms showed identical 
peaks for PEG control solutions and PEG derived from the incubation process (data 
not shown). These data prove the assumed influence of the pH on the coupling 
reaction and provides at the same time a successful negative control for the described 
quantification procedure. This could be verified by control studies additionally 
performed in the absence of gelatin nanoparticles that revealed unchanged detection 
signals for each applied PEG concentration thus demonstrating the successful 
PEGylation. 
Figure 1.5.6 and Figure 1.5.7 have as well been published by Klaus Zwiorek 
[Zwiorek, 2006] with permission of the author (Jan Carl Zillies). But, the pertaining 
data have been produced in the course of this thesis. 
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Visualization of the PEGylation reaction via AFM 
The images derived from AFM analysis of the cationized versions of the non 
PEGylated and the PEGylated nanoparticles are depicted below (Figure 1.5.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.8 AFM images of plain (A1/A2) and PEGylated (B1/B2) gelatin nanoparticles; A/B 1: 
error channel image, A/B 2: height channel image [pictures provided by Christian Löbbe from JPK 
Instruments, Berlin, Germany] 
 
Overview images being employed in the amplitude mode demonstrated the good 
homogeneity of the applied samples (Figure 1.5.8 A1 / B1). No significant 
differences between both batches were seen. So, previous SEM data, where gelatin 
nanoparticles were assessed as homogeneous smooth spheres, were substantiated 
(data not shown). But, analyzing height images, PEGylated nanoparticles seemed to 
possess an indifferent surface (Figure 1.5.8 A2 / B2). Observing the respective cross 
sections of these height images finally revealed more detailed information (Figure 
1.5.9). Converse to the smooth surface of plain gelatin nanoparticles, PEGylated 
nanoparticles exhibited a cragged surface when analyzing their height profile, which 
indicates the presence of PEG-chains on the nanoparticles’ surface. 
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Figure 1.5.9 AFM analysis of a) plain and b) PEGylated gelatin nanoparticles; diagrams represent 
the respective cross sections of height images displayed in Figure 1.5.8 (cp. black lines) [diagrams 
provided by Christian Löbbe from JPK Instruments, Berlin, Germany] 
 
The displayed AFM pictures could thus contribute to the proof of a successful 
PEGylation of gelatin nanoparticles by a direct, independent method. 
1.5.3 Summary 
After establishing AF4 in the work with gelatin nanoparticles (see chapter 1.4) 
this method could be used for further analysis of modified gelatin nanoparticles. The 
quantitative description of the PEGylation process of gelatin nanoparticles via an 
AF4 separation followed by a direct RI detection was shown. With regard to the 
broad separation range AF4 spans, an application of the described analytical set-up in 
other PEGylation (e.g. the PEGylation of proteins) and PEG quantification (e.g. the 
release from controlled release devices) scenarios seems to be possible. 
AFM, as the second analytical tool, completed the set of data and demonstrated 
its strength by visualizing the presence of PEG chains on the nanoparticles’ surface. 
Especially the combination of both techniques appears to be ideal to track the 
PEGylation of colloidal carrier systems. The results obtained are of high quality and 
suggest using both methods as state-of-the-art analysis for various other colloidal 
systems as the number of existing techniques is rather limited. 
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1.6 Concluding Remarks 
In the beginning of this work research in colloidal drug delivery utilizing gelatin 
nanoparticles and in investigating aggregation in protein pharmaceuticals via AF4 
were separately pursued in our department. Based on the idea to merge these two 
areas, an AF4 protocol was established that enabled the quantification of single-
stranded oligonucleotide-loading onto gelatin nanoparticles. The limits of this 
quantitative analytical approach were reached while describing the loading of gelatin 
nanoparticles with a double-stranded oligonucleotide, which could be referred to 
certain methodical restrictions. Furthermore, insights into the manufacturing process 
of gelatin nanoparticles were gained as the molecular weight distribution of the 
gelatin bulk material could be characterized by coupling AF4 and MALS detection. 
Finally, the knowledge acquired during the quantification of oligonucleotide-loading 
onto gelatin nanoparticles could be transferred to their PEGylation. Due to the poor 
spectrophotometrical properties of PEG, quantifying the PEGylation was not 
accessible via centrifugation and UV-spectroscopy as it was known from 
oligonucleotide loading. This hindrance was successfully circumvented by 
employing the combination of AF4 separation and RI detection. 
The reported studies prove the outstanding ability of AF4 to separate dissolved 
from suspended samples during one sample run. And, in the end asymmetrical flow 
field-flow fractionation can now be stated as well established in the work with 
gelatin nanoparticles providing the basis for future work in the field of colloidal drug 
carrier analysis. 
 
The reported work comprises analytical data and results from nanoparticle 
preparation. The first attempts in analyzing gelatin nanoparticles by AF4 were 
accomplished by Wolfgang Fraunhofer at this chair. He as well described gelatin 
bulk matrial via SE-HPLC/MALS. The quantification of single-stranded 
oligonucleotide-loading of gelatin nanoparticles was conducted together with him to 
continue the work with AF4 after he would have had finished his Ph.D. thesis. Klaus 
Zwiorek in turn contributed to the practical realization of the analytical data from 
gelatin bulk material investigations by AF4/MALS. He developed the described one-
step desolvation procedure for the preparation of gelatin nanoparticles and he 
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provided PEG-modified gelatin nanoparticles for the quantification of the 
PEGylation process via AF4/RI. AFM anaylsis was conducted by Christian Löbbe at 
JPK Instruments, Berlin, Germany. 
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CHAPTER II 
Formulation Development of Freeze-Dried Gelatin 
Nanoparticles 
Abstract 
Researching gelatin nanoparticles spans preparation technology as well as 
application in various in vitro and in vivo test systems. To provide a convenient 
nanoparticle formulation for their application either in research or (potentially in 
future) in clinical studies the freeze-drying properties of gelatin nanoparticles were 
evaluated. During these studies successful freeze-drying and rehydration of gelatin 
nanoparticles could be demonstrated. Various freeze-drying excipients and different 
rehydration volumes were as well investigated as the drying of empty and 
DNA / RNA oligonucleotide-loaded gelatin nanoparticles. An NF-κB decoy 
oligonucleotide-loaded gelatin nanoparticle formulation could be developed and was 
successfully applied in a drug targeting approach in an animal model. Finally short 
term storage stability of empty and oligonucleotide-loaded gelatin nanoparticles 
under accelerated conditions was assessed utilizing sucrose, trehalose, mannitol, as 
well as mannitol and sucrose in the ratio of 4:1 as freeze-drying excipients. Size, size 
distribution, residual moisture content, and cake morphology were investigated. 
Sucrose and trehalose containing formulations provided the best results and mannitol 
containing formulations showed notable stabilization despite their crystalline nature. 
 
Keywords: freeze-drying, gelatin nanoparticles, colloidal stability, formulation 
development 
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2.1 Introduction 
The application of nanoparticles in targeted drug delivery has already been 
reviewed more than 20 years ago [Oppenheim, 1981; Douglas et al., 1987]. Since 
then enormous progressions have been made in the development of nanoparticulate 
drug carrier systems, prepared of a broad variety of starting materials, for numerous 
drugs and therapeutic applications. However, despite intensive research work the 
current status of colloidal drug delivery still reveals liposomes ahead of nanoparticles 
in terms of marketed pharmaceuticals [Gruber, 2004; Wagner et al., 2006]. During 
the step of drug development shelf live and stabilization of the respective products 
are an important matter of interest. In this context lyophilization was already 
proposed in 1978 to improve long term stability of liposomes [Van Winden et al., 
1997], which finally led to the market authorization for AmbisomeTM as the first 
freeze-dried liposomal drug formulation in Germany in 1992 (source: homepage of 
the manufacturer*) and in the USA in 1997 (source: U.S. Food and Drug 
Aministration#). Freeze-drying as industrial process is in general known since 
World War II [Franks, 1998] and is widely applied in stabilizing pharmaceuticals 
especially labile drugs like proteins [Tang et al., 2004]. Furthermore, freeze-drying 
of liposomes has been intensively investigated and was recently summarized by Van 
Winden [Van Winden, 2003]. Nanoparticles in contrast are still part of basic research 
and only little is reported about their freeze-drying properties in general. Several 
authors report about freeze-drying in the end of the manufacturing process of their 
respective systems but did not provide further information about the applied freeze-
drying cycle or particle characteristics before and after lyophilization. Others gave 
some more detailed information about the freeze-drying procedure but only chitosan, 
poly(lactide) (PLA) / poly(lactide-co-glycolide) (PLGA), and solid lipid 
nanoparticles (SLN) as well as nanoparticulate lipid- or polycation-DNA complexes 
(by the group of Anchordoquy) were more precisely investigated for their freeze-
drying properties. Table 2.1.1 lists nanoparticle preparations originating form 
different starting materials that have already been freeze-dried according to literature. 
 
 
 
 
*http://www.gilead-sciences.de/index.php?csrc=http://www.gilead-sciences.de/public/01gilead/c_meilensteine.htm 
#http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist 
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Table 2.1.1 Freeze-dried nanoparticle preparations that have already been described in literature 
 
Nanoparticle preparation References 
Crosslinked acrylamido-2-desoxy-glucose (AADG) 
nanoparticles [Nimesh et al., 2006]
 1 
Chitosan-DNA nanoparticles [Mao et al., 2001] 1 
Core-shell type lecithin / Pluronic® nanoparticles [Oh et al., 2005] 
Core-shell type poly(γ-glutamic acid) (γ –PGA) / L-
phenylalanineethylester (L-PAE) nanoparticles [Akagi et al., 2005] 
Gelatin nanoparticles [Kaul et al., 2002; 2004; 2005]
 1 
[Farrugia et al., 1999] 1 
Glucomannan-coated chitosan nanoparticles [Cuna et al., 2006] 
Lipid-DNA complexes [Allison et al., 2000] [Molina et al., 2004] 
Polyethylenimine (PEI)-DNA complexes (Polyplexes) 
[Armstrong et al., 2004] 
[Anchordoquy et al., 2005] 
[Brus et al., 2004] 
[Talsma et al., 1997] 
Poly-ε-caprolactone nanospheres / nanocapsules 
[de Chasteigner et al., 1996] 
[Abdelwahed et al., 2006b] 
[Choi et al., 2004] 
Poly(isobutylcyanoacrylate) (PIBCA) nanoparticles [Layre et al., 2006] 
Poly(L-lactic acid) (PLA) nanoparticles 
[Hirsjarvi et al., 2006] 
[Bala et al., 2004]2 
[De Jaeghere et al., 2000] 
Poly(lactide-co-glycolide) (PLGA) 
[Avgoustakis, 2004] 
[Birnbaum et al., 2000] 
[Jeong et al., 2005] 
Poly(methylidene malonate 2.1.2) nanoparticles [Roy et al., 1997] 
Solid lipid nanoparticles (SLN) [Maeder et al., 2005]
2 
[Schwarz et al., 1997] 
 
1Data without further information about the freeze-drying cycle or particle characteristics before and after lyophilization 
2Review articles 
 
Based on the (re-)introduction of gelatin nanoparticles into the field of colloidal 
oligonucleotide and plasmid DNA delivery by Coester [Coester et al., 2000; Coester, 
2003] our research group gained comprehensive knowledge and experience in 
several in vitro and in vivo applications of gelatin nanoparticles reflected by the 
dissertation of Klaus Zwiorek [Zwiorek, 2006] and this thesis. As all data obtained 
from these studies were produced with regard to a later potentially marketed 
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pharmaceutical product a need for gelatin nanoparticle formulations that are easy to 
ship, to handle, and to store arose in the meantime. In consequence the aim of the 
present work was to show the principle applicability of freeze-drying for gelatin 
nanoparticles and to systematically describe their freeze-drying properties. So, 
different common freeze-drying excipients namely, sucrose and trehalose as well as 
mannitol known for their good lyoprotecting and bulking properties respectively 
[Kim et al., 1998; Wang, 2000] were assessed for their stabilizing potential of empty 
and oligonucleotide-loaded gelatin nanoparticles. The rehydration volume was varied 
and the storage stability was intensively studied. In all cases the integrity of size and 
size distribution of nanoparticles subsequent to freeze-drying are most important and 
were followed by photon correlation spectroscopy (PCS). In evaluating storage 
stability residual moisture content and structural changes of the lyophilized products 
have in addition to be taken into account. Thus, Karl-Fischer titration and differential 
scanning calorimetry (DSC) were utilized in this context. 
Initial freeze-drying experiments took place during a research stay in the labs of 
Prof. Thomas J. Anchordoquy at the School of Pharmacy of the University of 
Colorado in Denver, CO, USA. The work was continued in Munich in the labs of 
Prof. Gerhard Winter at the Department of Pharmacy, Pharmaceutical Technology 
and Biopharmaceutics of the Ludwig-Maximilians-University Munich, Germany. 
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2.2 Materials and Methods 
Reagents 
Reagent Description Supplier 
Acetone p.a. VWR International GmbH (Ismaning, Germany) 
Acetoned p.a. Fischer Scientific L.L.C. (Pittsburgh, PA, USA) 
Cholaminechloride 
hydrochloride 
(2-aminoethyl)-trimethyl- 
ammoniumchloride hydrochloride 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
Dextran 3000  Spectrum Chemical Corp (New Brunswick, NJ, USA) 
DMF Dimethylformamide, < 50ppm water Acros Organics (Morris Plains, NJ, USA) 
ds NF-κB decoy ODN  5´-AGT TGA GGG GAC TTT CCC AGG C-3´ phophorothioate 
biomers.net GmbH 
(Ulm, Germany) 
ds scr decoy ODN 5´-CCT TGT ACC ATT GTT AGC C-3´ phosphorothioate 
biomers.net GmbH 
(Ulm, Germany) 
ds siRNA ODN 5’-CUG GAC UUC CAG AAG AAC A-3’ amidate 
Sirna Therapeutics, Inc. 
(Boulder, CO, USA) 
EDC 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
Gelatin type A 175 Bloom Sigma-Aldrich GmbH (Taufkirchen, Germany) 
Glutaraldehyde 25 % aqueous solution  Sigma-Aldrich GmbH (Taufkirchen, Germany) 
HCl 2 N VWR International GmbH (Ismaning, Germany) 
HCld 2 N Fischer Scientific L.L.C. (Pittsburgh, PA, USA) 
D-Mannitol Riedel-de Haën, p.a. Sigma-Aldrich GmbH (Seelze, Germany) 
D-Mannitold  Ferro Pfanstiehl Lab., Inc (Waukegan, IL, USA) 
Sucrose  Suedzucker AG (Mannheim, Germany) 
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Reagent Description Supplier 
Sucrosed  Ferro Pfanstiehl Lab., Inc (Waukegan, IL, USA) 
Trehalose α, α-Dihydrate Ferro Pfanstiehl Lab., Inc (Waukegan, IL, USA) 
Tween® 80 Polysorbat 80, Ph. Eur. Merck KGaA (Darmstadt, Germany) 
 
dSame excipients from different suppliers utilized during formulation development experiments conducted at the School of 
Pharmacy of the University of Colorado in Denver, CO, USA and at the Department of Pharmacy, Pharmaceutical Technology 
and Biopharmaceutics of the Ludwig-Maximilians-University Munich, Germany are listed twice. 
Preparation and surface modification of gelatin nanoparticles 
Gelatin nanoparticles were manufactured by the two step desolvation method 
and optionally surface modified (cationized) with cholamine as described in 
chapter 1.2. 
Oligonucleotide-loading of gelatin nanoparticles 
NF-κB decoy, scr decoy and siRNA oligonucleotide-loading was accomplished 
in highly purified water. 47.3 µL of an aqueous nanoparticle dispersion containing 
1.700 µg surface modified gelatin nanoparticles were incubated with 85 µg or rather 
170 µg of the respective oligonucleotide in aqueous solution (i.e., 5 % or 10 % [w/w] 
oligonucleotide loading) and adjusted with varying freeze-drying excipient 
containing solutions to a final volume of 1,200 µL for two 2 h at 22 °C and 800 rpm 
under constant shaking (Thermomixer Comfort, Eppendorf AG, Hamburg, 
Germany). 
Freeze-drying of empty and oligonucleotide-loaded gelatin nanoparticles 
Empty gelatin nanoparticles and gelatin nanoparticle formulations loaded with 5 
and 10 % [w/w] oligonucleotide containing 1.4 µg/mL nanoparticles were prepared 
in solutions of mannitol, mannitol and sucrose in a ratio of 4:1, sucrose, and trehalose 
exhibiting varying concentrations related to the oligonucleotide content, even if no 
oligonucleotide was added. The following excipients to oligonucleotide mass ratios 
were investigated: 47, 100, 200, 300, 400, 500, 600, 700, 800, 900, and 1000, 
representing a total amount of 0.3 up to 7 % [w/v]. After preparation aqueous 
nanoparticle dispersions were transferred to glass vials for freeze-drying. During 
Freeze-Drying of Gelatin Nanoparticles 
71 
initial formulation development experiments 300 µL per vial were filled in 1R glass 
vials (West Pharmaceutical Services, Inc., Lionville, PA, USA), later samples 
prepared for storage stability and animal studies contained 300 µL and 1,200 µL per 
vial respectively in 2R glass vials (Schott AG, Mainz, Germany) prior freeze-drying.  
 
 
 
 
 
 
 
 
 
Figure 2.2.1 Freeze-drying cycles with shelf temperature (□) and chamber pressure (○) applied 
for all samples during formulation development experiments performed at the School of Pharmacy of 
the University of Colorado in Denver, CO, USA 
 
Freeze-drying during formulation development in the labs of Prof. Thomas J. 
Anchordoquy at the School of Pharmacy of the University of Colorado in Denver, 
CO, USA was conducted in a Dura-Stop™ lyophilizer (FTS Systems, Inc., Stone 
Ridge, NY, USA) following the above stated freeze-drying cycle (Figure 2.2.1). 
Samples prepared for storage stability and animal studies in the labs of the 
Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics of the 
Ludwig-Maximilians-University Munich, Germany were freeze-dried in an 
EPSILON 2- 6D pilot scale freeze dryer and an EPSILON 2- 12D freeze dryer 
respectively (Martin Christ Freeze Dryers GmbH, Osterode, Germany). Nanoparticle 
formulations containing mannitol-sucrose (4:1), sucrose, and trehalose were dried 
with the freeze-drying cycle shown in Figure 2.2.2. Mannitol containing samples 
were dried at increased temperature and pressure as displayed in Figure 2.2.3. Upon 
completion of the respective cycles the chamber was vented with nitrogen, samples 
were stoppered under slight vacuum at 800 mbar, and the sealed vials were stored at 
20 °C. Rehydration was conducted with different volumes of highly purified water 
ranging from 1/30th of the original volume to the original volume. All samples were 
prepared in triplicates. Where used, placebos were accordingly prepared without the 
addition of gelatin nanoparticles or oligonucleotide. 
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Figure 2.2.2 Freeze-drying cycles with shelf temperature (□) and chamber pressure (○) for 
lyophilization of mannitol-sucrose (4:1), sucrose, and trehalose containing samples prepared for 
storage stability and animal studies 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.3 Freeze-drying cycles with shelf temperature (□) and chamber pressure (○) for 
lyophilization of mannitol containing samples prepared for storage stability and animal studies 
 
Storage conditions during stability studies 
Samples were stored under accelerated conditions in sealed vials at 30 °C and 
40 °C as well as open vials at 30 °C / 30 % relative humidity (RH) and 
30 °C / 60 % RH. Storage was performed for 4 weeks and 10 weeks in drying 
chambers, whereas defined relative humidity was adjusted in closed containers by 
saturated solutions of magnesium chloride (maintaining 30 % RH at 30 °C) and 
ammonium nitrate (maintaining 60 % RH at 30 °C). 
Characterization of gelatin nanoparticles 
Size determination of gelatin nanoparticle batches was conducted by dynamic 
light scattering (DLS) using a Nicomp 380 Particle Sizer (Particle Sizing Systems, 
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Santa Barbara, CA, USA) and a Nanosizer ZS (Malvern Instruments, Worcestershire, 
UK). In contrast to the polydispersity index (PDI) calculated by the Malvern 
software, the Particle Sizing Systems instrument expresses the width of the size 
distribution by a so called coefficient of variation. As the results of the initial 
formulation development experiments are acquired with the Nicomp 380 Particle 
Sizer, their quality is estimated by means of this coefficient. Prior to measurements 
samples were diluted 10x in highly purified water. 
Karl-Fischer titration 
Residual moisture content of samples was determined by coulometric Karl-
Fischer titration either with a Mettler DL37 Coulometer (Mettler-Toledo, Inc., 
Columbus, OH, USA) or with an Aqua 40.00 titrator comprising a headspace module 
(Analytik Jena AG, Halle, Germany). Using the DL37 Coulometer samples were 
dissolved in anhydrous DMF and sonicated prior to analysis. The exact mass of DMF 
was determined gravimetrically. Samples were prepared in a dry-nitrogen-purged 
glove box to avoid hydration resulting from atmosphere. Aliquots were withdrawn 
with a syringe through the rubber stopper of the instrument to the titration solution 
(Pyridine Free Vessel Solution, Photovolt Instruments, Inc., St. Louis Park, MN, 
USA) where the water amount was determined. Blank values of DMF were acquired 
with every test series. For measurements with the Aqua 40.00 titrator no further 
sample preparation was necessary. After placing into the headspace module samples 
were heated up to 80 °C and the evaporated water was transferred to the titration 
solution (HYDRANAL®-Coulomat AG, Riedel-de Haën, Sigma-Aldrich GmbH, 
Seelze, Germany), where its amount was determined. Blank values were obtained 
from empty vials identically treated like verum samples throughout preparation and 
storage. 
Differential scanning calorimetry (DSC) 
DSC was used to study the glass transition of the maximally freeze-concentrated 
solution (Tg’) of gelatin nanoparticle formulations and depending on the applied 
freeze-drying excipient glass transition (Tg) or melting temperature (mp) of 
lyophilized verum and placebo samples. Around 20 mg of liquid samples and with 
respect to the investigated formulation between 1 and 8 mg of the dried samples, 
handled in a dry-nitrogen-purged glove box to avoid hydration resulting from 
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atmosphere, were analyzed in crimped aluminum crucibles. Tg’ was determined with 
a Perkin-Elmer Diamond DSC (PerkinElmer, Inc., Wellesley, MA, USA). Tg and mp 
respectively were determined with a Netzsch 204 Phoenix® DSC (Netzsch-
Geraetebau GmbH, Selb, Germany). Applied temperature programs are summarized 
in Table 2.2.1 a) and b). 
Table 2.2.1 a) Temperature programs for determination of Tg’ of sucrose containing gelatin 
nanoparticle formulations and of Tg of sucrose and trehalose containing gelatin nanoparticle (verum) 
and placebo formulations 
 
Tg’suc Tg suc Tg tre 
T[°C] Scanning rate / Time T[°C] 
Scanning 
rate / Time  T[°C] 
Scanning 
rate / Time  
25 1 min 0 1 min 0 1 min 
25 → -50 2.5 K/min 0 → 80 10 K/min 0 → 130 10 K/min 
-50 10 min 80 1 min 130 1 min 
-50 → 25 10 K/min 80 → -10 10 K/min 130 → -10 10 K/min 
  -10 1 min -10 1 min 
  -10 → 150 10 K/min -10 → 180 10 K/min 
  150 1 min 180 1 min 
  150 → 20 50 K/min 180 → 20 50 K/min 
 
Table 2.2.1 b) Temperature programs for determination of mp of mannitol and mannitol and 
sucrose in a ratio of 4:1 containing gelatin nanoparticle (verum) and placebo formulations 
 
mpman mpman-suc 
T[°C] Scanning rate / Time T[°C] 
Scanning 
rate / Time  
0 1 min 0 1 min 
0 → 80 10 K/min 0 → 80 10 K/min 
80 1 min 80 1 min 
80 → -10 10 K/min 80 → -10 10 K/min 
-10 1 min -10 1 min 
-10 → 180 10 K/min -10 → 180 10 K/min 
180 1 min 180 1 min 
180 → 20 50 K/min 180 → -10 10 K/min 
  -10 1 min 
  -10 → 180 10 K/min 
  180 1 min 
  180 → 20 50 K/min 
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Glass transition (point of inflection) of the maximally freeze-concentrated 
solution (Tg’), glass transition (point of inflection) (Tg), and melting temperature 
(peak) (mp) of the excipients were determined from heating scans. 
In vivo hepatic lipopolysaccharide (LPS) (sepsis) rat model 
To evaluate, beside the quality, the biological function of nanoparticulate bound 
NF-κB decoy oligonucleotide after storage formulations were tested in an in vivo 
LPS rat model established during the work described in chapter 3.4. Experiments 
were conducted twice for each nanoparticle formulation. During the experiments 
lipopolysaccharides (LPS) were used as exogenous stimulus for the NF-κB activation 
within rat liver. The NF-κB decoy oligonucleotide delivered on the surface of the 
gelatin nanoparticles binds to the activated transcription factor which is in the 
following no longer available for detection during the electrophoretic mobility shift 
assay (EMSA) conducted after terminating the animal experiment. For the detailed 
mechanism of the decoy effect it is referred to chapter 3.1.4. A successful inhibition 
of NF-κB in vivo can be proven by diminished or even erased NF-κB bands from the 
electrophoresis gel of the shift assay. For a detailed description of the experiments 
and the subsequent determination of the NF-κB activity via EMSA it is referred to 
the according sections of chapter 3.4.  
All animal studies and electrophoretic mobility shift assays were conducted by 
Florian Hoffmann at the department of pharmaceutical biology of the Ludwig-
Maximilians-University Munich, Germany. 
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2.3 Results and Discussion 
2.3.1 Applicability of freeze-drying for gelatin nanoparticle suspensions 
Characterization of nanoparticles 
During the initial experiments conducted in the labs of the School of Pharmacy 
of the University of Colorado in Denver a Nicomp 380 Particle Sizer was available 
for particle size determination. The coefficient of variation calculated by the Nicomp 
software to describe the quality of the particle size distribution varies within broader 
ranges than it is known from the polydispersity index determined with particle sizing 
machines from Malvern Instruments. To compare coefficient of variation data 
obtained for gelatin nanoparticles manufactured in the Denver labs and 
polydispersity indices samples were shipped to Munich and analyzed with a 
Nanosizer ZS. Interestingly, even high coefficients of variation represent 
homogenously distributed nanoparticle populations with polydispersity indices 
clearly below 0.100. These findings are in good accordance to the optical properties 
of the nanoparticle suspensions macroscopically assessed. All suspensions exhibited 
the typical opalescent appearance without any visible particulate matter. In addition, 
particle sizes slightly vary with the emphasis on bigger numbers determined with the 
Nanosizer ZS. Data from particle size analysis of gelatin nanoparticles applied 
during freeze-drying experiments are summarized in Table 2.3.1.  
Table 2.3.1 Size, coefficient of variation, polydispersity, and surface charge of the nanoparticle 
formulations applied in the freeze-drying applicability studies 
 
 
Gelatin 
nanoparticles 
Surface modified 
gelatin nanoparticles 
 GNPCO3 GNPCO5 GNPCO3pos GNPCO4pos 
Nanosizer ZS 160.9 172.0 185.6 n/a* 
size [nm] 
Nicomp 380 
Particle Sizer 122.9 174.3 151.7 190,2 
PDI Nanosizer ZS 0.061 0.032 0.087 n/a* 
coefficient 
of variation 
Nicomp 380 
Particle Sizer 0.343 0.213 0.501 0.641 
 
*As aggregation of gelatin nanoparticles occurred during storage this batch was no longer available for particle sizing after 
the return to Munich 
 
Freeze-Drying of Gelatin Nanoparticles 
78 
Initial freeze-drying experiments 
Good stabilizing properties of sucrose are well known for freeze-dried protein 
pharmaceuticals [Wang, 2000]. In addition, successful stabilization of viral and non 
viral gene delivery systems during freeze-drying by adding sucrose is reported [de 
Chasteigner et al., 1996; Talsma et al., 1997; Anchordoquy et al., 2005; Jeong et al., 
2005]. Thus, sucrose was chosen as lyoprotectant for the first freeze-drying attempts. 
As the later aim of the experiments was to develop a freeze-dried formulation for 
oligonucleotide-loaded gelatin nanoparticles, the amount of sucrose was calculated 
related to the mass of the oligonucleotide present in particular formulations based on 
a 5 % [w/w] oligonucleotide-loading on gelatin nanoparticles. The sucrose to ODN 
ratio was adjusted in increments of 100 ranging from 0 to 1000, which at the same 
time arises the formulation’s denomination. At the same time masses of 
oligonucleotide and nanoparticles were kept constant for all formulations. The 
resulting sucrose amount and the formulation name were applied over all studies 
conducted with and without oligonucleotide. 
The freeze-drying cycle stated above (Figure 2.2.1) was adopted from the work 
of Prof. Anchordoquy and his group with liposomes and polyplexes after checking 
the Tg’ of sucrose containing gelatin nanoparticle suspensions to be above the chosen 
freezing temperature of -40 °C (Table 2.3.2). Tg’ was investigated for pure 
nanoparticle suspensions (0) and for the lowest (100) and the highest (1000) applied 
sucrose amount. Values for sucrose containing formulations are confirmed by Liu as 
well as Her and Nail [Her et al., 1994; Liu, 2006]; they saw as well the slight 
increase of Tg’ as a function of concentration of sucrose as it can be taken from data 
displayed in Table 2.3.2 [Her et al., 1994]. 
Table 2.3.2 Tg’ (point of inflection) of sucrose containing freeze-drying solutions / suspensions 
of empty gelatin nanoparticles (GNPCO3) 
 
Formulation Tg’ [°C] Stdv [°C] 
0 -34.47 0.04 
100 -33.40 0.11 
1000 -31.69 0.07 
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The same observation was made by Allison for nanoparticulate lipid-DNA 
complexes. Tg’ ranged from -37.2 °C to -31.6 °C with increasing sucrose to DNA 
ratio [Allison et al., 2000]. For freeze concentrated, pure nanoparticle suspensions 
the glass transition could be determined slightly below Tg’ of sucrose containing 
formulations. No Tg’ was observed for pure poly(D,L-lactic-glycolic) (PLGA) 
nanoparticle suspensions [Saez et al., 2000] and DOTAP/DOPC liposomes in a 
comparable set-up (Michael Wiggenhorn, personal communication). Formulated 
with sucrose Tg’ of polycaprolactone (PCL) and PLGA nanoparticle suspensions 
appeared at -33 °C [Saez et al., 2000] whereas Ugwu detected a Tg’ of -47.7 °C for 
cholesterol containing DOPC liposomes at the same sucrose to lipid ratio [w/w] like 
formulation 100 [Ugwu et al., 2005]. Interestingly, they reported an increase of Tg’of 
10 °C by doubling the sucrose to lipid ratio which is in contrast to our results that 
show Tg’ to be risen only for 1.24 °C after increasing the sucrose to nanoparticle 
ratio by factor 10. In terms of efficient freeze-drying these findings are advantageous 
as they offer the possibility to optimally dry the different gelatin nanoparticle 
formulations applying the same freeze-drying cycle. 
Results from initial freeze-drying experiments of gelatin nanoparticle 
formulations 100 to 1000 are displayed in Figure 2.3.1 and Figure 2.3.2. With respect 
to size and size distribution a successful stabilization can be stated for all 
investigated formulations. Subsequent to freeze-drying and rehydration none of the 
formulations showed increasing particle sizes or particle aggregation and the 
coefficient of variation remains almost unaffected, which reflects the constant quality 
of the samples (Figure 2.3.1 a) and b). Comparable results from particle sizing could 
be obtained for all formulations despite sucrose amounts rising from formulation 100 
to 1000 by diluting samples prior to PCS analysis, which rules out viscosity derived 
alteration of PCS data. The slightly reduced particle size obtained after rehydration 
may possibly be explained with an incomplete recovery of the swollen state of the 
gelatin nanoparticles present prior to freeze-drying. Nanoparticles are manufactured 
of gelatin in an aqueous surrounding causing certain water content within the 
nanoparticle matrix even after stabilizing them by crosslinking. After nearly 
complete extraction of water during freeze-drying a porous structure of the dried 
nanoparticles can be assumed according to Kang who could demonstrate the porosity 
of crosslinked gelatin scaffolds produced by freeze-drying [Kang et al., 1999].  
Freeze-Drying of Gelatin Nanoparticles 
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.1 a) size and b) coefficient of variation of empty gelatin nanoparticles (GNPCO3) 
formulated with sucrose before freeze-drying and rehydrated right after freeze-drying 
 
Driven by these porous structures certain shrinkage of nanoparticles may occur, 
which is obviously not completely reversible after rehydration expressed in reduced 
hydrodynamic diameter. Reduced particle sizes determined via PCS were as well 
reported by Schwarz for solid lipid nanoparticles dried with trehalose [Schwarz et al., 
1997] and by Abdelwahed for PCL nanoparticles dried with sucrose [Abdelwahed et 
al., 2006a]. PCL nanoparticles dried without further excipients could not sufficiently 
be stabilized, whereas particle growth was correlated with the freezing rate [Choi et 
al., 2004]. Drying of pure gelatin nanoparticle suspensions in contrast led to 
completely aggregated samples where particle size analysis was no longer possible. 
The pertaining residual moisture contents [% (w/w)] are displayed in Figure 
2.3.2 a). All samples exhibit very low water content between 0.2 and 0.4 %. 
Interestingly, values pass through a minimum and do not constantly decrease with 
rising total solid content, as it might be expected for percent declaration. But, with 
respect to the almost identical very low amounts this seems to be negligible.  
0
50
100
150
200
100 200 300 400 500 600 700 800 900 1000
formulation
Si
ze
 [n
m
]
before after
0.000
0.200
0.400
0.600
0.800
1.000
100 200 300 400 500 600 700 800 900 1000
formulation
co
ef
fic
ie
nt
 o
f v
ar
ia
tio
n
before after
a) 
 
 
 
 
 
 
 
 
 
b) 
Freeze-Drying of Gelatin Nanoparticles 
81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.2 a) residual moisture content and b) Tg (point of inflection) of sucrose containing 
formulations of empty gelatin nanoparticles (GNPCO3) right after freeze-drying 
 
The shape of the curve obtained for the glass transition temperatures of the 
formulations reflects the findings of residual moisture analysis with passing through 
a flat maximum (Figure 2.3.2 b). This inversely proportional relationship of 
increased residual moisture and decreased glass transition temperatures of 
amorphous solids is already described by te Booy and was systematically 
investigated by Hancock and Zografi [Te Booy et al., 1992; Hancock et al., 1994]. 
Basically Tg of sucrose is confirmed by literature [Wang, 2000; Liu, 2006]. 
After demonstrating the successful freeze-drying of empty gelatin nanoparticles 
oligonucleotide-loaded gelatin nanoparticles were investigated in the next step. 
Therefore, nanoparticles were loaded with the NF-κB and the scr decoy 
oligonucleotide respectively applied during the in vitro and in vivo studies described 
in CHAPTER III. In addition, siRNA oligonucleotide-loaded gelatin nanoparticles 
were freeze-dried. Stability of oligonucleotide-loading was checked via UV-
spectroscopy before and after freeze-drying and proven to be stable for all 
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investigated formulations (data not shown). Particle sizes and size distributions of scr 
decoy ODN-loaded nanoparticle formulations 100 to 1000 are depicted in Figure 
2.3.3. Again no particle aggregation could be observed and the coefficient of 
variation data express the constant quality of the samples. Solely the formulations 
100 and 200 show minor but significantly increased particle sizes. However, with 
respect to their coefficient of variation obtained after freeze-drying and rehydration 
and their optical properties strong effects on particle quality can be excluded.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.3 a) size and b) coefficient of variation of ds scr decoy ODN-loaded gelatin 
nanoparticles (GNPCO3pos) formulated with sucrose before freeze-drying and rehydrated right after 
freeze-drying 
 
At the same time the impact of the applied oligonucleotide seems to be 
negligible for the outcome of the experiments. According to the manufacturer and to 
literature freeze-drying properties of 18-25 base pair long phosphorothioate ODNs 
(PTOs) are exceptional. Even without any excipients drying is easily possible. 
Aggregation is not induced and the Tg’ as well as the collapsing temperature (Tc) 
between -20 °C and -8 °C fit to the applied freeze-drying cycle resulting in a stable 
amorphous product exhibiting a Tg above 100 °C [biomers.net GmbH, Ulm, 
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Germany personal communication; Jameel et al., 2001]. Only exposure to repeated 
freeze/thaw cycles leads to degradation of oligonucleotides depending on their base 
sequence [Davis et al., 2000]. 
Comparable results were reported by Brus for the stabilization of 
oligonucleotide-polyethylenimine (PEI) complexes during freeze-drying [Brus et al., 
2004]. For the low sucrose to ODN ratios ranging from 5 to 26, compared to 100 
which was the lowest ratio investigated during our work, they saw as well slightly 
increased particle sizes upon freeze-drying with sucrose. Residual moisture and 
thermal properties of ODN-loaded formulations were not investigated as there was 
not enough material, required for a series of triplicate studies of all the investigated 
formulations. 
During the work with NF-κB decoy oligonucleotide-loaded gelatin nanoparticles 
in the hepatic ischemia reperfusion (I/R) injury rat model introduced in chapter 3.4, 
the oligonucleotide amount deliverable per animal study was not high enough to 
initiate the aspired biological effect. Utilizing the oligonucleotide-loading method 
explained in CHAPTER I, based on electrostatic attraction forces of positively 
charged nanoparticles and negatively charged oligonucleotide molecules, it was not 
possible to further increase the concentration [mg/mL] of the oligonucleotide-loaded 
gelatin nanoparticles. Firstly, this procedure is limited by the given surface charge of 
the nanoparticles which is compensated by the oligonucleotide during loading. 
Secondly, increasing the concentration of both led to immediate aggregation during 
the loading process by formation of inter-nanoparticulate aggregates caused by 
“bridging” via the oligonucleotide. But, subsequent to oligonucleotide-loading the 
electrostatic situation with slightly positive charged ODN-loaded nanoparticles 
provides stable suspensions. It was the idea to concentrate these suspensions by 
means of freeze-drying i.e., the rehydration of freeze-dried samples with reduced 
volumes and the combination of a particular number of samples. Basically this 
method is used for protein pharmaceuticals [Shire et al., 2004] and was described by 
Anchordoquy for PEI/DNA complexes [Anchordoquy et al., 2005]. Based on his 
work freeze-dried ODN-loaded gelatin nanoparticles were firstly rehydrated in 
reduced volumes and secondly dried with dextran 3000 / sucrose blends to obtain 
isotonic formulations upon rehydration in a reduced volume concurrently 
maintaining the excipient mass necessary for stabilization of nanoparticles. 
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5 % and 10 % [w/w] NF-κB decoy ODN-loaded gelatin nanoparticle 
formulations were prepared with decreasing amounts of sucrose that provide isotonic 
solutions (10 % [w/v]) upon rehydration in 1/10th, 1/20th, and 1/30th of the original 
volume (450 µL). Particle sizing was conducted after rehydration in the original 
volume (“after 450”), after rehydration with the accordingly reduced volume 
(“conc.”), and after rehydration in a reduced volume which was completed to the 
original volume after waiting for 2 h (“conc. 450”). Besides, additional data were 
collected for empty nanoparticles. The resulting data are summarized in Figure 2.3.4. 
Due to the intended isotonicity only formulations containing sucrose to ODN ratios 
24, 71, and 141 [w/w] were investigated resulting in particle sizes slightly to 
moderately ranging above initial values as it was already seen in Figure 2.3.3 for the 
formulations 100 and 200.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.4 a) size and b) coefficient of variation of ds NF-κB decoy ODN-loaded (5 % and 
10 % [w/w]) (“5/X” and “10/X”) and empty (“5/10/X”) gelatin nanoparticles (GNPCO4pos) 
formulated with sucrose before freeze-drying and rehydrated in the original volume (“after 450”) and 
in 1/10th, 1/20th, and 1/30th (“X/10”, “X/20”, and “X/30”) of the original volume (“conc.” / “conc. 
450”) right after freeze-drying 
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Regarding the concentrated samples, the same tendency can be observed, 
whereas reduced particle sizes have to be stated for certain formulations at the same 
time. However, sizes determined before and after freeze-drying only varied within a 
small range and with respect to the margins of deviation no significant differences 
can be attributed to the investigated drug loading amounts and/or the chosen 
rehydration volume. Taking in addition the respective coefficient of variation into 
consideration it can be assumed that the concept of concentrating oligonucleotide-
loaded gelatin nanoparticles by freeze-drying is feasible. Experiments conducted 
with siRNA loaded gelatin nanoparticles basically confirmed the findings discussed 
above (Figure 2.3.5). Except nanoparticles loaded with 10 % (w/w) oligonucleotide, 
they initially exhibited high coefficients of variation but also clearly reduced particle 
sizes of formulation 10/10 and 10/30.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.5 a) size and b) coefficient of variation of ds siRNA ODN-loaded (5 % and 10 % 
[w/w]) (“5/X” and “10/X”) and empty (“5/10/X”) gelatin nanoparticles (GNPCO4pos) formulated with 
sucrose before freeze-drying and rehydrated in the original volume (“after 450”) and in 1/10th, 1/20th, 
and 1/30th (“X/10”, “X/20”, and “X/30”) of the original volume (“conc.” / “conc. 450”) right after 
freeze-drying 
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If sample aggregation would have been occurred during siRNA loading 
increased particles sizes would have to be expected. As those were not detectable and 
as the after freeze-drying measured particle sizes only slightly vary for all 
formulations, a corrupted sample quality is not likely. These data additionally 
demonstrate the independence of the outcome of the freeze-drying process from the 
surface charge i.e., zetapotential of gelatin nanoparticles. Experiments conducted 
with plain nanoparticles exhibiting a slightly negative zetapotential, ODN-loaded, 
surface modified nanoparticles exhibiting a slightly positive zetapotential, and empty 
surface modified nanoparticles exhibiting a clear positive zetapotential all maintained 
size and equal size distribution properties after freeze-drying and rehydration. 
Concurrently with the reduction of the rehydration volume the amount of sucrose 
required to provide isotonic solutions upon rehydration decreases. Thus, formulations 
designated to rehydration in 1/30th of the original volume contain only little sucrose 
i.e., total solid causing flimsy cakes. Substituting sucrose partially or in total by a 
lyoprotectant of higher molecular weight and with reduced osmotic activity like 
dextran 3000 could be an approach to improve cake morphology and was therefore 
investigated in the following. Figure 2.3.6 shows the data of empty nanoparticles 
formulated with dextran 3000 / sucrose blends (containing 10.0 % / 4.0 %, 
11.1 % / 3.3 %, 13.9 % / 1.7 %, and 16.7 % / 0.0 % dextran 3000 and sucrose 
respectively for both rehydration volumes: 1/20th and 1/30th of the original volume) 
which are characterized by increased excipient masses building stronger cakes but 
still providing isotonic solutions upon rehydration with reduced volumes. The 
resulting data set with slightly increased particle sizes and almost constant size 
distribution is in accordance with what has been described so far. Interestingly, both 
formulations merely containing dextran 3000, No. 79 and No. 118, are able to 
stabilize gelatin nanoparticles at their own, which confirms the findings of 
Anchordoquy who observed dextran 3000 to be an effective stabilizer for 
concentrated nanoparticulate PEI/DNA complexes [Anchordoquy et al., 2005].  
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Figure 2.3.6 a) size and b) coefficient of variation of empty gelatin nanoparticles (GNPCO5) 
formulated with dextran + sucrose containing solutions accounting for varying excipient to ODN 
ratios (“X/65”-“X/118”) before freeze-drying and rehydrated in 1/30th and 1/20th of the original 
volume (“30/X” and “20/X”) right after freeze-drying 
 
In sum the results of this first part not only show the general applicability of 
freeze-drying for gelatin nanoparticle suspensions but also the durability of gelatin 
nanoparticle populations throughout the process expressed by the good results 
obtained for different excipient to ODN / gelatin nanoparticle ratios, ODN-loaded 
gelatin nanoparticles, concentrated formulations, and the application of 
dextran 3000 / sucrose blends. 
Derived from the concentration experiments a formulation was developed to 
address the failure of NF-κB decoy ODN-loaded gelatin nanoparticles during the 
hepatic ischemia reperfusion studies (cp. chapter 3.4). A sucrose to ODN ratio of 200 
i.e., formulation 200 was chosen for freeze-drying of 10 % oligonucleotide-loaded 
gelatin nanoparticles to guarantee best possible stabilization and to enable at the 
same time rehydration to reduced isotonic volumes. Compared to former studies that 
utilized 5 % [w/w] oligonucleotide loading, which is the maximum amount 
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achievable under the ionic conditions of a PBS buffered environment the loading 
could be doubled to 10 % [w/w] while conducting it in sucrose solution. With the 
resulting sucrose amount an isotonic nanoparticle suspension was obtained after 
rehydration in 141.5 µL highly purified water, originating from an original volume of 
1 mL i.e., a concentration by factor 7. Four of these samples were unified, completed 
with isotonic sucrose solution (10 % [w/v]) to a total volume of 1 mL and applied in 
the hepatic I/R rat model. Unification of four samples led to a four times increased 
amount of oligonucleotide deliverable at once, whereas the nanoparticle load per 
animal study was only doubled due to increased oligonucleotide loading. The 
addition to a total volume of 1 mL was accomplished for technical reasons and can 
be abandoned in case of lower volumes required e.g., in mice or in case of 
demanding higher concentrations of ODN-loaded nanoparticles, obtainable by 
unification of more than the described four samples. 
But, upon exposure to blood plasma formulations were observed to aggregate 
immediately. This might be explained by the stabilizing repulsion, deriving from the 
positive surface charge of the ODN-loaded gelatin nanoparticles maintained in 
sucrose solution that is compensated after changing the environmental conditions 
towards an ionic milieu like blood plasma with its elevated ionic strength. Thus, 
further stabilization became crucial. Goetting reported similar results for 
oligonucleotide-loading of cationic polystyrene nanoparticles. To overcome this 
problem they successfully demonstrated a surfactant coating with poloxamer 388 that 
stabilized the ODN-loaded nanoparticles against aggregation [Goetting et al., 1999]. 
In accordance, we could proof our formulation to be macroscopically stable within 
blood plasma after incubating ODN-loaded nanoparticles for 1 h with Tween® 80. 
The Tween® 80 coating of the nanoparticles was conducted in a 1:1 [w/w] 
Tween® 80:nanoparticle ratio subsequent to rehydration and combination of four 
samples and before completion to the final volume. The resulting Tween® 80 
concentration of 0.28 % is considerably high but still clearly below the highest 
amount of 10 % contained in already FDA-approved drugs for intravenous injection 
(source: FDA Inactive Ingredients Database of inactive ingredients present in FDA-
approved drugs; http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm). The 
according results obtained from animal studies are discussed in detail in chapter 3.4. 
In the second part storage stability and further freeze-drying excipients are evaluated 
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for empty and oligonucleotide-loaded gelatin nanoparticles. Furthermore, the 
maintained biological activity of the NF-κB decoy oligonucleotide loaded onto 
gelatin nanoparticles was investigated after storage. 
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2.3.2 Storage stability tests of freeze-dried empty and oligonucleotide-loaded 
gelatin nanoparticles 
Four different excipient systems were chosen to evaluate their stabilizing 
capacity for gelatin nanoparticles: sucrose (S), trehalose (T), mannitol (M), and the 
combination of mannitol and sucrose in the ratio 4:1 (MS); whereas the later 
combines the good bulking properties of mannitol with the lyoprotection of sucrose 
as it is reported for protein stabilization [Johnson et al., 2002]. Trehalose was chosen 
as it is one of the most widely used freeze-drying excipients for biomaterials [Crowe 
et al., 1996] and is stated to be supposedly superior to sucrose due to its high Tg and 
temperature of “zero” mobility (T0) respectively [Yu, 2001]. Mannitol readily 
crystallizes during freeze-drying and possesses no lyoprotectant activity beneficial in 
terms of protein stabilization in the crystalline state [Cavatur et al., 2002]. Mannitol 
lyophilizates were therefore investigated in comparison to amorphous sucrose and 
trehalose cakes to evaluate whether crystalline structures negatively affect gelatin 
nanoparticle stabilization during freeze-drying. Based on the initially applied freeze-
drying cycle a shortened cycle was developed (Figure 2.2.2). With respect to the 
vapor pressure curve above ice the applied vacuum of 0.05 mbar maintained a 
product temperature of -48 °C during primary drying. Thus, sucrose and trehalose, 
exhibiting a Tg’ around -30 °C [Wang, 2000; Liu, 2006], and mannitol-sucrose (in 
the ratio of 4:1) containing formulations, exhibiting a Tg’ of -41.8 °C [Hawe, 2006] 
could be effectively dried during the same run using this cycle. Mannitol samples 
could be dried at a higher primary drying shelf temperature of -5 °C (Figure 2.2.3) 
due to the high melting point known for its ice eutectic mixture of -1.5 °C [Kim et 
al., 1998]. 
Empty nanoparticles were investigated in five formulations: 47, 100, 200, 400, 
and 800, at the same time only formulation 200 was prepared from ds NF-κB 
oligonucleotide-loaded (5 % [w/w]) gelatin nanoparticles. Formulation 47 was 
already assessed during experiments discussed above and possesses a sucrose 
amount necessary for isotonic rehydration in 1/30th of the original volume. It was 
investigated to evaluate the lower limit of the system. Size, size distribution, residual 
moisture, and thermal properties of empty nanoparticle formulations were as well 
investigated as size, size distribution, and biological activity of the ds NF-κB decoy 
Freeze-Drying of Gelatin Nanoparticles 
91 
oligonucleotide-loaded gelatin nanoparticles. Accelerated storage conditions for 
closed samples (30 °C and 40 °C) and open samples (30 °C / 30 % RH and 
30 °C / 60 % RH) were chosen in terms of short term stress testing over a period of 4 
and 10 weeks respectively. Studies were conducted in comparison to placebo 
formulations. All samples were prepared and measured in triplicates except DSC 
scans which were accomplished in duplicates. Thus, data are presented as mean 
values with respective standard deviation (stdv). Besides displaying selected data for 
discussion all values measured for particle size and size distribution, residual 
moisture, and thermal properties are tabular summarized in the annex of this chapter. 
Due to the large number of samples required and the limited batch size of gelatin 
nanoparticles that is obtained from two step desolvation four nanoparticle batches, all 
exhibiting similar sizes, were utilized for sample preparation. To enable 
intra-excipient comparability of particle sizes one of the four batches was used for all 
formulations manufactured of sucrose, one for trehalose, one for mannitol, and one 
for mannitol-sucrose formulations respectively. Determining polydispersity indices 
allowed evaluation of intra- and inter-excipient data in terms of size distribution 
quality and was chosen for explaining stability data. Residual moisture and thermal 
properties are in any case comparable as they are almost excipient governed and thus 
independent from particular nanoparticle batches.  
Empty gelatin nanoparticles 
Particle sizing Data from all prepared gelatin nanoparticle formulations 
measured before and right after freeze-drying are summarized in Table 2.3.3. For all 
formulations PDIs below 0.100 were determined prior to freeze-drying reflecting the 
very good quality of all samples applied for storage stability testing. Freeze-drying of 
formulations 100 to 800 showed the same outcome as it was already observed during 
initial applicability studies (Figure 2.3.1), exhibiting slightly reduced particle sizes 
and maintained sample quality with PDIs still below 0.100. Formulation 47 in turn 
shows increased PDIs for all freeze-drying excipients. Sucrose and trehalose 
formulations showed both, increased particle sizes and PDIs, whereas the latter were 
still acceptable but ranged above 0.100. The highest PDI can be seen for the 
mannitol-sucrose formulation, remarkably with a decreased particle size at the same 
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time. Interestingly, only mannitol provides sufficient stabilization resulting in a PDI 
below 0.100, but also this value has already increased upon freeze-drying. 
Table 2.3.3 Size and polydispersity indices of empty gelatin nanoparticles before freeze-drying 
and rehydrated right after freeze-drying 
 
Size [nm] PDI 
Before After Before After Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 177.0 2.0 183.7 1.2 0.041 0.016 0.117 0.011 
100 177.0 1.0 174.3 1.2 0.073 0.014 0.048 0.006 
200 176.0 1.0 171.3 1.2 0.050 0.005 0.046 0.006 
400 176.0 1.0 171.7 1.5 0.059 0.016 0.051 0.011 
Sucrose 
800 179.0 1.7 171.0 1.0 0.092 0.012 0.035 0.005 
47 179.0 1.7 182.0 1.7 0.066 0.019 0.114 0.028 
100 177.0 1.0 172.0 1.0 0.054 0.009 0.055 0.008 
200 177.0 1.0 171.7 0.6 0.051 0.013 0.039 0.009 
400 177.3 0.6 170.3 2.5 0.062 0.002 0.051 0.012 
Trehalose 
800 178.3 0.6 172.0 1.0 0.059 0.017 0.061 0.011 
47 175.3 0.6 175.7 1.5 0.039 0.008 0.082 0.008 
100 175.3 1.5 170.0 1.7 0.059 0.002 0.082 0.012 
200 173.7 1.2 170.0 1.0 0.063 0.014 0.065 0.011 
400 174.3 2.1 169.7 2.1 0.054 0.006 0.047 0.025 
Mannitol 
800 175.0 1.0 174.3 6.8 0.068 0.011 0.051 0.005 
47 208.0 8.7 198.0 1.7 0.085 0.024 0.123 0.019 
100 210.3 2.1 188.0 1.0 0.094 0.006 0.075 0.013 
200 210.0 1.0 187.3 2.5 0.076 0.019 0.069 0.022 
400 203.7 7.6 186.7 1.5 0.080 0.006 0.072 0.009 
Man-Suc 
800 210.3 0.6 187.3 1.5 0.077 0.016 0.062 0.007 
 
Due to the different nature of the respective lyophilizates it can be assumed that 
vitrification is not exclusively crucial for the stabilization of gelatin nanoparticles. 
Even in crystalline (cp. DSC data stated below) mannitol formulations, known to 
inadequately stabilize most proteins in the dried solid, nanoparticle integrity is 
preserved. Allison formulated the particle isolation hypothesis to explain these 
findings [Allison et al., 2000]. Along their hypothesis aggregation of non viral 
vectors during freezing is prevented by virtually any excipient applied in sufficient 
amounts by a spatial separation of particles within the unfrozen fraction. 
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Different storage times and conditions reinforce intra- and inter-excipient 
differentiation. Figure 2.3.7 and Figure 2.3.8 show the changes in the quality of the 
samples indicated by increasing polydispersity occurring after 4 and 10 weeks of 
closed storage at 30 °C and 40 °C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.7 Polydispersity indices of freeze-dried gelatin nanoparticles rehydrated after a) 4 
weeks and b) 10 weeks closed storage at 30 °C 
 
In none of the investigated samples formulation 47 is able to provide sufficient 
stabilization. With increasing excipient amounts stabilizing properties are improving. 
Looking at the results after 10 weeks storage at 40 °C (Figure 2.3.8 b) the tendencies 
already seen after 10 weeks storage at 30 °C (Figure 2.3.7 b) are further pronounced. 
Only the formulations 400 and 800 containing the highest excipient amounts 
maintained the nanoparticle quality. The lyoprotectant activity of sucrose, trehalose, 
and mannitol can be thereby stated as equivalent. Mannitol-sucrose formulations in 
turn failed to sufficiently stabilize gelatin nanoparticles in all investigated 
formulations despite combining two excipients both with good stabilizing properties 
at their own.  
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Figure 2.3.8 Polydispersity indices of freeze-dried gelatin nanoparticles rehydrated after a) 4 
weeks and b) 10 weeks closed storage at 40 °C 
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Storage under open conditions at accelerated relative humidity led to nearly 
entire sample loss, which is almost completed already after 4 weeks (Figure 2.3.9 a 
and Figure 2.3.10 a). At 30 % RH trehalose formulations 400 and 800 notably reveal 
good stabilization after 10 weeks though they were already destroyed after 4 weeks. 
This indicates that the stabilization properties of trehalose under these conditions can 
not be assumed as undoubtful. Basically, only mannitol formulation 800 withstands 
the high relative humidity of 30 % and provides certain stabilization. The differences 
for sucrose and trehalose formulations between closed and open storage (Figure 2.3.7 
b and Figure 2.3.9 b) are thereby much more pronounced than for mannitol-sucrose 
formulations presumably reflecting the low hygroscopicity of mannitol in the 
crystalline state.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.9 Polydispersity indices of freeze-dried gelatin nanoparticles rehydrated after a) 4 
weeks and b) 10 weeks open storage at 30 °C / 30 % RH 
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None of the samples were recovered with acceptable sizes or size distribution, 
neither after 4 weeks nor after 10 weeks storage at 30 °C / 60 % RH. Missing bars in 
Figure 2.3.9 and Figure 2.3.10 thereby reflect complete sample destruction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.10 Polydispersity indices of freeze-dried gelatin nanoparticles rehydrated after a) 4 
weeks and b) 10 weeks open storage at 30 °C / 60 % RH 
 
Determination of residual moisture contents Analyzing Karl-Fischer titration 
data elucidates the findings from particle sizing. According to Shalaev and Zografi 
increasing water contents contribute to accelerated chemical degradation of small 
molecules and proteins especially in amorphous solids [Shalaev et al., 1996]. As they 
expect this to be related to changed molecular mobility it can be assumed that 
increasing water contents negatively influence nanoparticle stability based on the 
same mechanism. Thereby, chemical degradation presumably plays a minor role 
compared to particle aggregation. Derived from particle isolation hypothesis 
discussed above and the considerations of Shalaev and Zografi an increased 
molecular mobility may diminish the spatial separation of nanoparticles finally 
leading to their aggregation when getting once into direct contact. 
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In the following residual moisture is exemplarily displayed for all formulations 
after closed storage at 30 °C and for sucrose and trehalose formulations after open 
storage at 30 °C / 60 % RH. In addition trehalose verum and placebo formulations 
are compared after closed storage at 30 °C. Complete data sets for all formulations 
and storage conditions are presented in tables summarized in the annex of this 
chapter. 
Residual moisture was initially determined to be below 1 % except sucrose 
formulation 47 (Figure 2.3.11 a) and mannitol formulation 200 (Figure 2.3.12 a). 
Upon 4 weeks closed storage comparable amounts of water were absorbed by 
sucrose and trehalose formulations, whereas the latter were determined to be slightly 
more hygroscopic (Figure 2.3.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.11 Residual moisture content of freeze-dried gelatin nanoparticle formulations 
containing a) sucrose and b) trehalose right after the drying process and after 4 and 10 weeks closed 
storage at 30 °C 
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especially formulations 400 and 800 still possessed residual moisture contents below 
1 % . These findings are confirmed by Fakes who systematically investigated the 
sorption behavior of bulking agents used in lyophilized products [Fakes et al., 2000]. 
Residual moisture contents of mannitol-sucrose formulations ranged between pure 
sucrose and mannitol formulations as it could be expected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.12 Residual moisture content of freeze-dried gelatin nanoparticle formulations 
containing a) mannitol and b) mannitol-sucrose right after the drying process and after 4 and 10 weeks 
closed storage at 30 °C 
 
During closed storage at 30 °C and 40 °C comparable sorption of water occurred. 
Further increased amounts were absorbed during open storage at 30 °C / 30 % RH, 
which were additionally raised at 30 °C / 60 % RH (Annex: Table 2.6.7 and 
Table 2.6.9). Independent from the investigated excipient formulations 47, 100, and 
200 in general exhibited stronger hygroscopicity than the formulations with higher 
excipient amounts 400 and 800. In sum, highest values were obtained for trehalose 
followed by sucrose, mannitol-sucrose, and mannitol; only after storage at 
30 °C / 60 % RH sucrose adsorbed most water. 
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Residual moisture data gained after 10 weeks storage revealed no further 
progression of water sorption compared to 4 weeks storage (Figure 2.3.11 and Figure 
2.3.12, Annex: Table 2.6.7 and Table 2.6.9). Mere formulations containing sucrose 
and trehalose openly stored at 30 °C / 60 % RH absorbed additional water (Figure 
2.3.13). Related to particle sizing data it can be stated that the amount of initially 
absorbed water already present after 4 weeks was enough to enable continued sample 
destruction monitored after 10 weeks (Figures 2.3.7 to 2.3.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.13 Residual moisture content of freeze-dried gelatin nanoparticle formulations 
containing a) sucrose and b) trehalose right after the drying process and after 4 and 10 weeks open 
storage at 30 °C / 60 % RH 
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30 °C / 60 % RH. Thus, with respect to the particle isolation hypothesis the 
contribution of vitrification to nanoparticle stabilizing during freeze-drying is not 
negligible as the glassy structure of sucrose and trehalose seems to be superior in 
preventing nanoparticle aggregation even at higher residual moisture contents. 
Mannitol-sucrose formulations obviously suffer from their blended nature. Despite 
smaller residual moisture values the stabilizing properties of sucrose under closed 
conditions were not reached, and stored at 30 °C / 30 % RH the beneficial properties 
of pure mannitol formulations with a PDI still below 0.100 for formulation 800 could 
not be verified. 
The influence of the gelatin nanoparticles themselves on the sorption of water 
during storage was evaluated by comparing results with placebo data. Interestingly, 
the obtained values were within the same range for both verum and placebo 
formulations, why results are only exemplarily shown for closed storage of trehalose 
formulations at 30 °C in Figure 2.3.14.  
 
 
 
 
 
 
 
 
 
Figure 2.3.14 Residual moisture content of freeze-dried gelatin nanoparticle and placebo 
formulations containing trehalose right after the drying process and after 4 and 10 weeks closed 
storage at 30 °C 
 
The placebo control study was terminated after 4 weeks as there were already 
comparable water contents determined for placebo and verum samples. This was, 
with respect to verum data being almost unchanged after 10 weeks, expected to be 
the same for placebo data after 10 weeks. 
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Differential scanning calorimetry All samples were investigated for their Tg 
and their melting point (mp) respectively. Due to different thermal properties of the 
respective freeze-drying excipients results are discussed in distinct sections in the 
following. In addition to samples available for particle sizing and Karl-Fischer 
titration there was a set of verum samples stored for 4 weeks at room temperature 
that was analyzed via DSC. These samples were available due to technical problems 
with the DSC instrument causing a delay of 4 weeks in exploring samples actually 
prepared for analysis right after freeze drying. Data right after freeze-drying were 
then collected from newly prepared samples with the same nanoparticle batches. 
Glass transition temperatures monitored for sucrose clearly reflect findings from 
residual moisture content testing. According to Hancock and Zografi there is a clear 
relation between glass transition temperature and the water content of amorphous 
pharmaceutical solids [Hancock et al., 1994]. They described a rapid initial reduction 
of Tg as water is absorbed. This can be followed for sucrose samples (Figure 2.3.15) 
and is confirmed by literature [Hancock et al., 1994]. As similar water contents were 
absorbed, all formulations showed a comparable reduction of their glass transition 
temperatures, which can be recognized at a parallel shift of the respective curves 
obtained after 4 weeks storage at 30 °C and 40 °C (Figure 2.3.15 a and b). Even 
samples stored at 20 °C showed depression of Tgs which was stronger pronounced 
for samples with lower excipient contents (Figure 2.3.15 c). Especially formulation 
47 reached values of ~30 °C as well seen for storage at 30 °C and 40 °C. Invariably 
all samples stored at open conditions with accelerated relative humidity collapsed to 
rigorous chunks sticking at the bottom of the vials and were thus not applicable for 
DSC analysis. During closed storage at 40 °C collapse occurred for sucrose 
containing formulations 100 and 200 after 4 weeks and formulations 100, 200, and 
400 after 10 weeks. In accordance to Karl-Fischer data there were no significant 
differences detectable between data obtained after 4 and 10 weeks; almost unchanged 
water contents led to equivalent Tgs (Figure 2.3.15 a and b). The same can be stated 
for verum and placebo data, thus only summarized in Table 2.6.10 and Table 2.6.11 
of the Annex. Furthermore, starting values are characterized by Tgs concomitantly 
decreasing with the excipient amount. Taking the known inverse relation between Tg 
and residual moisture content discussed above and the corresponding residual 
moisture curve (Figure 2.3.11 a), which demonstrated increased relative water 
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contents coming along with declined excipient to nanoparticle ratios, into account, 
this could be expected to a certain extent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.15 Tg (point of inflection) of sucrose containing freeze-dried gelatin nanoparticle 
formulations a) right after freeze-drying and after 4 and 10 weeks closed storage at 30 °C, b) right 
after freeze-drying and after 4 and 10 weeks closed storage at 40 °C, and c) right after freeze-drying 
and after 4 and 10 weeks closed storage at 30 °C in comparison to 4 weeks storage at 20 °C 
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But with respect to the small differences in water contents determined right after 
freeze-drying the clear response in Tg variation was not assumed. As this 
phenomenon was also observed for the melting point of mannitol containing 
formulations (Figure 2.3.17 and Figure 2.3.18), which should be independent from 
residual moisture content, and as placebo studies ruled out these strong variations 
possibly driven by gelatin nanoparticles themselves a sample mass dependent 
mechanism is likely to be assumed as reason for these findings. Due to the aim of the 
study to develop a freeze-dried oligonucleotide-loaded gelatin nanoparticle 
formulation the amount of nanoparticles per sample was given and the ratio of 
excipient to ODN / nanoparticles was varied. This in turn led to varying total solid 
contents varying from 1.4 mg per vial up to 17 mg per vial. As the optimum sample 
weight for DSC analysis is stated with 3 mg, this amount was not reached for the 
smaller formulations and thus increasing masses were transferred into DSC pans. 
Sample mass dependent shifts of glass transition temperatures and melting points 
determined by DSC are described in literature [Hoehne et al., 1989; Mano et al., 
2004] and are confirmed by the manufacturer of the applied instrument (Netzsch-
Geraetebau GmbH, Selb, Germany). This correlation of thermal events taking place 
at reduced temperatures and decreasing sample mass can be seen for all investigated 
samples and has thus to be taken into consideration in assessing storage stability 
properties of freeze-dried gelatin nanoparticle formulations. Nevertheless, the 
influence of residual moisture contents in terms of thermally inducible conversions 
can be easily followed by DSC data. 
 
The DSC analysis of trehalose formulations in general revealed residual 
moisture and sample mass dependent alterations of the glass transition temperature of 
trehalose similar to those observed for sucrose formulations (Figure 2.3.16). The 
influence of the residual moisture content on the Tg of trehalose is basically 
confirmed by literature [Surana et al., 2004]. Upon closed storage for 4 weeks at 
30 °C and 40 °C a comparable reduction of Tgs could be followed and the depression 
of Tgs monitored for 4 weeks closed storage at 20 °C, which was pronounced for 
samples with lower excipient contents, was confirmed. Open storage as well led to 
complete sample loss but in contrast to sucrose, trehalose was able to maintain 
sample integrity during closed storage at 40 °C as collapse did not occur. Again, in 
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accordance to Karl-Fischer data there were no significant differences detectable 
between data obtained after 4 and 10 weeks storage (Figure 2.3.16 a and b) as well as 
data obtained from verum and placebo samples (Annex: Table 2.6.12 and Table 
2.6.13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.16 Tg (point of inflection) of trehalose containing freeze-dried gelatin nanoparticle 
formulations a) right after freeze-drying and after 4 and 10 weeks closed storage at 30 °C, b) right 
after freeze-drying and after 4 and 10 weeks closed storage at 40 °C, and c) right after freeze-drying 
and after 4 and 10 weeks closed storage at 30 °C in comparison to 4 weeks storage at 20 °C 
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Absolute numbers initially determined for the Tgs of gelatin nanoparticle 
formulations 800 containing sucrose or trehalose ranged with just under 60 °C or 
94 °C respectively within values known from literature [Te Booy et al., 1992; Wang, 
2000; Imamura et al., 2003] and were verified by placebo data (Annex: Table 2.6.11 
and Table 2.6.13). In comparison Tg values determined during initial applicability 
studies in the first part of this chapter (Figure 2.3.2 b) ranged higher and did not 
show a sample mass dependent behavior. As these former investigations were 
accomplished using a Perkin-Elmer Diamond differential scanning calorimeter a 
different sensitivity of these two systems could presumably be the reason for this 
discrepancy. 
 
In contrast to sucrose and trehalose formulations, mannitol formulations 
exhibited maintained thermal properties for verum and placebo formulations right 
after freeze-drying and over all tested storage conditions. Hence, just one part of 
mannitol data is exemplarily summarized in Figure 2.3.17. The melting point was 
constantly calculated around 164 °C for formulation 800 (Annex: Table 2.6.14 to 
Table 2.6.16) as described in literature for α and β modification of D-mannitol 
respectively [Burger et al., 2000]. No further exotherms or endotherms were detected 
during heating indicating the complete crystallization of mannitol in α or β 
modification and concomitantly the absence of mannitol hemihydrate or the 
δ polymorph of mannitol [Nunes et al., 2004].  
 
 
 
 
 
 
 
 
 
Figure 2.3.17 Melting point (peak) of mannitol containing freeze-dried gelatin nanoparticle 
formulations right after freeze-drying and after 4 and 10 weeks open storage at 30 °C / 30 % RH 
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The parallel shifted course of the resulting curves was related to sample mass 
effects as already discussed above, which lead to melting points decreasing with 
reduced mannitol to gelatin nanoparticle ratios. 
 
Basically observations made for mannitol formulations correspond to those of 
mannitol-sucrose formulations. An unaffected melting point was obtained for all 
verum and placebo formulations regardless of storage time and conditions. Again the 
influence of the sample mass could be derived from respective data exemplarily 
displayed in Figure 2.3.18. 
 
 
 
 
 
 
 
 
 
Figure 2.3.18 Melting point (peak) of mannitol-sucrose containing freeze-dried gelatin 
nanoparticle formulations right after freeze-drying and after 4 and 10 weeks open storage at 
30 °C / 30 % RH 
 
Compared to pure formulations the melting point of mannitol itself is reduced 
and was calculated around 156 °C for formulation 800 (Annex: Table 2.6.17 to Table 
2.6.19). This reduced melting temperature may be addressed to the presence of 
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addition, glass transition of sucrose could be determined for the formulations 200 - 
800 (data not shown), whereas the signal intensity was only weak and the values 
ranged below 30 °C. As only 1/5th of the whole excipient amount was sucrose, it was 
assumed that the resulting low amount of sucrose was the reason for both. 
 
 
 
 
 
 
 
 
Figure 2.3.19 DSC (2nd) heating scans of mannitol-sucrose containing freeze-dried gelatin 
nanoparticle formulations 47 (7), 100 (1), 200 (2), 400 (4), and 800 (8) after 4 weeks closed storage at 
40 °C 
 
A reduced Tg for mannitol and sucrose containing lyophilizates is already 
described by Lueckel [Lueckel et al., 1998] and has to be taken into consideration in 
terms of microcollapse of sucrose within a mannitol matrix [Chatterjee et al., 2005] 
and its outcome for storage conditions and stability of lyophilized gelatin 
nanoparticles. Finally an assumption could be deduced from DSC scans that could 
explain the bad stabilizing properties of mannitol-sucrose containing formulations for 
gelatin nanoparticles identified during storage stability tests. Samples investigated 
right after freeze-drying clearly showed crystallization during the first DSC scan 
(Figure 2.3.20) indicating the presence of at least partially amorphous mannitol 
emerged during freeze-drying.  
 
 
 
 
 
 
 
 
Figure 2.3.20 DSC heating scans of mannitol-sucrose containing freeze-dried gelatin nanoparticle 
formulation 47 right after freeze-drying 
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This can possibly be attributed to the presence of sucrose, generally recovered in 
its amorphous state upon freeze-drying. In contrast after cooling and reheating up to 
180 °C the weak Tg of Sucrose, afore masked by the crystallization exotherm of 
mannitol, appeared (Figure 2.3.20, 2nd scan) and the melting of the α or β polymorph 
of mannitol respectively [Burger et al., 2000] could be followed. None of the 
samples analyzed after storage neither after 4 weeks nor after 10 weeks showed 
comparable thermograms. Taking additionally the low Tg of amorphous mannitol of 
13.7 °C into consideration [Cavatur et al., 2002] it can be therefore concluded that 
mannitol crystallization occurred during storage at all storage conditions and led to 
the reported poor stability data of gelatin nanoparticles. Interestingly, the crystalline 
state at its own did not negatively affect storage stability as it is described above for 
pure mannitol formulations, but the conversion from the amorphous to the crystalline 
state obviously had a clear negative effect. Similar findings are described by Hawe, 
she could demonstrate the development of partial amorphous mannitol within 
lyophilized mixtures of mannitol and sucrose in the ratios 1:1 and 3:1, but not in the 
ratio 4:1 [Hawe, 2006]. Including an annealing step into the freeze-drying cycle 
fosters crystallization of mannitol and can be used to circumvent this problem 
[Hawe, 2006]. Concomitantly increasing amounts of mannitol hydrate which in turn 
may as well negatively affect storage stability due to the release of water can be 
prevented by conducting secondary drying at higher temperatures [Johnson et al., 
2002]. 
The described observations were made for verum as well as placebo 
formulations, thus ruling out a direct correlation between gelatin nanoparticles and 
amorphous emerging mannitol during freeze-drying. 
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Oligonucleotide-loaded gelatin nanoparticles 
Storage stability of oligonucleotide-loaded gelatin nanoparticles was investigated 
with the major emphasis laid on the assessment of maintained ODN function within 
an LPS (sepsis) rat model (cp. chapter 3.4). In addition, particle sizing data were 
gained to estimate the respective formulation’s quality prior to animal studies. 
Besides, the influence of the oligonucleotide on the storage stability of gelatin 
nanoparticles could be evaluated based on PCS data. As four samples had to be 
combined for application in vivo and lyophilizates for two experiments were 
prepared for every excipient high amounts of oligonucleotide were required. 
Therefore the study was restricted to 4 weeks storage and only formulation 200 
which was developed for the use in the hepatic ischemia reperfusion injury rat model 
(cp. chapter 2.3.1 and chapter 3.4) was studied. 
Figure 2.3.21 shows the particle sizes and polydispersity indices of all employed 
gelatin nanoparticles batches loaded with the NF-κB decoy oligonucleotide. 
Nanoparticle sizes varied for the different excipient formulations as four different 
batches were utilized. In contrast to the as well successful oligonucleotide-loading 
studies described in chapter 2.3.1 and in accordance to freeze-drying of empty 
nanoparticles (Figure 2.3.1 and Table 2.3.3) freeze-drying caused a decrease in 
particles sizes. Together with respective PDIs the introduced good freeze-drying 
properties of oligonucleotide-loaded and empty gelatin nanoparticles were again 
confirmed. Compared to empty nanoparticles higher PDI values were measured for 
ODN-loaded nanoparticles prior to freeze-drying what was already known from 
former work. However, PCS raw data revealed a broader but still monomodal size 
distribution curve indicating the absence of bigger aggregates, which could be 
macroscopically confirmed. Here interestingly, the PDI of all investigated 
nanoparticle excipient combinations significantly decreased as a result of freeze-
drying. Taking the already discussed particle isolation hypothesis of Allison into 
consideration [Allison et al., 2000] this concept seems to be beneficial even for 
improving nanoparticle size distribution slightly disturbed by oligonucleotide 
loading. 
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Figure 2.3.21 a) size and b) polydispersity indices of NF-κB decoy ODN-loaded gelatin 
nanoparticles formulated with sucrose (S), trehalose (T), mannitol (M), and mannitol-sucrose (MS) 
before freeze-drying and rehydrated right after freeze-drying 
 
Subsequent to storage the resulting particle sizes and PDIs are in good 
accordance to data obtained for empty nanoparticles (Figure 2.3.22). Sucrose and 
trehalose provided good stabilizing properties after closed storage, whereas mannitol 
and mannitol-sucrose failed to sufficiently stabilize the ODN-loaded gelatin 
nanoparticles at all storage conditions. None of the samples stored at 30 °C / 60 % 
RH were recovered with acceptable size or size distribution (data not shown). 
Surprisingly nanoparticles formulated with trehalose exhibited almost retained 
polydispersity after storage at 30 °C / 30 % RH. This was not expected from empty 
nanoparticle investigations, so no trehalose containing samples were prepared for in 
vivo testing after storage at 30 °C / 30 % RH. Prior to the storage stability study, all 
formulations were examined for their ODN effect i.e., the NF-κB inhibition in the 
LPS rat model right after freeze-drying. Therefore, samples were firstly rehydrated 
according to the procedure described in chapter 2.3.1 for the newly developed 
sucrose based NF-κB decoy loaded gelatin nanoparticle formulation. 
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Figure 2.3.22 a) size and b) polydispersity indices of NF-κB decoy ODN-loaded gelatin 
nanoparticles formulated with sucrose (S), trehalose (T), mannitol (M), and mannitol-sucrose (MS) 
rehydrated right after freeze-drying, after 4 weeks closed storage at 30 °C and 40 °C, and after 4 
weeks open storage at 30 °C / 30 % RH 
*formulations that were further investigated in vivo within the LPS rat model 
 
Independent from the contained excipient samples were rehydrated with the 
same amount of water leading to an excipient concentration of 10 % [w/v] and after 
unification of four of them adjusted with isotonic sucrose solution to the final volume 
of 1 mL. This procedure provided isotonic sucrose and trehalose solutions 
(c = 0.292 osmol/L) as they exhibit the same osmotic activity and slightly hypertonic 
mannitol and mannitol-sucrose solutions with concentrations of 0.437 osmol/L and 
0.408 osmol/L respectively. Due to formulations prepared with identical excipient 
masses and the smaller molecular weight a higher number of mannitol molecules was 
contained thus leading to accordingly increased osmolarity. However, as the 
intravenous administration performed over a period of 5 min was slow enough to 
allow dilution within blood, isotonicity of the applied solutions became less 
important [DeLuca et al., 1984]. Samples investigated after storage stability tests 
were treated the same way. 
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Particle sizing data obtained from sucrose and trehalose formulations stored for 4 
weeks in closed vials at 30 °C and 40 °C revealed maintained sample quality. Thus, 
these formulations were investigated for the biological activity of the NF-κB decoy 
oligonucleotide loaded onto the gelatin nanoparticles in an LPS rat model. For 
optimum comparison EMSA was accomplished with samples from all animal studies 
conducted with samples of the respective excipient and of the respective storage 
condition at once. The resulting electrophoresis gel demonstrates the excipient 
independent maintained ODN function upon freeze-drying and underlines the good 
storage stability properties of gelatin nanoparticles under closed conditions at 30 °C 
and 40 °C respectively even for their oligonucleotide-loaded state (Figure 2.3.23). In 
all cases the NF-κB band is clearly diminished or almost completely erased 
compared to the control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.23 Hepatic NF-κB activation after stimulation with 10 µg LPS of animals treated with 
20 nmol NF-κB decoy oligonucleotide-loaded gelatin nanoparticles and of untreated animals; 
nanoparticle formulations containing sucrose (S) and trehalose (T) were investigated right after 
freeze-drying and after 4 weeks closed storage at 30 °C and 40 °C, mannitol (M) and mannitol-sucrose 
(MS) containing formulations are only investigated right after freeze-drying; one band represents one 
animal study 
 
Derived from sucrose experiments inter individual variability typically seen 
during animal studies can be stated to cause unequal NF-κB band intensities. 
Regarding initial (Figure 2.3.23: “start”) experiments the nature of the cake emerging 
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from lyophilization either amorphous for sucrose and trehalose or crystalline for 
mannitol and mannitol-sucrose formulations did not differentiate the in vivo results in 
terms of altered ODN activity upon freeze-drying. Thus, data are congruent with 
those of empty gelatin nanoparticles discussed above. In addition, it can be assumed 
that good particle size and size distribution properties preserved during storage 
guarantee a maintained function of the investigated NF-κB decoy oligonucleotide 
bound onto the surface of gelatin nanoparticles. All animal studies and subsequent 
EMSA were conducted twice, to confirm the described results. 
Molina and co-workers evaluated the stabilizing properties of lipid/DNA 
complexes formulated with glucose, sucrose, and trehalose for plasmid DNA in a 
long term stability study over 2 years without further stress factors at -20 °C, 4 °C, 
and 22 °C [Molina et al., 2004]. Their results reveal particle size independent 
reduced transfection rates of the applied plasmid already after 10 weeks further 
progressing during the investigated 2 years period. They propose the formation of 
reactive oxygen species (ROS) in the dried solid to be responsible. Due to the 
respective molecular size the requirements for oligonucleotide and plasmid DNA 
stabilization may not be the same but these findings have to be taken into 
consideration in future long term stability studies of oligonucleotide-loaded gelatin 
nanoparticles. 
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2.4 Summary 
During the present work the applicability of freeze-drying for the stabilization of 
gelatin nanoparticles was demonstrated. Formulations of gelatin nanoparticles 
containing sucrose, trehalose, mannitol, as well as mannitol and sucrose in the ratio 
of 4:1 were prepared with total excipient amounts ranging from 0.3 to 7.0 % [w/v]. 
With exception of formulations possessing the lowest excipient contents size and size 
distribution of gelatin nanoparticles were preserved over the drying process, whereas 
a tendency to slightly reduced particle sizes resulting from freeze-drying could be 
observed. Interestingly, no differences were observed with respect to amorphous or 
crystalline emerging cakes. In accordance to the particle isolation hypothesis of 
Allison this led to the assumption that the spatial separation of nanoparticles during 
freeze-drying is even more decisive than vitrification of the utilized excipient 
[Allison et al., 2000]. 
Furthermore, experiments were conducted with NF-κB and scr decoy 
oligonucleotide as well as siRNA oligonucleotide-loaded gelatin nanoparticles. The 
good results from empty nanoparticles were verified and in addition, rehydration in, 
compared to freeze-drying suspensions / solutions, reduced volumes down to 1/30th 
of the original volume could successfully be accomplished. Prior to drying sucrose 
was thereby added as freeze-drying excipient in amounts accounting for isotonic 
concentrations after rehydration in reduced volumes. Low excipient contents could 
be circumvented at concomitantly maintained osmotic activity by substituting 
portions of sucrose by dextran 3000. At the same time surface modified but unloaded 
gelatin nanoparticles were evaluated as controls. As they were recovered from 
freeze-drying with unaffected size and size distribution independence of the process 
from the nanoparticles’ zetapotential was proven. Based on the results obtained with 
oligonucleotide-loaded gelatin nanoparticles and reduced rehydration volumes 
isotonic samples with increased ODN concentration could be prepared. Compared to 
the regular oligonucleotide-loading process a four times higher ODN concentration 
was achieved. In the following these samples were successfully applied in the hepatic 
ischemia reperfusion rat model established during the cooperation work described in 
chapter 3.4, where they contributed to the breakthrough in terms of a selective NF-
κB inhibition in the Kupffer cells of the liver. 
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Finally a storage stability study was performed which differentiated the 
stabilization properties of the respective freeze-drying excipients. In sum sucrose and 
trehalose showed a comparable performance whereas the higher Tg of trehalose 
caused better stabilization during storage at 40 °C while some of the sucrose 
formulations collapsed. A threshold of 3 % water content could be determined above 
which nanoparticle aggregation occurred. Thus, storage at accelerated relative 
humidity leading to clearly elevated residual moisture contents revealed the failure of 
both to sufficiently stabilize gelatin nanoparticles. Higher excipient masses can be 
stated as superior as for the sorption of identical amounts of water the described 
threshold is reached later. Mannitol and mannitol-sucrose containing formulations in 
turn are characterized by a certain resistance against water sorption even at open 
storage at 30 % and 60 % RH. Despite these findings both excipients were unable to 
provide nanoparticle stabilization after storage at 60 % RH. On the other hand the 
formulation containing the highest amount of mannitol was the only one that kept 
size and size distribution almost constant after storage at 30 %RH. According to 
sucrose and trehalose, mannitol containing formulations demanded higher excipient 
amounts to provide comparable stabilization. With respect to the newly developed 
concentrated and isotonic samples this has to be assessed as disadvantageous. 
Otherwise, under special geographical circumstances when handling or storage of 
lyophilizated gelatin nanoparticles occurs under extreme climatic conditions the 
marginal water sorption of mannitol would become vital. Mannitol-sucrose 
containing formulations provided worst stabilization properties of all applied 
excipients which were not expected especially regarding the good results obtained 
for pure mannitol formulations. In this context DSC analysis could prove the 
conversion of partially amorphous mannitol present upon freeze drying into its 
crystalline state during storage. This led to the conclusion that crystallizing mannitol 
contributed to the observed nanoparticle aggregation in mannitol-sucrose 
formulations. Including an annealing step into the freeze-drying cycle could foster 
complete mannitol crystallization throughout drying which presumably improves 
stabilization properties of mannitol-sucrose formulations for gelatin nanoparticles. In 
the end storage stability data were completed by evaluating oligonucleotide-loaded 
gelatin nanoparticles. Results confirmed the observations made so far demonstrating 
that only sucrose and trehalose provided sufficient stabilization of the selected 
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formulations of ODN-loaded gelatin nanoparticles. The oligonucleotide itself did not 
disturb the drying process or negatively affected the stability of gelatin nanoparticles. 
It could rather be proven to function in vivo upon freeze-drying on the surface of 
gelatin nanoparticles and storage. 
In conclusion freeze drying of gelatin nanoparticles could be successfully 
demonstrated and based on the presented results it can be characterized as a 
convenient and robust method that provides excellent stabilization. At least it should 
be mentioned that every application of gelatin nanoparticles requires specific 
characteristics which can not be covered with a general freeze-dried product, but 
based on the acquired results respective adaptation might be feasible. The newly 
developed NF-κB decoy oligonucleotide-loaded gelatin nanoparticle formulation for 
example could be further customized by adding Tween® 80 already to the freeze-
drying solution, by adjusting the sucrose content to enable rehydration only with 
water to the desired final isotonic volume, and by increasing the sample volume 
dried per vial by factor 4 to avoid the sample unification step prior to use. 
Furthermore, long term stability testing of gelatin nanoparticles in general has to be 
accomplished in future to step forward towards a well defined product applicable for 
manifold research projects. 
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2.6 Annex 
2.6.1 Stability data of empty gelatin nanoparticles 
Photon correlation spectroscopy (PCS) data 
Table 2.6.1 Size of freeze-dried gelatin nanoparticles rehydrated after 4 weeks closed storage at 30 °C and 40 °C and open 
storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Size [nm] 
4w 30 °C 4w 40 °C 4w 30 °C / 30 % RH 
4w 30 °C / 
60 % RH 
Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 289.0 16.7 4990.0 833.5 n/a n/a n/a n/a 
100 185.7 2.5 249.7 17.6 n/a n/a n/a n/a 
200 178.7 0.6 172.7 0.6 761.5 393.9 n/a n/a 
400 177.0 2.0 172.0 1.0 262.0 29.8 1130.7 953.8 
Sucrose 
800 177.0 3.6 171.0 1.7 197.7 3.1 400.7 59.8 
47 233.7 1.5 336.7 29.2 n/a n/a n/a n/a 
100 184.7 3.2 186.7 4.0 n/a n/a n/a n/a 
200 176.3 2.3 170.7 0.6 1445.3 1153.0 n/a n/a 
400 173.7 1.2 170.0 1.7 239.7 22.1 n/a n/a 
Trehalose 
800 173.7 2.1 168.7 2.1 273.0 54.0 n/a n/a 
47 1303.3 66.6 4743.3 950.0 1696.7 330.8 8563.3 1385.5 
100 235.3 2.5 362.7 25.9 614.3 464.1 1573.3 433.6 
200 217.7 50.6 197.7 1.5 192.0 2.6 555.0 532.7 
400 188.7 11.9 183.7 1.2 209.7 21.0 377.0 266.0 
Mannitol 
800 179.7 0.6 182.3 1.5 190.3 5.1 689.0 771.6 
47 2300.0 636.6 4243.3 1525.7 10290.0 1391.2 15833.3 11938.4 
100 546.7 410.0 1076.3 964.5 6213.3 1866.3 8023.3 805.3 
200 215.3 2.5 313.3 122.7 1138.7 480.7 6260.0 4380.4 
400 206.0 2.0 216.3 2.3 277.7 5.0 2082.0 1446.9 
Man-Suc 
800 203.3 0.6 208.3 1.5 225.7 5.9 4073.3 1123.2 
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Table 2.6.2 Polydispersity indices of freeze-dried gelatin nanoparticles rehydrated after 4 weeks closed storage at 30 °C 
and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
PDI 
4w 30 °C 4w 40 °C 4w 30 °C / 30 % RH 
4w 30 °C / 
60 % RH 
Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 0.406 0.050 0.832 0.291 n/a n/a n/a n/a 
100 0.100 0.014 0.414 0.082 n/a n/a n/a n/a 
200 0.044 0.022 0.062 0.007 0.611 0.271 n/a n/a 
400 0.046 0.006 0.038 0.007 0.374 0.040 0.655 0.310 
Sucrose 
800 0.048 0.012 0.066 0.014 0.139 0.020 0.492 0.042 
47 0.364 0.008 0.647 0.086 n/a n/a n/a n/a 
100 0.118 0.020 0.145 0.034 n/a n/a n/a n/a 
200 0.063 0.013 0.068 0.004 0.780 0.328 n/a n/a 
400 0.046 0.006 0.042 0.008 0.285 0.063 n/a n/a 
Trehalose 
800 0.057 0.023 0.055 0.005 0.289 0.079 n/a n/a 
47 0.910 0.038 1.000 0.000 0.964 0.062 1.000 0.000 
100 0.329 0.019 0.490 0.011 0.570 0.235 0.906 0.109 
200 0.207 0.178 0.145 0.017 0.131 0.018 0.390 0.182 
400 0.105 0.046 0.082 0.007 0.154 0.063 0.302 0.213 
Mannitol 
800 0.051 0.004 0.062 0.012 0.066 0.012 0.303 0.174 
47 1.000 0.000 1.000 0.000 0.736 0.457 0.928 0.125 
100 0.534 0.187 0.685 0.273 1.000 0.000 0.997 0.005 
200 0.127 0.021 0.310 0.193 0.707 0.101 0.466 0.365 
400 0.077 0.022 0.109 0.011 0.351 0.034 0.419 0.187 
Man-Suc 
800 0.077 0.013 0.078 0.003 0.139 0.023 0.437 0.161 
 
Table 2.6.3 Size of freeze-dried gelatin nanoparticles rehydrated after 10 weeks closed storage at 30 °C and 40 °C and 
open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Size [nm] 
10w 30 °C 10w 40 °C 10w 30 °C / 30 % RH 
10w 30 °C / 
60 % RH 
Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 463.3 127.6 5596.7 4746.5 n/a n/a n/a n/a 
100 179.0 0.0 765.0 268.7 n/a n/a n/a n/a 
200 170.3 0.6 200.7 3.2 n/a n/a n/a n/a 
400 168.0 1.0 169.3 1.2 222.0 11.1 274.3 14.8 
Sucrose 
800 170.0 1.0 169.3 4.2 188.0 6.9 207.7 6.7 
47 264.7 8.0 614.0 180.3 n/a n/a n/a n/a 
100 188.0 3.6 201.0 6.2 n/a n/a n/a n/a 
200 177.3 0.6 176.0 1.0 201.3 4.5 n/a n/a 
400 175.7 1.5 174.3 1.5 177.3 2.1 n/a n/a 
Trehalose 
800 176.0 1.0 173.7 1.5 174.7 1.2 n/a n/a 
47 3251.0 2112.7 6823.3 755.1 3916.7 2761.6 4630.0 2592.8 
100 568.0 315.7 565.7 204.6 335.7 135.4 2685.0 3128.3 
200 187.3 1.5 371.0 264.2 212.7 33.5 220.3 7.5 
400 178.7 4.7 174.0 1.0 192.3 10.7 434.0 421.8 
Mannitol 
800 179.7 3.2 172.3 1.2 185.7 5.7 212.3 14.8 
47 4413.3 2992.2 3056.7 2674.2 n/a n/a n/a n/a 
100 1337.7 1605.1 2263.3 1204.3 n/a n/a n/a n/a 
200 1162.7 1574.0 1677.3 1274.5 1096.7 580.3 n/a n/a 
400 233.0 31.4 265.3 69.1 283.7 31.5 n/a n/a 
Man-Suc 
800 210.0 17.8 820.7 511.8 216.3 0.6 n/a n/a 
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Table 2.6.4 Polydispersity indices of freeze-dried gelatin nanoparticles rehydrated after 10 weeks closed storage at 30 °C 
and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
PDI 
10w 30 °C 10w 40 °C 10w 30 °C / 30 % RH 
10w 30 °C / 
60 % RH 
Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 0.592 0.193 0.895 0.182 n/a n/a n/a n/a 
100 0.136 0.023 0.697 0.180 n/a n/a n/a n/a 
200 0.057 0.010 0.242 0.020 n/a n/a n/a n/a 
400 0.044 0.021 0.047 0.011 0.281 0.071 0.377 0.029 
Sucrose 
800 0.055 0.023 0.038 0.016 0.156 0.013 0.279 0.007 
47 0.464 0.043 0.717 0.285 n/a n/a n/a n/a 
100 0.136 0.020 0.204 0.021 n/a n/a n/a n/a 
200 0.051 0.013 0.069 0.019 0.159 0.019 n/a n/a 
400 0.058 0.013 0.037 0.014 0.074 0.018 n/a n/a 
Trehalose 
800 0.063 0.008 0.045 0.019 0.054 0.008 n/a n/a 
47 0.699 0.203 0.481 0.432 0.994 0.010 0.917 0.144 
100 0.530 0.231 0.600 0.068 0.495 0.136 0.623 0.145 
200 0.136 0.006 0.416 0.252 0.229 0.122 0.293 0.016 
400 0.062 0.012 0.080 0.009 0.103 0.043 0.269 0.220 
Mannitol 
800 0.051 0.013 0.072 0.009 0.081 0.009 0.170 0.023 
47 0.855 0.251 0.856 0.247 n/a n/a n/a n/a 
100 0.517 0.053 0.844 0.253 n/a n/a n/a n/a 
200 0.461 0.467 0.704 0.364 0.868 0.167 n/a n/a 
400 0.135 0.060 0.221 0.121 0.395 0.110 n/a n/a 
Man-Suc 
800 0.072 0.006 0.484 0.320 0.136 0.025 n/a n/a 
 
Karl-Fischer titration data 
Table 2.6.5 Residual moisture content of freeze-dried gelatin nanoparticle (verum) formulations right after the drying 
process 
 
 Residual moisture [%] 
Formulation SucroseV TrehaloseV MannitolV Man-SucV 
 Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 1.2 0.2 0.8 0.2 0.6 0.3 0.8 0.2 
100 0.7 0.1 0.6 0.2 1.0 0.0 0.7 0.1 
200 0.6 0.0 0.2 0.1 1.7 0.1 0.7 0.1 
400 0.3 0.0 0.2 0.0 1.0 0.1 0.7 0.1 
800 0.3 0.0 0.1 0.1 0.5 0.0 0.5 0.1 
 
Table 2.6.6 Residual moisture content of freeze-dried placebo formulations right after the drying process 
 
 Residual moisture [%] 
Formulation SucroseP TrehaloseP MannitolP Man-SucP 
 Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 0.9 0.2 1.0 0.3 1.4 n/a 0.8 0.1 
100 0.3 0.1 0.6 0.1 0.8 n/a 0.7 0.1 
200 0.6 0.0 0.2 0.0 2.9 1.0 0.7 0.7 
400 0.4 0.1 0.4 0.1 0.7 0.2 0.6 0.4 
800 0.4 0.1 0.7 0.1 0.7 0.3 0.5 0.2 
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Table 2.6.7 Residual moisture content of freeze-dried gelatin nanoparticle (verum) formulations after 4 weeks closed 
storage at 30 °C and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Residual moisture [%] 
SucroseV TrehaloseV MannitolV Man-SucV Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
30 °C 4.9 0.1 5.2 0.3 2.7 0.1 2.9 0.3 
40 °C 5.4 0.3 5.8 0.2 2.9 0.2 3.5 0.1 
30 °C / 30 % RH 6.8 0.5 8.6 0.3 2.9 0.3 4.0 0.5 
47 
30 °C / 60 % RH 9.6 0.8 9.4 0.4 3.6 1.4 6.6 0.0 
30 °C 3.8 0.0 4.2 0.1 1.7 0.1 2.0 0.1 
40 °C 3.9 0.2 4.7 0.2 1.8 0.0 2.4 0.2 
30 °C / 30 % RH 3.8 0.6 7.6 0.4 1.7 0.1 3.3 0.1 
100 
30 °C / 60 % RH 8.8 0.1 7.0 1.0 2.5 0.1 5.1 0.2 
30 °C 2.9 0.1 3.3 0.1 1.2 0.1 1.7 0.1 
40 °C 2.3 0.8 3.5 0.2 1.3 0.0 1.7 0.1 
30 °C / 30 % RH 3.7 0.4 6.2 0.2 0.9 0.1 2.8 0.1 
200 
30 °C / 60 % RH 9.1 0.6 6.2 1.1 1.4 0.0 4.6 0.0 
30 °C 2.1 0.0 2.3 0.1 0.8 0.0 1.4 0.0 
40 °C 2.5 0.1 2.7 0.0 0.8 0.0 1.3 0.0 
30 °C / 30 % RH 2.9 0.0 5.5 0.1 0.6 0.0 2.2 0.2 
400 
30 °C / 60 % RH 8.5 0.0 5.6 0.4 0.9 0.0 4.0 0.1 
30 °C 1.4 0.1 1.5 0.1 0.4 0.0 0.9 0.0 
40 °C 1.8 0.1 1.8 0.0 0.4 0.0 1.0 0.0 
30 °C / 30 % RH 2.6 0.1 5.3 0.1 0.3 0.0 2.1 0.0 
800 
30 °C / 60 % RH 8.8 0.0 5.6 3.0 0.4 0.0 2.8 1.4 
 
Table 2.6.8 Residual moisture content of freeze-dried placebo formulations after 4 weeks closed storage at 30 °C and 
40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Residual moisture [%] 
SucroseP TrehaloseP MannitolP Man-SucP Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
30 °C 4.0 0.4 6.0 0.1 3.1 0.1 3.3 0.3 
40 °C 3.3 0.3 7.0 0.2 2.4 0.0 3.2 1.2 
30 °C / 30 % RH 5.5 0.2 4.4 0.1 4.9 n/a 1.6 0.1 
47 
30 °C / 60 % RH 11.1 0.4 9.5 0.7 2.4 0.3 5.2 1.0 
30 °C 3.5 0.7 5.1 0.8 2.0 0.3 2.7 0.1 
40 °C 2.9 0.2 5.7 1.1 1.3 0.9 2.6 1.0 
30 °C / 30 % RH 3.4 0.5 3.2 0.4 1.5 n/a 1.6 0.2 
100 
30 °C / 60 % RH 11.3 0.7 6.6 1.8 1.0 1.9 4.1 1.2 
30 °C 3.1 0.1 3.6 0.1 1.2 0.0 2.5 0.4 
40 °C 2.5 0.1 4.0 0.0 0.9 0.4 2.2 1.3 
30 °C / 30 % RH 3.3 0.1 1.8 0.4 1.3 0.2 1.6 0.0 
200 
30 °C / 60 % RH 10.9 0.3 4.9 2.0 0.2 0.0 3.9 0.3 
30 °C 2.0 0.1 2.4 0.0 1.0 0.2 2.2 0.1 
40 °C 2.1 0.6 2.8 0.1 0.5 0.3 1.2 0.4 
30 °C / 30 % RH 2.4 0.3 1.2 0.1 0.3 0.0 1.4 0.0 
400 
30 °C / 60 % RH 6.0 3.6 4.2 0.9 0.2 0.1 2.7 0.0 
30 °C 1.5 0.1 1.5 0.0 0.6 0.2 1.1 0.1 
40 °C 1.6 0.1 1.9 0.1 0.3 0.1 1.0 0.3 
30 °C / 30 % RH 2.4 0.2 1.1 0.1 0.2 0.3 1.4 0.2 
800 
30 °C / 60 % RH 6.8 0.6 4.2 2.9 0.1 0.0 3.2 0.1 
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Table 2.6.9 Residual moisture content of freeze-dried gelatin nanoparticle (verum) formulations after 10 weeks closed 
storage at 30 °C and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Residual moisture [%] 
SucroseV SucroseV SucroseV SucroseV Formulation 
Mean Mean Mean Mean Mean Mean Mean Mean 
30 °C 4.1 0.4 5.0 0.3 2.5 0.2 2.7 0.0 
40 °C 3.7 0.6 2.0 0.0 2.6 0.3 3.7 0.2 
30 °C / 30 % RH 4.3 1.3 6.1 0.5 4.0 0.9 4.4 0.5 
47 
30 °C / 60 % RH 13.6 0.4 11.3 0.4 5.2 0.1 5.2 0.1 
30 °C 3.5 0.0 4.3 0.1 1.6 0.0 2.0 0.3 
40 °C 2.0 0.1 2.8 0.1 1.7 0.0 2.3 0.2 
30 °C / 30 % RH 1.7 0.5 5.3 0.1 1.9 0.1 2.6 0.1 
100 
30 °C / 60 % RH 10.9 0.4 10.0 1.0 3.0 0.1 4.0 0.2 
30 °C 2.8 0.1 3.4 0.1 1.2 0.0 1.7 0.1 
40 °C 2.7 0.1 3.6 0.1 1.1 0.1 1.7 0.1 
30 °C / 30 % RH 2.1 0.3 4.7 0.3 1.0 0.0 2.0 0.1 
200 
30 °C / 60 % RH 11.1 0.8 8.9 0.5 1.5 0.0 3.6 0.1 
30 °C 2.2 0.1 2.6 0.1 0.8 0.1 1.5 0.0 
40 °C 2.3 0.1 4.4 0.2 0.8 0.1 0.8 0.2 
30 °C / 30 % RH 2.0 0.0 3.7 0.2 0.7 0.0 1.7 0.1 
400 
30 °C / 60 % RH 10.2 0.0 7.9 0.2 1.0 0.0 3.6 n/a 
30 °C 1.5 0.1 1.7 0.1 0.4 0.0 0.9 0.1 
40 °C 1.8 0.0 5.3 0.3 0.5 0.1 0.9 0.0 
30 °C / 30 % RH 1.6 0.0 3.2 0.0 0.4 0.0 1.5 0.1 
800 
30 °C / 60 % RH 10.6 0.0 9.2 0.2 0.4 0.0 3.2 0.0 
 
Differential scanning calorimetry (DSC) data 
Table 2.6.10 Tg (point of inflection) of freeze-dried sucrose containing gelatin nanoparticle (verum) formulations right after 
the drying process and after 4 weeks closed storage at 20 °C, 30 °C, and 40 °C and open storage at 30 °C / 30 % RH and 
30 °C / 60 % RH 
 
Tg [°C] 
Start 4w 10w 
 20 °C 30 °C 40 °C 30 °C 40 °C Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 44.4 n/a 31.4 0.00 29.9 0.78 31.9 3.61 31.8 0.71 33.4 0.05 
100 49.5 0.00 36.4 0.00 32.8 0.71 n/a n/a 32.3 0.00 n/a n/a 
200 52.9 0.71 42.5 0.00 37.9 0.71 n/a n/a 36.3 0.00 n/a n/a 
400 55.0 3.61 49.5 0.00 43.0 2.12 41.4 0.00 43.4 0.00 n/a n/a 
800 57.5 1.41 53.1 0.71 49.0 0.71 43.0 7.85 49.9 0.71 45.4 0.00 
 
Table 2.6.11 Tg (point of inflection) of freeze-dried sucrose containing placebo formulations right after the drying process 
and after 4 weeks closed storage at 30 °C and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Tg [°C] 
Start 4w 
 30 °C 40 °C Formulation 
Mean Stdv Mean Stdv Mean Stdv 
47 41.9 0.71 n/a n/a n/a n/a 
100 49.5 0.07 n/a n/a n/a n/a 
200 54.5 n/a 34.7 0.78 n/a n/a 
400 57.5 0.07 43.8 0.71 38.8 0.78 
800 58.5 1.41 50.8 0.71 46.3 1.41 
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Table 2.6.12 Tg (point of inflection) of freeze-dried trehalose containing gelatin nanoparticle (verum) formulations right 
after the drying process and after 4 weeks closed storage at 20 °C, 30 °C, and 40 °C and open storage at 30 °C / 30 % RH and 
30 °C / 60 % RH 
 
Tg [°C] 
Start 4w 10w 
 20 °C 30 °C 40 °C 30 °C 40 °C Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 79.4 1.4 53.6 0.7 52.8 4.0 50.6 0.7 54.1 n/a 46.9 0.0 
100 82.4 n/a 65.4 0.0 54.2 2.8 57.7 0.7 52.8 5.4 53.1 1.4 
200 86.4 n/a 72.4 0.0 60.3 n/a 63.3 0.0 56.7 4.9 60.7 3.7 
400 84.3 7.4 79.9 0.7 72.4 1.4 68.4 0.0 73.4 0.0 66.8 0.7 
800 94.5 0.1 89.0 0.7 74.0 7.7 82.1 0.6 79.9 0.7 66.3 17.2 
 
Table 2.6.13 Tg (point of inflection) of freeze-dried trehalose containing placebo formulations right after the drying process 
and after 4 weeks closed storage at 30 °C and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Tg [°C] 
Start 4w 
 30 °C 40 °C Formulation 
Mean Stdv Mean Stdv Mean Stdv 
47 69.2 0.2 48.2 0.1 45.3 0.7 
100 80.4 0.0 56.7 0.0 54.6 0.8 
200 86.4 0.0 64.1 3.0 63.6 0.6 
400 88.2 0.4 75.6 1.5 68.3 0.0 
800 94.0 0.7 84.3 0.8 82.9 0.7 
 
Table 2.6.14 Melting point (peak) of freeze-dried mannitol containing gelatin nanoparticle (verum) formulations right after 
the drying process and after 4 weeks closed storage at 20 °C, 30 °C, and 40 °C and open storage at 30 °C / 30 % RH and 
30 °C / 60 % RH 
 
Melting point (peak) [°C] 
Start 4w 
 20 °C 30 °C 40 °C 30 °C / 30 % RH 
30 °C / 
60 % RH 
Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 158.2 0.9 157.6 0.1 156.6 0.1 157.5 0.0 156.6 0.1 155.0 0.7 
100 158.5 1.4 160.5 1.4 159.1 0.7 161.1 2.2 159.0 0.7 157.5 0.0 
200 160.5 2.8 163.1 2.1 164.5 2.8 164.1 0.6 163.5 1.4 161.5 0.0 
400 162.0 0.7 165.0 0.7 164.5 0.0 163.1 0.7 163.0 0.7 163.5 0.0 
800 163.5 0.0 163.5 0.0 165.0 2.1 163.6 0.1 163.5 0.0 163.5 1.4 
 
Table 2.6.15 Melting point (peak) of freeze-dried mannitol containing placebo formulations right after the drying process 
and after 4 weeks closed storage at 30 °C and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Melting point (peak) [°C] 
Start 4w 
 30 °C 40 °C 30 °C / 30 % RH 
30 °C / 
60 % RH 
Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 160.0 0.6 160.9 0.7 161.5 0.0 161.4 n/a 161.5 n/a 
100 161.4 0.1 162.4 0.0 163.0 0.6 163.4 0.0 163.4 0.0 
200 163.5 6.4 163.4 0.0 164.4 0.0 164.4 0.0 163.9 0.7 
400 165.0 0.7 162.4 0.0 163.9 0.7 163.4 0.0 164.4 0.1 
800 165.5 0.0 164.8 0.7 164.4 0.0 165.4 0.1 163.9 0.7 
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Table 2.6.16 Melting point (peak) of freeze-dried mannitol containing gelatin nanoparticle (verum) formulations after 10 
weeks closed storage at 30 °C and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Melting point (peak) [°C] 
10w 
30 °C 40 °C 30 °C / 30 % RH 
30 °C / 
60 % RH 
Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 155.5 0.0 157.1 0.6 155.5 0.0 155.5 n/a 
100 158.5 0.0 158.5 0.0 158.0 0.7 157.5 n/a 
200 164.5 1.4 164.0 2.1 161.5 n/a 161.5 0.0 
400 163.0 0.7 163.0 0.7 163.3 1.1 162.5 0.0 
800 164.0 0.7 161.5 0.1 163.0 0.7 164.5 0.0 
 
Table 2.6.17 Melting point (peak) of freeze-dried mannitol-sucrose containing gelatin nanoparticle (verum) formulations 
right after the drying process and after 4 weeks closed storage at 20 °C, 30 °C, and 40 °C and open storage at 30 °C / 30 % RH 
and 30 °C / 60 % RH 
 
Melting point (peak) [°C] 
Start 4w 
 20 °C 30 °C 40 °C 30 °C / 30 % RH 
30 °C / 
60 % RH 
Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 153.6 0.1 152.1 0.7 153.1 3.5 150.8 0.2 150.5 0.0 149.6 0.0 
100 154.1 0.8 153.6 0.0 153.6 0.0 153.6 0.0 152.5 0.0 151.6 0.1 
200 153.1 0.8 155.6 0.0 155.1 0.7 155.6 0.0 154.6 0.1 153.6 0.0 
400 153.5 1.4 156.1 0.7 156.6 0.1 157.1 0.7 157.0 0.7 157.6 1.3 
800 153.5 0.0 156.6 0.1 156.6 0.1 158.1 0.7 157.0 0.7 155.1 0.7 
 
Table 2.6.18 Melting point (peak) of freeze-dried mannitol-sucrose containing placebo formulations right after the drying 
process and after 4 weeks closed storage at 30 °C and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Melting point (peak) [°C] 
Start 4w 
 30 °C 40 °C 30 °C / 30 % RH 
30 °C / 
60 % RH 
Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 153.5 0.0 155.0 0.8 156.4 0.0 155.4 0.0 156.5 0.1 
100 151.0 0.7 154.5 0.0 157.5 0.1 156.4 0.0 156.5 0.1 
200 151.1 2.2 157.5 0.0 158.5 0.1 157.5 0.0 156.4 0.0 
400 154.1 0.8 155.0 0.7 158.5 0.1 157.9 2.1 156.5 0.1 
800 155.5 2.8 156.9 0.7 157.0 0.7 157.4 0.0 157.4 1.4 
 
Table 2.6.19 Melting point (peak) of freeze-dried mannitol-sucrose containing gelatin nanoparticle (verum) formulations 
after 10 weeks closed storage at 30 °C and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Melting point (peak) [°C] 
10w 
30 °C 40 °C 30 °C / 30 % RH 
30 °C / 
60 % RH 
Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
47 150.5 0.0 150.6 0.0 149.5 0.0 149.5 0.0 
100 152.6 0.1 152.6 0.1 152.5 0.0 152.5 0.0 
200 155.0 0.7 155.1 0.6 154.5 1.4 153.5 0.0 
400 156.6 0.1 158.1 0.8 155.5 1.4 156.0 0.7 
800 156.6 0.1 156.1 0.6 156.5 0.0 155.0 0.7 
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2.6.2 Stability data of oligonucleotide-loaded gelatin nanoparticles 
Photon correlation spectroscopy (PCS) data 
Table 2.6.20 Size and polydispersity indices of oligonucleotide-loaded gelatin nanoparticles before freeze-drying and 
rehydrated right after freeze-drying 
 
Size [nm] PDI 
Before After Before After Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
Sucrose 286.3 1.5 276.0 19.8 0.184 0.022 0.103 0.033 
Trehalose 297.7 9.0 263.3 1.5 0.245 0.110 0.094 0.023 
Mannitol 298.7 32.5 253.0 6.2 0.227 0.112 0.110 0.006 
200 
Man-Suc 349.0 41.1 329.0 6.0 0.210 0.051 0.140 0.020 
 
Table 2.6.21 Size of freeze-dried oligonucleotide-loaded gelatin nanoparticles rehydrated after 4 weeks closed storage at 
30 °C and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
Size [nm] 
4w 30 °C 4w 40 °C 4w 30 °C / 30 % RH 
4w 30 °C / 
60 % RH Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
Sucrose 257.3 1.5 273.0 4.9 312.3 12.9 456.0 86.3 
Trehalose 267.7 2.1 270.0 1.7 270.7 3.1 n/a n/a 
Mannitol 378.7 9.1 548.3 42.6 404.7 33.0 962.7 124.3 
200 
Man-Suc 380.7 7.5 769.7 116.4 493.3 29.4 1800.0 631.0 
 
 
Table 2.6.22 Polydispersity indices of freeze-dried oligonucleotide-loaded gelatin nanoparticles rehydrated after 4 weeks 
closed storage at 30 °C and 40 °C and open storage at 30 °C / 30 % RH and 30 °C / 60 % RH 
 
PDI 
4w 30 °C 4w 40 °C 4w 30 °C / 30 % RH 
4w 30 °C / 
60 % RH Formulation 
Mean Stdv Mean Stdv Mean Stdv Mean Stdv 
Sucrose 0.090 0.012 0.142 0.048 0.277 0.061 0.604 0.028 
Trehalose 0.136 0.025 0.140 0.011 0.158 0.018 n/a n/a 
Mannitol 0.384 0.009 0.546 0.022 0.439 0.074 0.834 0.022 
200 
Man-Suc 0.311 0.022 0.602 0.118 0.433 0.055 0.950 0.087 
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CHAPTER III 
Gelatin Nanoparticles for Targeted Oligonucelotide 
Delivery to Kupffer Cells During Hepatic Ischemia 
Reperfusion (I/R) Injury 
Abstract 
Hepatic ischemia reperfusion injury is a common and severe adverse reaction in 
several clinical situations. Basic understanding of the mechanisms behind led to the 
assumption of the transcription factor NF-κB released in Kupffer cells playing a 
central role in the inflammatory cascade finally causing loss of liver tissue. The aim 
of the present work was to provide the basis for further elucidation of the processes 
related to NF-κB activation. Therefore a selective Kupffer cell targeting of an NF-κB 
inhibiting decoy oligonucleotide was proposed as pharmacological intervention 
facilitated by a nanoparticulate drug carrier system based on gelatin in a warm 
hepatic I/R injury rat model. During initial studies the exclusive Kupffer cell uptake 
of NF-κB decoy oligonucleotide-loaded gelatin nanoparticles within liver was 
proven. The evaluation of plasma protein adsorption patterns conducted in 
comparison to solid lipid nanoparticles via 2D-PAGE analysis could contribute to the 
explanation of these data and compared to liposomes a superior Kupffer cell 
selectivity can be stated for gelatin nanoparticles. In the following the successful 
inhibition of NF-κB with NF-κB decoy oligonucleotide-loaded gelatin nanoparticles 
in the rat model could be demonstrated in a concentration dependent manner. Based 
on the established model future work can now be accomplished in terms of clarifying 
the role of NF-κB in the course of hepatic ischemia reperfusion injury. 
 
Keywords: Hepatic I/R injury, NF-κB, drug targeting, gelatin nanoparticles, decoy 
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3.1 Introduction 
Interruption of blood flow to an organ or tissue (ischemia) and subsequent 
reperfusion lead to an acute inflammatory response that may cause significant 
cellular damage and organ dysfunction. This phenomenon is named as ischemia 
reperfusion (IR) injury. 
The clinical relevance of this disease for the liver and liver transplantation 
respectively was already described in 1975. But the term “Hepatic Ischemia 
Reperfusion Injury” became widely accepted among experts not until the 1980s. 
Depending on external circumstances two types of hepatic IR injury are 
differentiated. Together with surgical interventions, liver transplantations, 
hemorrhagic shock, toxic or vein occlusive events, and the Budd-Chiari syndrome 
the so called warm hepatic ischemia reperfusion injury (warm I/R) occurs. Resulting 
from preservation conditions during transport of the removed organ or storage during 
transplantation, the occurrence of the so called cold hepatic ischemia reperfusion 
injury (cold I/R) is also possible during liver transplantation. Both share the basic 
pathophysiological mechanism but there are as well clear differences [Teoh et al., 
2003a]. Consequences of hepatic ischemia reperfusion injury include liver failure 
and in more severe cases liver failure in association with remote organ failure, both 
with significant rates of morbidity and mortality [Lentsch et al., 2000]. 
The aim of the presented work was to establish an animal model enabling the 
demonstration of an effective interruption of the inflammatory cascade during 
hepatic I/R injury. In terms of a drug targeting approach the application of a 
nanoparticulate drug delivery system should be the therapeutical basis. To keep the 
long term perspective of investigating the newly developed system in a clinical trial, 
it was decided to focus on a model based on warm ischemia reperfusion injury. 
Mechanisms on cellular and subcellular stage leading to ischemia reperfusion injury 
are very complex and there is still a need to better understand the pathophysiology 
[Jaeschke, 2003]. In the following these processes are therefore only explained in 
brief, while the pathophysiological quintessences and the resulting targets are 
elucidated in detail. 
The work was part of a DFG funded cooperation (subproject C, research group 
FOR 440) between the chairs of pharmaceutical biology (Prof. A. Vollmar / PD Dr. 
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S. Zahler / Ph.D. student Florian Hoffmann) and pharmaceutical technology (Prof. G. 
Winter / Dr. C. Coester / Ph.D. student Jan C. Zillies) of the Ludwig-Maximilians-
University Munich, Germany. The obtained data are a result of the close 
collaboration between the author and Florian Hoffmann and are accordingly denoted. 
3.1.1 Anatomic fundamentals 
The liver is composed of two major groups of cells, the parenchymal and the 
non-parenchymal cells. The parenchymal cells are the so called hepatocytes that 
maintain the metabolic function of the liver. They account for 65% of all liver cells 
and above 90% of the entire liver mass. Kupffer cells, endothelial cells, and Ito cells 
(fat storing cells) form the non-parenchymal part of the liver tissue. The Kupffer 
cells are part of the mononuclear phagocytosis system (MPS) and are the largest 
single population of macrophages in body. They originate form stem cells of the 
bone marrow and are embedded into the capillaries (sinusoids) of the liver after 
transformation into tissue macrophages. The Kupffer Cells account for 15% of all 
liver cells but only for 3% of the entire liver mass [Ponnappa et al., 2002; Löffler et 
al., 2003b]. 
Liver blood supply is sustained by Arteria hepatica (liver artery), feeding oxygen 
rich blood and Vena portae (portal vein) feeding venous blood carrying the metabolic 
products from stomach and intestine. Despite this twofold blood supply and the 
possibility of an anaerobic metabolism hypoxic damage of the liver may occur 
[Ponnappa et al., 2002; Mutschler, 2003; Teoh et al., 2003a]. 
The macroscopic view shows the four different sized lobes of the liver: two big 
ones, the larger right lobe (Lobus dexter) and the smaller left lobe (Lobus sinister) 
separated by the peritoneal duplication and two minor lobes (Lobus caudatus and 
Lobus quadratus). In addition the liver is devided in “Partes” and Divisiones”. This 
classification derives from the branching of A. hepatica, V. portae, and Ductus 
hepaticus. They are separated by externally invisible fissures [Sobotta, 1999]. 
The hepatic lobules are the units the liver is made of on the microscopic stage. 
The human liver consists of approximately 500,000 of these hexagonal appearing 1-
2 mm in diameter sized lobules. The above mentioned parenchymal and non-
parenchymal cells are the basic modules of this system. The hepatocytes within the 
particular lobules are radially arranged around a central vein (Vena centralis) and 
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build a three dimensional network (liver parenchyma) permeated by an as well 
radially arranged capillary network (sinusoids). The non-parenchymal cell types are 
preferentially located along the sinusoids being in close anatomical and functional 
relationship with the parenchymal cells. The endothelial cells cover the sinusoids at 
the inner wall and form an open work endothelium, the endothelial fenestrae 
measuring 150 – 175 nm in diameter [Braet et al., 2002]. The Kupffer cells adhere at 
the walls of the sinusoid too. But they are able to detach from the united cell 
structure after a rounding and circulate afterwards with the blood stream. The Ito 
cells are tightly associated with the hepatocytes, in addition they form cytoplasmic 
extensions wrapped around the endothelium of the sinusoids. They are located in the 
Disse’s space, a small fissure that separates the walls of the endothelium from the 
hepatocytes. The hepatocytes bear so called microvilli at their surface extending into 
the Disse’s space. This layout allows an intensive exchange between the capillaries 
of the lobules and the hepatocytes [Löffler et al., 2003b]. According to their function 
the hepatocytes contain many mitochondria with a broad spectrum of metabolic 
enzymes [Thews et al., 1999]. 
3.1.2 Pathophysiological mechanisms 
Consequences of ischemia and reperfusion can not be definitely attributed to one 
of these two events; in fact the changes caused by the hypoxic state during ischemia 
predispose to the later reoxygenation injury [Li et al., 2002]. 
Hypoxia alters enzyme activities and mitochondrial functions and affects the 
structure of the cytoskeleton, the membrane transport and antioxidant defenses. Thus 
the activity of the mitochondrial cytochrome oxidase is reduced, whereby an electron 
acceptor is missing that leads to enhanced production of reactive oxygen species 
(ROS). ROS in turn cause the oxidative inhibition of the Na+-K+-ATPase which is 
among other things responsible for swelling and subsequent cytolysis during 
reoxygenation [Li et al., 2002]. The processes taking place during ischemia are thus 
not the direct reason for I/R injury but part of the triggering of the pathophysiological 
mechanisms that are activated with reperfusion. There are two distinct phases of liver 
injury after warm I/R. The initial or early phase (< 2 h after reperfusion) is 
characterized by the production of ROS, the late phase (6-48 h after reperfusion) by 
inflammatory events mediated by neutrophils [Lentsch et al., 2000; Teoh et al., 
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2003a]. Figure 3.1.1 shows the cascade of early and late phase of liver injury. By 
reperfusion endothelial cells and Kupffer cells as well as complement are activated 
(1). Within the Kupffer cells ROS are produced in the following in a mainly 
NADPH-Oxidase mediated process (2). This again activates endothelial cells (5) and 
leads to the release of several cytokines (7, 10) and chemokines (8) via the 
transcription factor NF-κB (4). Besides inducible nitric oxide synthase (iNOS) is 
expressed in the different liver cell types (9). It is discussed whether this disturbs via 
the increased nitric oxide (NO) production the equilibrium between the vasodilator 
NO and the, at the same time released, vasoconstrictor endothelin (ET). This 
imbalance would lead to a failure of the microcirculation (9a) and finally contribute 
to I/R injury [Teoh et al., 2003a]. As the vasodilatory properties of NO and its 
influence on neutrophils can positively affect the course of I/R, amount and origin of 
released NO have to be taken into consideration.  
 
 
 
Figure 3.1.1 Pathophysiological mechanism of early and late phase of hepatic I/R injury 
[modified after Lentsch et al., 2000; Jaeschke, 2003; Teoh et al., 2003a] 
 
NO produced by the constitutive present endothelial NO-synthase (eNOS) has a 
positive influence while guaranteeing the blood circulation of the liver whereas an 
Gelatin Nanoparticles for Targeted Oligonucelotide Delivery to Kupffer Cells 
139 
exaggerated iNOS mediated NO production has a negative effect caused by the 
enhanced formation of peroxynitrite [Jaeschke, 2003]. NF-κB is an inducible 
transcription factor, located in its inactivated state in the cytosol while being 
complexed with inhibitory κB (IκB). The NF-κB transcription factor family 
comprises the proteins p50, p52, p65 (RelA), c-Rel, and RelB. The activated state of 
NF-κB is in general a heterodimer of the subunits p50 and p65 [Zwacka et al., 1998]. 
But depending on the particular cell type homodimers and further heterodimers are 
known. In general driven by prime pathogenous stimuli like physical or chemical 
stress as well as viruses and bacteria or cytokines IκB is rapidly phosphorylated at 
serine residues 32 and 36. Afterwards it is ubiquitinylated and ultimately degraded 
by proteolytic cleavage (6). At the same time NF-κB is released and binds after 
translocation into the nucleus (6) to its recognition (consensus) sequence within the 
genome where it regulates the transcription of various genes. Different consensus 
sequences are thereby described in literature followed from the composition of the 
NF-κB dimers [Chen et al., 1999; Löffler et al., 2003a]. Additionally, during I/R NF-
κB activation independent from IκB degradation based on a tyrosine phosphorylation 
is known to be a likely pathway [Zwacka et al., 1998]. 
The release of cyto- and chemokines marks the change from early to late phase 
of liver injury. Interleukin 1 (IL-1) fosters further production of ROS in terms of a 
positive feedback (10a) and contributes to the activation of endothelial cells (10b). 
The activation of neutrophils results from TNFα and CINC (cytokine induced 
neutrophil chemoattractant) (11), a very potent chemotactic chemokine [Teoh et al., 
2003a]. TNFα itself is as well part of a positive feedback loop (7a) and neutrophils 
also induce ROS production (12). Endothelial cells, hepatocytes, platelets, and 
neutrophils express adhesion molecules and selectins (13-16) that initially mediate 
the adsorption (17) and later the transmigration (18) of neutrophils at the 
endothelium and into the liver parenchyma respectively. P- and E-selectin are surface 
glycoproteins that are responsible for interception and adhesion of circulation 
neutrophils. The adhesion molecules VCAM (vascular cell adhesion molecule) and 
ICAM (intracellular adhesion molecule) are members of the immunoglobulin 
superfamily. They are expressed on the surface of endothelial cells and provide a 
firm binding of at first slightly adhered neutrophils at the endothelium. Thus they 
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allow a subsequent immigration of neutrophils to the site of inflammation [Jaeschke, 
2003; Teoh et al., 2003a]. 
In sum the coaction of the various described mechanisms, the formation of ROS 
(3, 12a) and TNFα, the microcirculatory failure (9b) as well as the neutrophil 
mediated inflammatory processes finally cause the destruction of liver tissue (19). 
Attributing cell death to the mode of apoptosis or necrosis is thereby still 
controversially discussed in literature [Gujral et al., 2001; Kim et al., 2003; Meguro 
et al., 2003; Vilatoba et al., 2005]. 
3.1.3 Therapeutic options 
To minimize the loss of blood during surgical interventions at the liver e.g., after 
severe traumata or during liver transplantation, it is necessary to interrupt the blood 
supply of parts of the organ or the organ in total for a certain period of time. The 
concurrent clamping of Arteria hepatica and Vena portae, known as Pringle 
maneuver, is still widely used to completely interrupt the blood flow through the 
liver. The main disadvantage is the often appearing warm I/R injury followed from 
the transient hypoxia. 
To reduce or to exclude the post surgical liver injury one tries to improve the 
surgical options on the one hand and to selectively interact with the above described 
pathophysiological cascade on the other hand. 
Surgical options 
Aim of the surgical options is the increasing abdication of the Pringle maneuver 
with its long lasting organ wide ischemic period. This is feasible by clamping single 
arterial branches, prevention of bleeding by coagulating injured blood vessels with 
an argon laser, or the application of supersonic assisted tissue sections [Lentsch et 
al., 2000; Teoh et al., 2003a]. 
Interruption of pathophysiological signal transduction pathways 
Hepatic preconditioning The concept of ischemic preconditioning is based on 
the biological principle that tissue primed by various types of sublethal stress 
develops tolerance to subsequent lethal injury [Kang, 2002]. 
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During ischemic preconditioning liver is exposed to short intervals (5-10 min) of 
ischemia and reperfusion, whereby negative consequences of warm I/R can be 
clearly reduced. The underlying mechanisms of the protective effect are so far not 
completely understood, altered TNFα release, involvement of adenosine A2 receptors 
and NO, maintenance of the microcirculation as well as an enhanced cytoprotection 
mediated by an accelerated entrance into cell cycle are discussed in literature 
[Lentsch et al., 2000; Kang, 2002; Koti et al., 2003; Teoh et al., 2003a; Teoh et al., 
2003b]. 
Aside it is reported about positive effects towards oxidative stress caused by 
Kupffer cells that were activated by hormonal preconditioning with atrial natriuretic 
peptide (ANP) [Bilzer et al., 2000; Kang, 2002]. 
Pharmacological interventions There are certain clinical situations e.g., acute 
liver traumata, where a time frame for preventive strategies as described above is not 
given. In these cases pharmacotherapeutic approaches are necessary to attenuate or to 
avoid hepatic I/R injury. The application of particular pharmaceuticals may be 
carried out before or during ischemia and reperfusion. The first is described as 
pharmacological preconditioning [Kang, 2002]. 
Arising from the numerous illustrated factors leading to liver injury (chapter 
3.1.2) several points of attack are imaginable based on antioxidative strategies, 
gentherapeutical approaches, receptor blockade, and anti-inflammatory or 
immunosuppressive mediators. 
In the beginning ROS formation plays the main role in the pathological events 
[Teoh et al., 2003a]. Thus different antioxidative strategies that should diminish the 
outcome of the excessive ROS production are described in this context. Apart from 
the application of antioxidative active low molecular weight substances like 
vitamin E [Serracino-Inglott et al., 2001; Jaeschke, 2002] or the endogenous 
glutathione [Bilzer et al., 2000; Kang, 2002], the reduction of ROS is aimed for by 
the administration of enzymes. From initially built peroxides superoxide anions are 
produced within hepatocyte mitochondria which in turn are degraded by the 
superoxide dismutase (SOD). This rapidly proceeding reaction circumvents the 
oxidation of NO to peroxynitrite explaining the cytoprotective effect of SOD 
[Jaeschke, 2002]. Beside the direct administration of the modified enzyme [Yabe et 
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al., 2001] a combined genetherapeutic and antioxidative approach is described. To 
amplify the enzymatic potency its gene is transferred into hepatocytes via an 
adenoviral vector where it is subsequently expressed [Jaeschke, 2002]. A further 
adenoviral mediated gene expression is utilized for the application of hemoxygenase 
(HO). As oxidative events foster the natural transcription of HO an advanced 
protection from ischemia induced oxidative stress by an enhanced HO expression is 
suggested which could already be proven in several models [Fondevila et al., 2003]. 
Within the inflammatory cascade activation of Kupffer cells play the main role. 
In an animal model it could be shown that a gadolinium chloride induced suppression 
of Kupffer cell activity lead to an attenuated hepatic I/R injury [Mosher et al., 2001; 
Giakoustidis et al., 2003]. Augmentation of Kupffer cell activity by latex beads in 
comparison worsens the state of the liver after ischemia and reperfusion [Shiratori et 
al., 1994]. Modulation of Kupffer cell activity and therefore the impact on numerous 
released inflammatory mediators is thus a potential target for pharmacotherapeutical 
interventions [Mosher et al., 2001]. So it could be shown that blocking TNFα and IL-
1 as well as subsequent mediators like VCAM or certain chemokines clearly reduce 
hepatic I/R injury [Lentsch et al., 2000]. Most of the mentioned proinflammatory 
mediators have the regulation of their transcription via the inducible transcription 
factor NF-κB in common [Morishita et al., 1998; Serracino-Inglott et al., 2001]. This 
is crucial for the inflammatory processes followed from Kupffer cell activation and 
has to be taken into consideration as potential target during anti-inflammatory 
therapy [Banafsche et al., 2001]. 
A further point of attack within the pathophysiological mechanism of I/R injury 
is the maintenance of the microcirculation. Microcirculation is controlled by the 
interaction of the functional antagonists’ nitric oxide and endothelin as described in 
chapter 3.1.2. The administration of exogenous nitric oxide via an NO donor (FK 
409) improves the hepatic microcirculation, suppresses the production of endogenous 
NO and therewith the formation of peroxynitrite as well as the activation of 
neutrophils [Nozaki et al., 2003]. On the other hand endothelin receptor antagonists 
and inhibitors of the endothelin converting enzyme also contribute to an improved 
microcirculation after ischemia and reperfusion [Ricciardi et al., 2001; Uhlmann et 
al., 2001; Witzigmann et al., 2002]. 
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Further more it was reported about hepatoprotective effects against ischemia and 
reperfusion for the immunosuppressive substances azathioprine and cyclosporine as 
well as tacrolimus (FK 506) proved in transplantation-medicine [Kawano et al., 
1993; Baron et al., 2002]. 
3.1.4 Therapeutic strategy – Gelatin nanoparticles for targeted delivery of an 
NF-κB decoy oligonucleotide to Kupffer cells 
Due to the central function NF-κB takes within the mechanisms leading to 
hepatic I/R injury, the inhibition of the NF-κB controlled proinflammatory mediator 
release in Kupffer cells was chosen as target. But, the role NF-κB plays in the liver is 
ambivalent. Besides the described contribution to hepatic I/R injury there is a 
protective effect known. Subsequent to liver transplantation it helps to regenerate 
liver tissue and leads to a reduced apoptosis of hepatocytes. Thus if NF-κB activation 
is unselectively eliminated in each of the liver cell types an increased rate of 
apoptosis would be the outcome, finally damaging liver tissue [Lentsch et al., 2000]. 
This double role causes the need for the intended inhibition of NF-κB to be limited to 
the Kupffer cells [Banafsche et al., 2001]. Kupffer cells are the resident macrophages 
of the liver and part of the MPS (chapter 3.1.1). Due to their strategic position inside 
the sinusoids Kupffer cells are the first within the group of macrophages that 
encounter foreign material entering the circulation via the portal vein [Ponnappa et 
al., 2002]. Thus they strongly influence bioavailability and biodistribution of 
colloidal drug carrier systems [Kreuter, 1983; Kreuter, 1992; Thews et al., 1999] as 
they recognize and phagocyte colloidal structures like liposomes and nanoparticles 
due to the rapid opsonization immediately occurring after application [Yan et al., 
2005; Owens et al., 2006]. To invert this drawback of resulting low plasma half lives 
that minimizes most therapeutic effects to a selective Kupffer cell targeting is the 
basic idea behind the therapeutical approach it is aimed at. A successful Kupffer cell 
targeting was already shown for oligonucleotides incorporated in anionic and 
cationic (HVJ-) liposomes [Ponnappa et al., 2002; Yoshida et al., 2002] as well as 
poly(isobutylcyanoacrylate) nanoparticles and low density lipoprotein (LDL) bound 
oligonucleotides [Nakada et al., 1996; Bijsterbosch et al., 2001]. Here, gelatin 
nanoparticles were chosen as vehicle for the targeted delivery to the Kupffer cells of 
the liver. 
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Active principle of the therapeutical approach is to inhibit the NF-κB controlled 
release of proinflammatory mediators using a decoy strategy. Decoys are single- or 
doublestranded DNA oligonucleotides (ODNs) whose base sequences are identical 
with the consensus sequence of a particular transcription factor. To circumvent fast 
enzymatic degradation by nucleases in vivo these oligonucleotides can be substituted 
by so called phosphorothioates, DNA analogues comprising sulphur instead of non-
bridging oxygen in the phosphodiester backbone [Agrawal et al., 2000]. Figure 3.1.2 
shows the mechanism of the decoy induced transcription factor blockade. 
 
Figure 3.1.2 Mechanism of the decoy effect 
 
Triggered by an exogenous stimulus receptor mediated transcription factor 
activation (1) is followed from its translocation into the nucleus (2). But, in the 
presence of a decoy the subsequent transcription factor binding to its respective 
consensus sequence is stopped. Instead a bonding is formed between the 
transcription factor and the consensus sequence within the decoy oligonucleotide, 
whereby the transcription factor is not able to maintain its regulatory function for 
gene expression. The described reaction between decoy oligonucleotide and 
transcription factor already occurs in the cytoplasm directly after activation of the 
transcription factor (1) and without the necessity of a previous translocation into the 
nucleus. A successful inhibition of an NF-κB induced mediator release could be 
proven for single stranded [Tan et al., 2002] as well as double stranded [Ogushi et 
al., 2003] decoy oligonucleotides. Since the utilized consensus sequences clearly 
vary and there are several NF-κB consensus sequences described in literature as 
already indicated in chapter 3.1.2 it makes it difficult to focus on “the one” sequence. 
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Based on promising results obtained during former experiments of some members of 
our research group [Kupatt et al., 1999] it was decided to apply a double stranded 
phosphorothioate (PTO) oligonucleotide bearing the following NF-κB consensus 
sequence for the present work: 
5´-AGT TGA GGG GAC TTT CCC AGG C-3´ 
A phosphorothioate oligonucleotide was chosen as those ODNs exhibit an 
improved stability against enzymatic degradation, which is due to substitution of a 
non-bridging oxygen atom with a sulphur atom in the nucleic acid backbone [Ciafre 
et al., 1995]. 
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3.2 Proof of Principle – Kupffer Cell Targeting 
Before any effect, induced by delivery of the NF-κB decoy oligonucleotide, 
could be interpreted it had to be ensured that this effect is related to the selective 
inhibition of NF-κB within Kupffer cells. For this reason the solely Kupffer cell 
targeting of gelatin nanoparticles had to be proven at first. For this purpose 
biodistribution studies in rats were accomplished with fluorescent-labeled gelatin 
nanoparticles. Rats were chosen for the later establishing of the hepatic I/R model as 
there was already certain experience existing in the work with them and as the size of 
liver and other organs offer a simplified handling esp. in comparison with mice. Thus 
biodistribution data were as well acquired from studies conducted in rats. 
3.2.1 Materials and methods 
Reagents 
Reagent Description Supplier 
Acetone p.a. VWR International GmbH (Ismaning, Germany) 
Cholaminechloride 
hydrochloride 
(2-aminoethyl)-trimethyl- 
ammoniumchloride hydrochloride 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
EDC 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
Gelatin type A 175 Bloom Sigma-Aldrich GmbH (Taufkirchen, Germany) 
Glutaraldehyde 25 % aqueous solution  Sigma-Aldrich GmbH (Taufkirchen, Germany) 
HCl 2 N VWR International GmbH (Ismaning, Germany) 
PBS Dulbecco’s phosphate buffered saline pH 7.4 (1x concentrate) 
PAA Laboratories GmbH 
(Linz, Austria) 
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Cell culture  
Reagent Description Supplier 
Collagenase H  Roche Diagnostics (Mannheim, Germany) 
DMEM Dulbecco’s modified eagle medium pH 7.0-7.5 
Cambrex Profarmaco Landen 
Landen, Belgium 
FBS fetal bovine serum PAA Laboratories GmbH (Linz, Austria) 
Formalin solution  neutral buffered, 10 % Sigma-Aldrich GmbH (Taufkirchen, Germany) 
L-Glutamine solution 200 mM  Cambrex Profarmaco Landen Landen, Belgium 
Penicillin/Streptomycin 
(Pen/Strep) solution 100x concentrate 
PAA Laboratories GmbH 
(Linz, Austria) 
Trypsin solution 1x concentrate PAA Laboratories GmbH (Linz, Austria) 
 
Fluorescent staining 
Reagent Description Supplier 
Alexa Fluor® 488 goat-
anti-mouse IgG1 (γ1) 
λem 519 nm 
Invitrogen GmbH 
(Karlsruhe, Germany) 
BSA bovine serum albumin, Cohn Fraction V 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
ds NF-κB decoy ODN488  
5´-AGT TGA GGG GAC TTT CCC AGG C-3´ 
5’ Alexa Fluor® 488 labeled, 
λem 519 nm, phosphorothioate 
biomers.net GmbH 
(Ulm, Germany) 
Hoechst 33342  trihydrochloride, trihydrate, λem 461 nm 
Invitrogen GmbH 
(Karlsruhe, Germany) 
Mouse-anti-rat CD163 
IgG1 
 
AbD Serotec GmbH 
(Duesseldorf, Germany) 
 
Permafluor aqueous mounting medium Beckmann Coulter GmbH (Krefeld, Germany) 
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Reagent Description Supplier 
Texas Red® sulfonyl 
chloride  mixed isomers, λem 615 nm 
Invitrogen GmbH 
(Karlsruhe, Germany) 
Triton® X-100  Sigma-Aldrich GmbH (Taufkirchen, Germany) 
VybrantTM DiD cell 
labeling solution λem 665 nm 
Invitrogen GmbH 
(Karlsruhe, Germany) 
 
Solutions 
Solution Components* Concentration 
Buffer A (pH 7.35) 
NaCl 
NaHCO3 
KCl 
MgCl2 
NaH2PO4 
Na2SO4 
CaCl2 
Hepes 
115 mM 
25 mM 
5.9 mM 
1.18 mM 
1.23 mM 
1.2 mM 
2.5 mM 
20 mM 
Medium A 
DMEM 
FBS 
Glutamin sol. 
Pen/Strep sol. 
83 % [v/v] 
15 % [v/v] 
1 % [v/v] 
1 % [v/v] 
Medium B 
DMEM 
FBS 
Glutamin sol. 
84 % [v/v] 
15 % [v/v] 
1 % [v/v] 
 
*All buffer salts were purchased from Sigma-Aldrich GmbH (Taufkirchen, Germany) 
 
Preparation and surface modification of gelatin nanoparticles 
Gelatin nanoparticles were manufactured by the two step desolvation method 
and surface modified (cationized) with cholamine as described in chapter 1.2. 
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Preparation of fluorescent cationic gelatin nanoparticles 
Fluorescent-labeled gelatin nanoparticles were prepared by covalent coupling of 
the gelatin base material with an amino reactive fluorescent dye. After the first 
desolvation step the remaining gelatine sediment was dissolved in 25 mL of water 
under constant stirring (500 U/min) and heating up to 50 °C. 1 mg of the fluorescent 
dye (Texas Red®) was added to this solution after dissolving in acetone and the 
mixture was constantly stirred for 1 h (500 U/min) at 50 °C. After this incubation 
period the regular gelatin nanoparticle manufacturing process was continued with the 
second desolvation step. Subsequent to purification cationization was conducted as 
usual (chapter 1.2). 
Oligonucleotide-loading of gelatin nanoparticles 
540 µL of an aqueous nanoparticle dispersion containing 3.6 mg surface 
modified fluorescent gelatin nanoparticles was incubated with 120 µL of an aqueous 
oligonucleotide solution containing 6 nmol NF-κB decoy ODN488 (i.e., 2.5 % [w/w] 
drug loading) in PBS adjusted to a final volume of 1,200 µL for 2 h at 22 °C and 
800 rpm under constant shaking (Thermomixer Comfort, Eppendorf AG, Hamburg, 
Germany). 
Characterization of nanoparticles 
Size and zetapotential of the gelatin nanoparticle batches were determined by 
dynamic light scattering (DLS) using a Zetasizer 3000 HSA (Malvern Instruments, 
Worcestershire, UK). Zetapotential measurements were conducted under 
standardized ionic conditions in 10 mM NaCl at pH 7.0. 
Isolation and purification of Kupffer cells 
Initially rat livers were digested by rinsing with 80 mg of Collagenase in 100 mL 
buffer A. Subsequently, livers were resected and stored in 100 mL ice cold PBS (1x). 
After gentle mincing and filtration (150 µm mesh) hepatocytes were separated from 
non parenchymal cells (cp. chapter 3.1.1) by centrifugation for 5 min at 50 g and 
4 °C. Remaining supernatant was centrifuged for 10 min at 500 g and the pellet was 
resuspended in 40 mL medium A. The resulting suspension was transferred to a cell 
culture vessel to allow cells to adhere for 1 h at 37 °C in an incubator. Afterwards 
endothelial cells were removed by adding 7 mL of trypsin solution. Remaining 
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Kupffer cells were washed with medium A, suspended by scraping and centrifuged 
for 10 min at 500 g. Finally 15 mL of medium were added; cells were resuspended 
and cultivated in cell culture vessels. 
Kupffer cell uptake studies 
At first cover slips were placed in each well of 24-well plates. Subsequent 1 mL 
of a Kupffer cell suspension acquired from isolation process (~ 0.3 x 106 cells/mL) 
was plated to each well of the prepared well plates. After 1 h of adherence to the 
cover slips, cells were washed with medium B once and 450 µL medium B were 
added. Cells were then incubated with 50 µL of an NF-κB decoy ODN488 loaded 
fluorescent gelatin nanoparticle suspension. The final decoy ODN concentration per 
well was adjusted to 0.5 µmol/L i.e., 3.7 µg ODN per well. The according 
nanoparticle concentration resulting from 2.5 % [m/m] drug loading accounted for 
148.4 µg gelatin nanoparticles per well. After 15 min and 1 h respectively of 
incubation cells were fixed with 3 % formalin in PBS for 10 min and washed thrice 
with PBS. 
In vivo biodistribution experiments 
Experiments were conducted in male Sprague-Dawley rats. Fluorescent-labeled 
gelatin nanoparticle formulations were prepared in PBS (1 mg/mL) and injected 
(1 mL) into rat either via the crural vein or directly into the portal vein. Prior to 
injection rats were anesthetized by i.p. injection of 0.005 mg/kg Fentanyl and 
2.0 mg/kg Midazolam. Anesthesia was maintained over the whole experiment with 
1.5 % Isofluran continuously applied using a vaporizer with Carbogen (5 % 
CO2 / 95 % O2) as carrier gas. To monitor blood pressure and control anesthesia the 
jugular artery was cannulated with a 16 gauge PE catheter and connected to a blood-
pressure gauge. For intraportal injection the abdomen was opened by midline-
laparotomy and the portal triad was prepared. The body temperature was kept 
between 36.0 °C and 37.0 °C with a warming lamp. 
After 1h rats were sacrificed and blood was rinsed out. Brain, heart, kidneys, 
liver, lungs, parts of femoral muscle, and spleen were resected, frozen with liquid 
nitrogen and stored at -80 °C. The distribution of nanoparticles into the different 
organs was determined via confocal laser scanning microscopy (CLSM).  
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CLSM imaging 
Isolated Kupffer cells Subsequent to fixing and washing Kupffer cells were 
permeabilized for 2 min with 0.2 % Triton® X in PBS and washed three times with 
PBS. Afterwards cells were blocked with 0.2 % BSA in PBS for 10 min and washed 
another three times with PBS. Nuclear staining was then performed by incubating 
cells with 10 µL Hoechst solution (50 µg/mL) in 500 µL PBS for 10 min. After 
washing thrice with PBS cells were incubated with 2.5 µL VybrantTM DiD cell 
labeling solution in 500 µL PBS for 10 min to accomplish endosomal membrane 
staining. Following finally washing for three times with PBS cover slips were taken 
from well plates and were fixed with Permafluor on a microscopic slide. After 
storing over night the Kupffer cell preparations were analyzed with a Zeiss LSM 510 
Meta confocal laser scanning microscope (Carl Zeiss Microscope Systems, Jena, 
Germany). 
Tissue samples from biodistribution studies 10 µm thin slices of the frozen 
organs from the in vivo biodistribution experiments were prepared using a HM 500 
Kryostat (Microm International AG, Volketswil, Switzerland) and transferred to 
microscopic slides. After thawing samples were mounted in Permafluor with a cover 
slip. In addition liver tissue slices were further stained for Kupffer cells prior to 
mounting. Right after thawing preparations were fixed with 3 % formalin in PBS for 
3 min and stored in PBS until staining. For the staining procedure microscopic slides 
were adjusted in a staining trough. Preparations were initially washed three times for 
3 min with PBS, and blocked with 1.0 % BSA in PBS (100 µL) for 20 min. 
Subsequent incubation with the primary antibody (mouse-anti-rat CD 163 IgG1, 
1:100) was conducted for 40 min in 100 µL of 0.2 % BSA in PBS. After a washing 
step (3x 3 min with PBS) the staining procedure was completed applying a secondary 
antibody (Alexa Fluor® 488 goat-anti-mouse IgG1, 1:400) in 100 µL of 0.2 % BSA in 
PBS for another 40 min. Finally preparations were washed twice for 3 min with PBS 
and tissue slices were sealed in Permafluor with a cover slip. CLSM imaging was 
performed with a Zeiss LSM 510 Meta confocal laser scanning microscope (Carl 
Zeiss Microscope Systems, Jena, Germany). 
 
Kupffer cell isolation, in vitro uptake studies, in vivo biodistribution studies and 
fluorescent staining of the obtained cell and tissue samples were conducted together 
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with Florian Hoffmann at the department of pharmaceutical biology of the Ludwig-
Maximilians-University Munich, Germany. So, the present data are a result from the 
cooperation between the chairs of Pharmaceutical Technology and Pharmaceutical 
Biology of the Ludwig-Maximilians-University described at the beginning of this 
chapter and will be discussed under further aspects in the thesis of Florian Hoffmann 
[Hoffmann, 2007]. 
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3.2.2 Results and discussion 
Characterization of nanoparticles 
Both fluorescent-labeled nanoparticle formulations applied during 
biodistribution and cell culture experiments had almost the same size (~270 nm) and 
the same homogenous size distribution with a PDI around 0.060. Zetapotential values 
differed due to the conducted surface modification of G-NPTex 04-024 pos, which 
was required for oligonucleotide loading. Initially conducted biodistribution 
experiments focused on the in vivo distribution and the selective Kupffer cell uptake 
of empty and not surface-modified gelatin nanoparticles in general. Whether surface 
modification and oligonucleotide-loading i.e., different surface charges affect 
biodistribution and phagocytotic uptake by macrophages is discussed in detail in 
chapter 3.3. The experiments performed with isolated Kupffer cells in turn addressed 
the intracellular distribution of NF-κB decoy oligonucleotide loaded gelatin 
nanoparticles and the intracellular release of the oligonucleotide. The selective 
Kupffer cell uptake of oligonucleotide loaded gelatin nanoparticles is reviewed in 
chapter 3.4. 
Table 3.2.1 Size, polydispersity, and surface charge of the fluorescent-labeled nanoparticle 
formulations applied for biodistribution# and cell culture experiments§ 
 
 
#Fluorescent gelatin 
nanoparticles 
(G-NPTex 04-002 ) 
§Surface modified and 
fluorescent gelatin 
nanoparticles 
(G-NPTex 04-024 pos) 
size [nm] 269,8 268.1 
PDI 0.056 0.066 
ZP [mV] -3.4 +17.2 
Biodistribution of intravenously and intraportally applied gelatin nanoparticles 
Based on the knowledge of a suppressed Kupffer cell activity reducing hepatic 
ischemia reperfusion injury [Mosher et al., 2001; Giakoustidis et al., 2003] and of the 
role of NF-κB in the hepatic inflammatory response [Lentsch et al., 2000], we 
proposed a Kupffer cell targeted delivery of an NF-κB decoy to positively affect 
hepatic I/R injury. Thus, it was at first crucial to demonstrate that the chosen drug 
delivery vehicle i.e., gelatin nanoparticles is selectively taken up by Kupffer cells 
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after intraportal application, as it can be assumed from former biodistribution studies 
with colloidal drug delivery systems [Kreuter, 1983]. Therefore slices from deep-
frozen organs were prepared for CSLM analysis subsequent to biodistribution studies 
conducted with fluorescent-labeled gelatin nanoparticles in rat. At first, the impact of 
the route of administration was explored. Thereby, compared to systemic application 
a clear liver accumulation of gelatin nanoparticles could be demonstrated after 
intraportal injection. Figure 3.2.1 shows the nanoparticle distribution after systemic 
application to the organs of the MPS, liver (A), spleen (B), and lung (C), typically 
involved in the clearance of particulate matter (cp. chapter 3.3). In addition, none of 
the gelatin nanoparticles could be detected in kidney. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.1 CLSM pictures of (A) liver, (B) spleen, (C) lung, and (D) kidney taken from organs 
resected 1 h after injection of G-NPTex 04-002 (red dots) into the crural vein 
 
The resulting pronounced liver accumulation after intraportal application is 
displayed in Figure 3.2.2. Liver (A) uptake is increased and at the same time fewer 
nanoparticles could be detected in spleen (B) and lung (C). In kidney, again no 
nanoparticles were observed. Presumably liver macrophages i.e., Kupffer cells were 
not able to phagocyte the complete amount of nanoparticles applied as their total 
amount exceeded the phagocytotic capacity of the Kupffer cells. 
As each CLSM image only covers small sections of whole preparations these 
findings were confirmed by taking a series of pictures both from the same and from 
different liver tissue slices. 
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Figure 3.2.2 CLSM pictures of (A) liver, (B) spleen, (C) lung, and (D) kidney taken from organs 
resected 1 h after injection of G-NPTex 04-002 (red dots) into the portal vein 
 
However, within liver the selective Kupffer cell uptake of gelatin nanoparticles 
is much more important for the proposed NF-κB decoy strategy than an exclusive 
organ distribution to the liver. To prove the intraorgan distribution a Kupffer cell 
selective fluorescent secondary antibody staining of liver tissue slices was performed 
for CLSM analysis. The successful staining is shown in Figure 3.2.3 B. The overlay 
of Kupffer cell (B) and nanoparticle (A) images demonstrates the distinct 
colocalization of both (Figure 3.2.3 C), which indicates the distribution of gelatin 
nanoparticles within the liver being confined to Kupffer cells.  
 
 
 
 
 
 
Figure 3.2.3 CLSM pictures of liver tissue taken from liver resected 1 h after injection of 
G-NPTex 04-002 into the portal vein; pictures show (A) gelatin nanoparticles (red), (B) fluorescent 
stained Kupffer cells (green), and (C) the overlay of both 
 
Again data were confirmed by taking a series of pictures from the same and from 
different liver preparations. 
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Figure 3.2.4 CLSM pictures of liver tissue taken from liver resected 1 h after injection of 
G-NPTex 04-002 into (A) portal vein and (B) crural vein; both pictures show gelatin nanoparticles (red) 
and fluorescent stained Kupffer cells (green) 
 
Figure 3.2.4 reveals the Kupffer cell accumulation of gelatin nanoparticles after 
intraportal application in an overlay of nanoparticle and Kupffer cell images. 
Administering the same amount of nanoparticles either intraportally or systemically, 
the intensity of the emitted fluorescence of gelatin nanoparticles seen per Kupffer 
cell is much stronger after intraportal application. In addition to Figure 3.2.1 and 
Figure 3.2.2 this further clarifies the aspired selective Kupffer cell targeting of 
gelatin nanoparticles to be feasible. 
Intracellular distribution of gelatin nanoparticles in Kupffer cells 
Besides the discussed targeting issues the uptake of gelatin nanoparticles loaded 
with NF-κB decoy oligonucleotide into Kupffer cells was closer looked at. Thus, 
Kupffer cells isolated from rat liver were incubated with fluorescent-labeled gelatin 
nanoparticles loaded with fluorescent-labeled NF-κB decoy ODN. Loading of 
G-NPTex 04-024 pos with the Alexa Fluor® 488 labeled ds NF-κB decoy ODN was 
successfully conducted in PBS. The applied 2.5 % [w/w] ODN were completely 
attached onto the surface of the nanoparticles, which could be proven via UV-
spectroscopy. 
To further describe the intracellular distribution, endosomal membranes were as 
well stained with a fluorescent dye as the nucleus. In Figure 3.2.5 the single stained 
elements are summarized (A-D). Pictures E and F show an isolated Kupffer cell and 
an overly of all taken pictures respectively. From the overlay colocalization of single 
elements revealing e.g., endosomal uptake or ODN loaded nanoparticles can be 
derived.  
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Figure 3.2.5 CLSM pictures of a Kupffer cell taken after 15 min of incubation with ds NF-κB 
decoy ODN488 loaded G-NPTex 04-024 pos; pictures show different fluorescent stained structures (A) 
nucleus (violet), (B) decoy ODN (green), (C) gelatin nanoparticles (red), and (D) endosomal 
membranes (blue) as well as (E) the isolated Kupffer cell and (F) an overlay of all 
 
To achieve improved visualization and interpretation of these colocalizations 
selected pictures are chosen for different overlay diagrams in Figure 3.2.6. Picture Fi 
demonstrates the endosomal uptake of gelatin nanoparticles as the pronounced pink 
combination color results from the blue endosomal membrane staining and the red 
nanoparticle staining located at the same position. An endosomal uptake of gelatin 
nanoparticles is all well described by Zwiorek who successfully addressed the 
endosomal standing Toll Like Receptor 9 (TLR9) [Zwiorek, 2006]. Basically the 
cellular uptake of most of the nonviral gene or drug delivery systems follows, 
according to the current state of knowledge, endocytosis [Wattiaux et al., 2000; 
Maitra, 2005]. 
At the same time few extra endosomal appearing nanoparticles can be detected. 
In picture Fii NF-κB deoy ODN loaded onto gelatin nanoparticles expressed by the 
yellow combination color are displayed. Additionally, ODN release from 
nanoparticles could be observed already after 15 min of incubation with free 
nanoparticles (red dots) as wells as free decoy ODN (green dots) within the cells, 
which is furthermore substantiated by literature. Arnedo described an immediate 
release of a single stranded oligonucleotide electrostatically bound onto the surface 
of albumin nanoparticles under in vitro conditions in different buffered release media 
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[Arnedo et al., 2002]. Under similar conditions the complete release of plasmid DNA 
from gelatin nanoparticles within 8 h was reported by Kaul [Kaul et al., 2005]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.6 CLSM pictures of a Kupffer cells taken after 15 min of incubation with ds NF-κB 
decoy ODN488 loaded G-NPTex 04-024 pos; pictures show different fluorescent stained structures: (F) 
nucleus (violet), decoy ODN (green), gelatin nanoparticles (red), and endosomal membranes (blue) 
(cp. Figure 3.2.5); (Fi) nucleus (violet), gelatin nanoparticles (red), and endosomal membranes (blue); 
(Fii) nucleus (violet), decoy ODN (green), and endosomal membranes (blue); (Fiii) nucleus (violet), 
decoy ODN (green), and gelatin nanoparticles (red) 
 
In contrast ODN release from complexed protamine oligonucleotide 
nanoparticles started not until 24 h post administration [Dinauer et al., 2004]. As 
these data were obtained in a comparable approach applying CLSM analysis of 
macrophages incubated with fluorescent-labeled protamine and ODN respectively, it 
reveals general differences in drug release between the delivery of ODN adsorbed 
onto the surface of nanoparticles or incorporated in a nanoparticulate matrix. 
Derived from the pink combination color seen in Figure 3.2.6 Fi nanoparticles 
were proven to be almost located within endosomes. Thus, decoy oligonucleotide 
loaded onto their surface is certainly as well colocalized with endosomal structures 
revealed by an azure combination color in picture Fiii. Likewise appearing green dots 
indicate the presence of some free oligonucleotide outside endosomes. Finally 
neither nanoparticles nor decoy ODN could be detected in the nucleus, which 
changes after 2 h of incubating Kupffer cells with oligonucleotide loaded gelatin 
nanoparticles. Figure 3.2.7 F clearly shows a progression of ODN release, which is 
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expressed in wider areas of green fluorescence in comparison to the yellow 
combination color caused by colocalized nanoparticles and oligonucleotide. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.7 CLSM pictures of a Kupffer cell taken after 2 h of incubation with ds NF-κB decoy 
ODN488 loaded G-NPTex 04-024 pos; pictures show different fluorescent stained structures (A) nucleus 
(violet), (B) decoy ODN (green), and (C) gelatin nanoparticles (red), as well as (E) an isolated 
Kupffer cell and overlay of pictures of (D) nucleus and oligonucleotide and (F) gelatin nanoparticles 
and oligonucleotide 
 
Free oligonucleotide is now detectable in the nucleus (Figure 3.2.7 D) and the 
fluorescence appears more diffusive than before, further indicating ODN release 
from particulate structures i.e., gelatin nanoparticles. The appearance of 
oligonucleotide in the nucleus has thereby not to be considered as decisive for the 
mode of action of the NF-κB decoy, as it functions within cytoplasm as well as in the 
nucleus and does not necessarily require a transfer to the nucleus (Figure 3.1.2). 
3.2.3 Summary 
CLSM data demonstrated biodistribution of gelatin nanoparticles to be limited to 
the organs of the MPS after systemical administration. Changing the route of 
administration towards the portal vein led to a clearly pronounced uptake of gelatin 
nanoparticles into the liver, whereas the basic biodistribution into the MPS organs 
was maintained. Within liver the exclusive distribution of gelatin nanoparticles to 
Kupffer cells could be proven by accomplishing selective immunostaining and 
following a perfect colocalization of Kupffer cells and gelatin nanoparticles in 
CLSM imaging. In addition intracellular CLSM analysis showed the oligonucleotide 
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loaded nanoparticles to be almost completely located in endosomes and an ODN 
release from nanoparticles already being visible after 15 min, which further advanced 
over 2 hours leading to a certain transfer to the nucleus. 
As the proven Kupffer cell uptake is prerequisite for the proposed NF-κB decoy 
strategy in the context of hepatic ischemia reperfusion injury, these data provided the 
basis to further progress with decoy ODN loaded gelatin nanoparticles in an hepatic 
I/R animal model. 
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3.3 Excursus – Comparing Plasma Protein Adsorption Pattern and 
Biodistribution of Gelatin Nanoparticles and Solid Lipid 
Nanoparticles (SLN) 
3.3.1 Introduction 
In vivo fate of colloidal drug carrier systems 
In terms of drug delivery most target sites within the body are accessible through 
either microcirculation by blood capillaries or pores present at various surfaces and 
membranes. As the majority of apertures, openings, and gates on cellular and 
subcellular levels are of nanometer size and the diameter of the narrowest capillaries 
is about 2,000 nm nanoparticulate drug carrier systems are most suitable in reaching 
this dimension [Gupta, 2006]. But, it is well known since the early days of colloidal 
or nanoparticulate drug delivery that the in vivo fate of such systems is 
predominately determined by a rapid clearance from circulation after intravenous 
injection by the cells of the Mononuclear Phagocytic System (MPS) [Wilkins et al., 
1966; Kreuter, 1983]. This leads to a typical body distribution pattern comprising the 
macrophage possessing organs of the MPS, namely liver, spleen, lungs, and bone 
marrow [Mueller et al., 1990; Kreuter, 1992]. The mechanisms behind this 
observation are related to endogenous processes that clear the body from foreign 
substances and particulate matter. Recognition of such material e.g., nanoparticles by 
phagocytic cells is mediated by so called opsonins (from the Greek “opson” = 
condiment) [Patel, 1992], proteins circulating with the plasma that interact with 
foreign material immediately after application [Goeppert et al., 2005]. Thus, finally 
triggering phagocytosis opsonization is decisive for the plasma half life of 
nanoparticulate drug carriers [Moghimi et al., 2003; Owens et al., 2006], whereas 
three physicochemical properties surface hydrophobicity / hydrophilicity, charge, 
and size determine the pattern of the adsorbed proteins [Moghimi et al., 2001; 
Passirani et al., 2005; Vonarbourg et al., 2006]. Basically hydrophobic surfaces are 
stronger prone to opsonization than hydrophilic surfaces because of hydrophobic 
interactions with proteins [Patel, 1992; Stolnik et al., 1995]. But, it has to be stated 
that hydrophilic surfaces do not necessarily protected from phagocytosis [Stolnik et 
al., 1995]. Referred to surface charges, findings are ambivalent. On the one hand it is 
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generally accepted that nanoparticles with negatively charged surfaces showed 
reduced circulation times compared to those with positively charged, and neutral 
surfaces [Patel, 1992; Stolnik et al., 1995]. On the other hand there was no difference 
in the circulation time of negatively charged, positively charged, or neutral albumin 
nanoparticles [Roser et al., 1998]. At the same time protein adsorption seems to be 
size dependent to a certain extent with liposomes larger than 100 nm being 
preferably opsonized [Moghimi et al., 2001]. 
Main opsonins are immunoglobulins (IgG and IgM) and components of the 
complement system (C3 and C4 fragments) [Patel, 1992; Passirani et al., 2005; 
Vonarbourg et al., 2006]. Due to the interaction between its Fc portion and an Fc 
receptor present on macrophages IgG exhibits a direct opsonic activity [Patel, 1992]. 
In addition, IgG is assumed to concomitantly increase the surface hydrophobicity of 
the opsonized particle [Patel, 1992; Allemann et al., 1997] as it is known for bacteria, 
whereas increased hydrophobicity is attributed to the Fc portion [Van Oss, 1978]. 
IgM, as well as IgG, activates the classical complement pathway leading to 
complement opsonization by forming an IgM / IgG – C3b complex. Whereas 
following the alternative complement pathway results in a direct C3b opsonization of 
exogenous surfaces. In both cases C3b initiates rapid phagocytosis via its 
macrophage receptor. The opsonic activity of C4 or C4b respectively is based on the 
same mechanism but less pronounced compared to C4 [Patel, 1992; Passirani et al., 
2005]. Further plasma proteins exhibiting a receptor on MPS cells are fibronection 
[Patel, 1992; Vonarbourg et al., 2006], fibrinogen [Altieri et al., 1986], transferrin 
[Vogel et al., 1987], and α2-macroglobuline [Van Leuven et al., 1986]. 
Besides these proteins there is a group of so called dysopsonins described. Their 
adsorption leads to a certain protection from phagocytosis [Absolom, 1986]. Well 
known dysopsonins are Albumin and IgA [Stolnik et al., 1995; Thiele et al., 2003; 
Ogawara et al., 2004], both decreasing surface hydrophobicity [Stolnik et al., 1995; 
Ogawara et al., 2004]. 
Based on the basic understanding of surface opsonization and phagocytotic 
uptake of colloidal drug carriers Müller and Heinemann formulated already in 1989 
the concept of differential opsonization [Mueller et al., 1990]. The concept makes the 
assumption that macrophages of different subpopulations recognize different 
opsonization patterns, which in turn could be used for a directed distribution of 
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accordingly surface modified nanoparticles by adsorbing only certain opsonins. 
However, despite the knowledge about opsonins and their governing properties today 
there is still a lack of the possibility to directly predict biodistribution patterns of 
colloidal drug carriers systems from their physicochemical properties. But, the look 
onto nanoparticulate opsonization patterns contributes to the understanding of related 
biodistribution data. In this context it was the aim of this study to correlate plasma 
protein adsorption patterns of gelatin nanoparticles with their respective 
biodistribution data in comparison to solid lipid nanoparticles (SLN). 
Two dimensional polyacrylamide gel electrophoresis (2D-PAGE or 2-DE) was 
applied as method of choice for the description of the plasma protein adsorption 
patterns. Biodistribution experiments with fluorescent-labeled gelatin and solid lipid 
nanoparticles were performed in rats and the results were visualized by confocal 
laser scanning microscopy (CLSM) as well as fluorescence assorted cell sorting 
(FACS). 
Two dimensional polyacrylamide gel electrophoresis (2D-PAGE) 
For the detailed qualitative and quantitative description of a protein collectivity 
2D-PAGE is the state of the art analytical tool [Goerg et al., 2004]. During analysis 
proteins are separated by two independent physicochemical properties. After an 
isoelectric focusing in the first dimension a molecular weight related differentiation 
in the second dimension takes place. Both underlying methods isoelectric focusing 
(IEF) and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
were developed during the 1960ies [Righetti, 2004]. But it lasted until the mid 1970s 
till the potential of the (orthogonal) combination of these two techniques was 
recognized when three groups independently published their first 2-DE approaches 
[Klose, 1975; O'Farrell, 1975; Scheele, 1975]. Since these early days two major 
drawbacks of the method had to be overcome. At first the application of soluble 
carrier ampholytes for the generation of the pH gradient during IEF suffered from 
variability between different brands and even batches of the ampholytes due to their 
manufacturing by “chaotic” synthesis [Righetti, 2004]. This led to a cathodic drift of 
the analytes and finally to not reproducible results [Righetti et al., 1973]. The 
introduction of immobilized pH gradients (IPGs), gained by covalent linkage of 
buffering groups to the polyacrylamid matrix, described by Bjellqvist could solve 
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this problem [Bjellqvist et al., 1982]. Second the complete identification of 
thousands of protein spots remained almost impossible limiting the wide spread 
application of 2-DE [Beranova-Giorgianni, 2003; Righetti, 2004]. Coupling 2-DE 
with mass spectrometry (MS) nowadays allows the accurate profiling and 
quantification of complex protein mixtures. This finally led to a number of 10,000 
proteins to be highly reproducibly separated and identified on one gel, compared to 
300 in the very beginning [Sperling, 2001; Goerg et al., 2004]. 
Besides addressing the current challenges in proteomics [Sperling, 2001; 
Beranova-Giorgianni, 2003; Goerg et al., 2004] 2D-PAGE is applied in clinics 
[Young et al., 1995] and was established for the work with colloidal drug carrier 
systems by the groups of Rainer H. Müller [Blunk et al., 1993; Luck et al., 1998; 
Goeppert et al., 2003] and Robert Gurny [Leroux et al., 1994; Allemann et al., 1997]. 
In sum the basic steps of a 2D-PAGE analysis with IPGs and MS identification 
comprises [Goerg et al., 2004]: 
a) sample preparation and protein solubilization 
b) protein separation by 2-DE 
c) protein detection and quantification 
d) computer assisted analysis of 2-DE patterns 
e) protein identification and characarization, and 
f) 2-D protein database construction. 
 
The presented data emerged from cooperation between the chairs of 
pharmaceutical technology of the Free University of Berlin, Germany (Prof. R. H. 
Müller / Ph.D. student Torsten Göppert) and of the Ludwig-Maximilians-University 
Munich, Germany (Prof. G. Winter / Dr. C. Coester / Ph.D. student Jan C. Zillies). 
Animal studies were conducted by Florian Hoffmann (Chair of pharmaceutical 
biology, Prof. A. Vollmar, Ludwig-Maximilians-University Munich, Germany). The 
contributions of our cooperation partners are accordingly denoted in the text. 
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3.3.2 Materials and methods 
Reagents 
Reagent Description Supplier 
Acetone  VWR International GmbH (Ismaning, Germany) 
Cetylpalmitate Cutina® CP Henkel KGaA (Düsseldorf, Germany) 
Cholamine chloride 
hydrochloride 
(2-aminoethyl)-trimethyl- 
ammoniumchloride hydrochloride 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
ds NF-κB decoy ODN  5´-AGT TGA GGG GAC TTT CCC AGG C-3´ phosphorothioate 
biomers.net GmbH 
(Ulm, Germany) 
Dulbecco’s Phosphate 
Buffered Saline  pH 7.4 
PAA Laboratories GmbH 
(Linz, Austria) 
EDC 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
BD PharmLyse™ FACS Lysis Buffer (10x concentrate) Becton Dickinson GmbH (Heidelberg, Germany) 
Gelatin type A 175 Bloom Sigma-Aldrich GmbH (Taufkirchen, Germany) 
Glutaraldehyde 25 % aqueous solution  Sigma-Aldrich GmbH (Taufkirchen, Germany) 
HCl 2 N VWR International GmbH (Ismaning, Germany) 
Lutrol® F68 Poloxamer 188 BASF AG (Ludwigshafen, Germany) 
PBS Dulbecco’s phosphate buffered saline pH 7.4 (1x concentrate) 
PAA Laboratories GmbH 
(Linz, Austria) 
Permafluor aqueous mounting medium Beckmann Coulter GmbH (Krefeld, Germany) 
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Fluorescent dyes 
Reagent Description Supplier 
Coumarin 6 laser grade, 98 %, λem 497 nm 
Acros Organics 
(Geel, Belgium) 
FluoProbes® 488  NHS, λem 517 nm 
FluoProbes (Interchim) 
(Montluçon Cedex, France) 
 
2D-PAGE analysis 
Reagent* Description Supplier 
Acrylamide  
SERVA Electrophoresis 
GmbH 
(Heidelberg, Germany) 
Acrylamide / Bis 
Solution  (37.5:1), 30 % (w/v) 
SERVA Electrophoresis 
GmbH 
(Heidelberg, Germany) 
Agarose  Bio-Rad Laboratories GmbH (München, Germany) 
Acetic acid  99 % Merck KGaA (Darmstadt, Gemany) 
Bromphenol blue  Merck KGaA (Darmstadt, Gemany) 
CHAPS 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate 
Sigma-Aldrich Co. 
(St. Louis, USA) 
DTE 1,4-dithioerythritol Merck KGaA (Darmstadt, Gemany) 
Ethanol  undenaturated, 96 % Branntwein-Monopolstelle (Berlin, Germany)  
Human plasma citrate stabilized German Red Cross (Berlin, Germany) 
Iodoacetamide   Sigma-Aldrich GmbH (Taufkirchen, Germany) 
N,N´-Methylene 
bisacrylamide  
SERVA Electrophoresis 
GmbH 
(Heidelberg, Germany) 
Rat plasma citrate stabilized from Wistar rats 
Institute for Infection 
Medicine, Free University 
(Berlin, Germany) 
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Reagent* Description Supplier 
SDS Sodium dodecyl sulfate Merck KGaA (Darmstadt, Gemany) 
Silver nitrate  Merck KGaA (Darmstadt, Gemany) 
Sodium phosphate 
dibasic dodecahydrate  
Merck KGaA 
(Darmstadt, Gemany) 
Sodium phosphate 
monobasic dihydrate  
Merck KGaA 
(Darmstadt, Gemany) 
TRIS  Tris(hydroxymethyl)aminomethane Merck KGaA (Darmstadt, Gemany) 
Urea  Merck KGaA (Darmstadt, Gemany) 
 
*For detailed composition of the applied solutions during 2D-PAGE experiments see Goeppert 2005: Plasma protein 
adsorption patterns on intravenously injectable colloidal drug carriers for drug delivery across the blood-brain barrier, 
Ph.D. thesis 
Preparation and surface modification of gelatin nanoparticles 
Gelatin nanoparticles were manufactured by the two step desolvation method 
and optionally surface modified (cationized) with cholamine as described in 
chapter 1.2. 
Preparation of fluorescent cationic gelatin nanoparticles 
Fluorescent-labeled gelatin nanoparticles were prepared by covalent coupling of 
the gelatin base material with FluoProbes® 488 NHS (cp. chapter 3.2.1). FluoProbes® 
488 was chosen instead of TexasRed® to visualize the nanoparticles in a 
FACScalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) 
equipped with a laser unit emitting the according excitation wavelength. 
Oligonucleotide-loading of gelatin nanoparticles 
113.5 µL of an aqueous nanoparticle dispersion containing 1.2 mg surface 
modified and fluorescent-labeled gelatin nanoparticles was incubated with 84.4 µL 
of an aqueous oligonucleotide solution containing 4.22 nmol NF-κB decoy ODN 
(i.e., 5 % [w/w] drug loading) in PBS adjusted to a final volume of 1,200 µL for 2 h 
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at 22 °C and 800 rpm under constant shaking (Thermomixer Comfort, Eppendorf 
AG, Hamburg, Germany). 
Manufacturing of SLN 
SLN were prepared by hot high pressure homogenization according to literature 
[Mehnert et al., 2001; Goeppert, 2005] using a Micron LAB 40 lab scale high 
pressure homogenizer (APV Systems, Unna, Germany). The batch size was 40 g 
comprising 10 % cetylpalmitate, 1.2 % Poloxamer 188, and water. Lipid and aqueous 
phase were heated up to 70 °C, whereas the emulsifier was dissolved in the aqueous 
phase. Subsequent the lipid phase was dispersed in the aqueous surfactant solution 
with an Ultra-Turrax TP 18-10 (Janke and Kunkel, Staufen, Germany) for 1 min at 
20,000 rpm in a vessel at 70 °C. The obtained pre-emulsion was then passed through 
the homogenizer three times with a pressure of 500 bar per cycle. Due to the lack of 
a temperature control jacket the product touching parts of the homogenizer were 
tempered in a drying oven to 80 °C over night to guarantee a working temperature 
above the melting point of the lipid. Finally the resulting hot nanoemulsion was 
cooled down under constant stirring (500 rpm) whereby nanoparticles are formed by 
recrystallization of the lipid matrix. 
Manufacturing of fluorescent-labeled SLN 
Fluorescent labeling of SLN was conducted by incorporating a fluorescent dye 
into the lipid phase: 5 mg of Coumarin 6 were dissolved in the cetylpalmitate melt 
under stirring prior to emulsification. The manufacturing process was afterwards 
continued as described above. 
Characterization of nanoparticles 
Size and zetapotential (ZP) of the applied gelatin nanoparticle batches were 
determined by dynamic light scattering (DLS) using a Zetasizer 3000 HSA and a 
Nanosizer ZS respectively (both from Malvern Instruments, Worcestershire, UK). 
Zetapotential measurements were conducted under standardized ionic conditions in 
10 mM NaCl at pH 7.0. 
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In vivo biodistribution experiments 
Experiments were conducted in male Sprague-Dawley rats. Fluorescent-labeled 
gelatin and solid lipid nanoparticle formulations were prepared in PBS (1 mg/mL) 
and injected (1 mL) into rat via the jugular vein. Prior to injection rats were 
anesthetized by i.p. injection of 0.005 mg/kg Fentanyl and 2.0 mg/kg Midazolam. 
Anesthesia was maintained over the whole experiment with 1.5 % Isofluran 
continuously applied using a vaporizer with Carbogen (5 % CO2 / 95 % O2) as carrier 
gas. To monitor blood pressure and control anesthesia the jugular artery was 
cannulated with a 16 gauge PE catheter and connected to a blood-pressure gauge. 
After 1h rats were sacrificed and blood was rinsed out. Brain, heart, kidneys, 
liver, lungs, parts of femoral muscle, and spleen were resected, frozen with liquid 
nitrogen and stored at -80 °C. The distribution of nanoparticles into the different 
organs was determined via confocal laser scanning microscopy (CLSM). 
All animal studies were conducted by Florian Hoffmann at the department of 
pharmaceutical biology of the Ludwig-Maximilians-University Munich, Germany. 
CLSM imaging 
10 µm thin slices of the frozen organs from the in vivo biodistribution 
experiments were prepared using a HM 500 Kryostat (Microm International AG, 
Volketswil, Switzerland) and transferred to microscopic slides. After thawing 
samples were mounted in Permafluor with a cover slip. Preparations were not further 
stained for specific cell types or organelles as it was the intention to just check the 
qualitative nanoparticle distribution into single organs. CLSM imaging was 
performed with a Zeiss LSM 510 Meta confocal laser scanning microscope (Carl 
Zeiss Microscope Systems, Jena, Germany). 
FACS analysis of rat whole blood and plasma 
600 µL of rat blood were taken during the in vivo biodistribution experiments at 
the following time points: 0, 15, 30, and 60 min. 100 µL whole blood were diluted 
with FACS lysis buffer in a FACS sample tube (1:10) and directly analyzed by flow 
cytometry in a FACScalibur (Becton Dickinson, Franklin Lakes, NJ, USA). 500 µL 
whole blood were centrifuged (10 min / 5,000 rpm) and the obtained plasma 
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supernatant was diluted with PBS pH 7.4 in the ratio 1:3. This solution was as well 
analyzed by flow cytometry. 
FACS analysis was conducted under assistance of Dr. Stefan Zahler at the 
department of pharmaceutical biology of the Ludwig-Maximilians-University 
Munich, Germany. 
2D-PAGE experiments 
Sample preparation Nanoparticle suspensions (0.5 mL) were incubated with 
1.5 mL of citrate stabilized plasma (human or rat) for 5 min at 37 °C. Following 
incubation particles were separated from bulk medium by centrifugation (22,940 g, 
60 min) and redispersed in 20 mM sodium phosphate buffer pH 7.4. This washing 
step was repeated another two times. Desorption of adsorbed plasmaproteins was 
conducted using a solubilizing solution containing 10 % (w/v) SDS and 2.32 % (w/v) 
DTE (5 min at 95 °C). After cooling, 190 µL of a solution containing DTE, CHAPS, 
urea, TRIS, and bromphenol blue were added. The mixture was vortexed and 
centrifuged (22,940 g, 15 min), 100 µL were transferred to Isoelectric focusing 
(IEF). 
Isoelectric focusing (IEF) IEF was performed within immobilized pH gradient 
(IPG) stripes (Immobiline DryStripes, pH 3-10, non linear) using a Multiphore II 
both from Amersham Pharmacia Biotech and an E 752 power supply from Consort 
(Turnhout, Belgium) with a total volt hour product of 20,375 Vh. 
Equilibration and SDS-PAGE IPG stripes were equilibrated with two SDS 
containing solutions: solution I additionally containing DTE (15 min residence time) 
and solution II additionally containing iodoacetamide (20 min residence time). 
Subsequent to equilibration IPG stripes were attached to the SDS-PAGE 
polyacrylamide gels and fixed with an agarose gel (0.5 %). SDS-PAGE was carried 
out in Protean II Multi Cells with a PowerPac 1000 power supply (Bio-Rad 
Laboratories, Munich, Germany). Gels had a size of 16x16 cm and a gradient 
ranging from 9 % T (total acrylamide concentration) to 16 % T using 2.67 % (related 
to the acrylamide content) N,N’-methylenbisacrylamide as cross-linking agent.  
Qualitative and quantitative analysis For qualitative and quantitative analysis 
proteins within the gels were initially fixed in a precipitation bath with undenaturated 
ethanol and acetic acid and visualized with a silver staining. Protein spots were 
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identified by comparison with 2-D-PAGE reference maps published for human and 
rat plasma [Anderson et al., 1991; Haynes et al., 1998]. In addition the ExPASy 
(Expert Protein Analysis System) proteomics server of the University of Geneva 
offers online access to reference maps of several organisms 
(http://www.expasy.ch/ch2d/). After scanning the gels (ImageScanner, Amersham 
Pharmacia Biotech) data were processed with the MELANIE III (Medical 
Electrophoresis Analysis Interactive Expert System) software (Bio-Rad 
Laboratories, Munich, Germany) allowing the quantitative analysis of the obtained 
proteins spots among different gels. 
 
All 2D-PAGE experiments were conducted by Torsten Göppert at the 
department of pharmaceutical technology of the Free University of Berlin, Germany. 
The described procedure is derived from literature [Hochstrasser et al., 1988; Blunk, 
1994] and is the standard protocol that was applied in our cooperation project and is 
published in his Ph.D. thesis [Goeppert, 2005]. For more detailed information about 
the conduction of the 2D-PAGE experiments it is referred to this thesis. 
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3.3.3 Results and discussion 
Characterization of nanoparticles 
All nanoparticle formulations applied during 2D-PAGE experiments (Table 
3.3.1) had a similar size (140 to 260 nm) and a homogenous size distribution with a 
PDI below 0.100. Due to surface modification and drug loading the surface charge of 
the single gelatin nanoparticles batches is different expressed in a zetapotential 
ranging from slightly negative values up to +15 mV. The negative zetapotential of 
P188-SLN results from acidic components always contained in the cetylpalmitate 
phase to a certain extent. At physiological pH values their carboxyl groups appear 
deprotonated and thus negatively charged. 
Table 3.3.1 Size, polydispersity, and surface charge of the nanoparticle formulations applied in 
2D-PAGE investigations 
 
 Gelatin 
nanoparticles 
(G-NP) 
Surface modified 
gelatin 
nanoparticles 
(G-NP pos) 
Surfacemodified and 
oligonucleotide 
loaded gelatin 
nanoparticles 
(G-NP pos + O) 
Cetylpalmitate 10% 
Poloxamer 188 1.2% 
Aqua purificata 
ad 100% 
P188-SLN 
size [nm] 139 164 166 259 
PDI 0.073 0.043 0.054 0.078 
ZP [mV] -2.5 +14.6 +3.6 -45.7 
 
The nanoparticle formulations applied for biodistribution experiments (Table 
3.3.2) had as well a similar size (200 to 300 nm) and a homogenous size distribution 
with a PDI around 0.100. The surface charge properties meet the dimensions 
described above for the not fluorescent-labeled nanoparticle batches. 
A comparable size for all nanoparticle batches > 100 nm is important as this 
threshold is assumed to be critical in determining the degree of opsonization (see 
chapter 3.3.1). The modification of gelatin with a fluorescent dye and the variability 
of the manufacturing process thereby caused the increased particle size observed for 
the gelatin nanoparticle batches applied during biodistribution experiments  
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Table 3.3.2 Size, polydispersity, and surface charge of the fluorescent-labeled nanoparticle 
formulations applied for biodistribution experiments 
 
 
Fluorescent 
gelatin 
nanoparticles 
(G-NP488) 
Surface modified 
fluorescent 
gelatin 
nanoparticles 
(G-NP488 pos) 
Surface modified and 
oligonucleotide 
loaded fluorescent 
gelatin nanoparticles 
(G-NP488 pos + O) 
Cetylpalmitate 10% 
Poloxamer 188 1.2% 
Coumarin 6 0.013 % 
Aqua purificata 
ad 100% 
P188-SLNC6 
size [nm] 223 310 305 205 
PDI 0.067 0.123 0.105 0.112 
ZP [mV] -10.7 +15.5 +4.0 -43.6 
 
Drug loading of G-NP pos and G-NP488 pos respectively with the ds NF-κB 
decoy oligonucleotide was successfully conducted in PBS. The applied 5 % [w/w] 
ODN were completely attached onto the surface of the nanoparticles, which could be 
proven via UV-spectroscopy. 
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Plasma protein adsorption patterns – gelatin nanoparticles vs. SLN 
Figure 3.3.1 shows the resulting 2-DE gels of G-NP, G-NP pos, and 
G-NP pos + O incubated with human plasma. Interestingly the different gelatin 
nanoparticle formulations possess a similar protein adsorption pattern, consisting of a 
distinct adsorption of albumin, fibrinogen, the opsonic immunoglobulins IgG and 
IgM, and α2-macroglobulin. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1 Plasma protein adsorption pattern on gelatin nanoparticles after incubation with 
human plasma: (i) G-NP, (ii) G-NPpos, (iii) G-NPpos + O, Abscissa: pH 4-9 (from left to right), 
Ordinate: MW 250 kDa-6 kDa (from top to bottom); 
Proteinspots: (1) α2-macroglobulin, (2) IgM µ chain, (3) albumin, (4) fibrinogen α chain, (5) 
fibrinogen β chain, (6) fibrinogen γ chain, (7) α1-b-glycoprotein, (8) IgA, (9) α1-antitrypsin, (10) α2-
hs-glycoprotein, (11) haptoglobin β chain, (12) ApoJ, (13) ApoA-I, (14) IgG γ chain, (15) Ig light 
chains, (16) transthyretin 
(i) 
(ii)  
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Assuming a given surface hydrophilicity related to the gelatin base material for 
all formulations, which is not basically altered by the oligonucleotide loading, the 
varying surface charge does not direct the adsorption pattern towards any qualitative 
changes. Thus, the surface hydrophilicity seems to determine the qualitative 
composition of the adsorbed protein spectrum. A semi quantitative summary of the 
identified proteins is given in Figure 3.3.2. Beside the described similarities 
regarding the kind of proteins the congruent masses of single proteins being adsorbed 
especially for G-NPpos and G-NPpos + O attracts attention as it further indicates that 
the drug loading process does not differentiate plasma protein adsorption. In fact, the 
surface charge seems to play a certain role in this context. On the surface of slightly 
negative G-NP the adsorption of immunoglobulins varied compared to G-NPpos and 
G-NPpos + O. The increased adsorption of Ig light chains is thereby accompanied by 
a diminished adsorption of IgM. In general, it can be stated that adsorption on the 
positively charged formulations G-NPpos and G-NPpos + O was almost identical 
and exhibited a pattern different from the one of negatively charged G-NP. 
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Figure 3.3.2 Portion of single proteins of the totally detected protein patterns on gelatin 
nanoparticles after incubation with human plasma (n = 2) 
 
However, differences are subtle and the predominant adsorption of strong 
opsonins leads to the assumption of all formulations being rapidly cleared from 
circulation by the phagocyting cells of the MPS. Furthermore α2-macroglobulin 
strengthens opsonization. Besides its macrophage receptor [Van Leuven et al., 1986] 
opsonic properties for α2-macroglobulin are described by Molnar [Molnar et al., 
Gelatin Nanoparticles for Targeted Oligonucelotide Delivery to Kupffer Cells 
179 
1977]. An adsorption of α2-macroglobulin has already been reported from Bucke for 
gelatin modified liposomes [Bucke et al., 1998]. As poloxamer and polysorbate 
modified liposomes did not show any adsorption, a certain gelatin affinity of α2-
macroglobulin can be derived from their findings. Interestingly the portion of 10-
13 % (Figure 3.3.2) of all adsorbed proteins matches the data of Bucke who detected 
a portion of 12 % [Bucke et al., 1998]. 
In Figure 3.3.3 plasma protein adsorption patterns of gelatin nanoparticles 
(G-NPpos + O) and solid lipid nanoparticles (P188-SLN) are opposed. Proteins 
adsorbed onto P188-SLN are basically apolipoproteins, at the same time 
immunoglobulins and albumin are only adsorbed to a very little extent. The 
subclasses of these apolipoproteins vary depending on the lipid matrix and the 
emulsifier the SLN are manufactured of. But, the high amount of apolipoproteins 
adsorbed onto the SLN’s surface remains constant [Goeppert, 2005]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.3 Plasma protein adsorption pattern on (i) gelatin nanoparticles (G-NPpos + O) and 
(ii) SLN (P188-SLN) after incubation with human plasma, Abscissa: pH 4-9 (from left to right), 
Ordinate: MW 250 kDa-6 kDa (from top to bottom); 
Proteinspots (G-NPpos + O): (1) α2-macroglobulin, (2) IgM µ chain, (3) albumin, (4) fibrinogen α 
chain, (5) fibrinogen β chain, (6) fibrinogen γ chain, (7) α1-b-glycoprotein, (8) IgA, (9) α1-antitrypsin, 
(10) α2-hs-glycoprotein, (11) haptoglobin β chain, (12) ApoJ, (13) ApoA-I, (14) IgG γ chain, (15) Ig 
light chains, (16) transthyretin; 
Proteinspots (P188-SLN): (1) albumin, (2) fibrinogen α chain, (3) fibrinogen β chain, (4) fibrinogen γ 
chain, (5) α1-antitrypsin, (6) ApoA-IV, (7) ApoJ, (8) ApoE, (9) ApoA-I, (10) ProapoA-I, (11) ApoC-
III, (12) ApoC-II, (13) ApoA-II, (14) transthyretin, (15) ApoH, (16) IgM µ chain, (17) IgG γ chain, 
(18) Ig light chains 
 
(i) (ii) 
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The enormous differences between gelatin and solid lipid nanoparticles are 
summarized in the histogram in Figure 3.3.4. 80 % adsorbed apolipoproteins on 
P188-SLN front only 3 % apolipoproteins adsorbed on G-NPpos + O. On the other 
hand about 50 % immunoglobulins dominate the adsorption pattern on 
G-NPpos + O. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.4 Plasma protein adsorption patterns on gelatin nanoparticles (G-NPpos + O) 
compared with SLN (P188-SLN) (n = 2) 
 
Related to these data a clear difference in circulation time and biodistribution has 
to be expected for gelatin and solid lipid nanoparticles. As biodistribution studies 
were conducted in rats to verify this hypothesis, 2D-PAGE analysis of plasma 
protein adsorption patterns obtained from incubation of gelatin nanoparticles with rat 
plasma were at first accomplished. These investigations should clarify whether the 
different adsorption patterns observed for gelatin and solid lipid nanoparticles after 
incubation with human plasma are maintained after the incubation with rat plasma 
and whether the assumed differences in circulation time and biodistribution could be 
expected to be the same in rats. The 2-DE gels of G-NP, G-NP pos, and G-NP 
pos + O after incubation with rat plasma are depicted in Figure 3.3.5. Again the 
adsorption patterns of the three investigated formulations are qualitatively identical.  
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Figure 3.3.5 Plasma protein adsorption pattern on gelatin nanoparticles after incubation with rat 
plasma: (i) G-NP, (ii) G-NPpos, (iii) G-NPpos + O, Abscissa: pH 4-9 (from left to right), Ordinate: 
MW 250 kDa-6 kDa (from top to bottom); 
Proteinspots: (1) α2-macroglobulin, (2) IgM µ chain, (3) albumin, (4) fibrinogen, (5) transferrin, (6) 
kallikrein-binding protein, (7) α1-b-glycoprotein, (8) α2-hs-glycoprotein, (9) α1-antitrypsin, (10) 
ApoA-IV, (11) haptoglobin β chain, (12) ApoJ, (13) ApoA-I, (14) IgG γ chain, (15) ApoC, (16) 
transthyretin 
 
The semi quantitative view reveals albumin, fibrinogen, the opsonic 
immunoglobulins IgG and IgM, and α2-macroglobulin to be the main proteins, 
whereas the similarities between G-NP pos and G-NP pos + O are likewise 
remarkable and the opsonization of G-NP is in comparison to those pronounced 
(Figure 3.3.6). Certainly some species specific differences were detected. The 
albumin portion accounts for more than 20 % and the apolipoproteins were stronger 
represented in total after incubation in rat plasma. But, the results obtained from 
 
(i) 
(ii) (iii) 
Gelatin Nanoparticles for Targeted Oligonucelotide Delivery to Kupffer Cells 
182 
0.0
5.0
10.0
15.0
20.0
25.0
30.0
al
bu
m
in
A
po
J
fib
rin
og
en
 β
ch
ai
n
tra
ns
th
yr
et
in
Ig
 li
gh
t c
ha
in
s
α
1-
an
tit
ry
ps
in
α2
-
m
ac
ro
gl
ob
ul
in
α
1-
b-
gl
yc
op
ro
te
in
vo
lu
m
e 
[%
]
incubation with human plasma could be confirmed in general, thus leading to the 
expectations formulated above to be proven in vivo. 
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Figure 3.3.6 Portion of single proteins of the totally detected protein patterns on gelatin 
nanoparticles after incubation with rat plasma (n = 2) 
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Biodistribution 
Basic idea behind the biodistribution experiments was to monitor the organ 
distribution of different nanoparticle formulations and to follow the kinetics of their 
clearance from circulation. The organ distribution was ascertained in an endpoint 
procedure via CLSM analysis of single organs, resected subsequent to termination of 
the animal study after 1 h of circulation. By contrast sampling of whole blood and 
plasma for FACS analysis was concurrently conducted during the animal studies at 0, 
15, 30, and 60 min. Figures 4.3.7 to 4.3.9 show the CLSM images taken of slices 
from liver, spleen, lung, kidney, and femoral muscle revealing the qualitative organ 
distribution of gelatin nanoparticles. As the emphasis lies on the qualitative 
description of the nanoparticle distribution into single organs no further fluorescent 
staining of different cell types or compartments was conducted. For all three 
investigated formulations the same biodistribution could be observed with 
nanoparticles accumulated in liver, spleen, and lung. Due to the opsonin dominated 
plasma protein adsorption monitored in 2D-PAGE analysis this was expected and is 
in accordance to basic considerations of nanoparticle biodistribution discussed in 
literature [Kreuter, 1983].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.7 CLSM pictures of (A) liver, (B) spleen, (C) lung, (D) kidney, and (E) femoral 
muscle taken from organs resected 1 h after injection of G-NP488 (green) into the jugular vein 
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Comparing the distribution into single organs among each other an equal 
distribution is observed in liver and lung, whereas the distribution within the spleen 
shows distinct heterogeneity. Caused by just displaying limited sections CLSM only 
reflects that to a certain extent (Figure 3.3.7 B and Figure 3.3.9 B).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.8 CLSM pictures of (A) liver, (B) spleen, (C) lung, (D) kidney, and (E) femoral 
muscle taken from organs resected 1 h after injection of G-NP488 pos (green) into the jugular vein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.9 CLSM pictures of (A) liver, (B) spleen, (C) lung, (D) kidney, and (E) femoral 
muscle taken from organs resected 1 h after injection of G-NP488 pos + O (green) into the jugular vein 
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But the view through the ocular of the microscope covering whole slices makes 
this impression obvious. Assuming a selective macrophage uptake the anatomy of 
the spleen might help to explain the described findings. Spleenic macrophages are 
not evenly spread within the organ, in fact they are attributed to the regions of the red 
pulp and the zones enclosing the white pulp, but not to the white pulp itself, which is 
anatomically separated from the other regions [Mebius et al., 2005]. 
The kinetic data indicated the clearance from circulation to be completed within 
the fist 15 min of the experiments. FACS analysis showed no freely circulating 
nanoparticles within plasma, neither after 15 min nor after 30 or 60 min. Formulation 
dependent differences did not occur like expected from CLSM data. Thus FACS 
results are in the following exemplarily shown for G-NP488. The histogram plots of 
rat plasma sampled before the application of nanoparticles and after 15 min of 
circulation are displayed in Figure 3.3.10. 
 
 
 
 
 
 
Figure 3.3.10 Histogram plots of rat plasma analyzed before (A) and 15 min after (B) the 
application of G-NP488 
 
Both plots exhibit almost the same shape, whereas a shift to the right i.e., 
towards a higher number of fluorescent events could not be detected (Figure 3.3.10 
B), indicating the rapid clearance of nanoparticles from circulation. The difference in 
total counts is related to sample preparation as it is very difficult to collect an 
identical sample volume at each sampling point.  
 
Figure 3.3.11 Dot plots of rat whole blood analyzed before (A) and 15 min (B), 30 min (C), and 
60 min (D) after the application of G-NP488; displayed cell types exemplarily highlighted in dot plot B 
are lymphocytes (a), monocytes (b), and neutrophile granulocytes (c) 
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Analyzing whole blood at every sampling point the typical pattern of leucocytes 
with lymphocytes, monocytes, and neutrophile granulocytes could be observed 
(Figure 3.3.11 B (a)-(c)). But, additional peripheral phagocytosis into blood 
monocytes was not detectable at any time as none of the detected cell populations 
was associated with fluorescence expressed by the black dot plots (Figure 3.3.11 A-
D). Figure 3.3.12 further confirms this finding by a missing shift of the according 
histogram plot towards increased fluorescence. 
 
 
 
 
 
 
Figure 3.3.12 Histogram plots of rat whole blood analyzed before (A) and 15 min after (B) the 
application of G-NP488 
 
The observation of a very rapid accumulation within the MPS organs 
independently from surface charge made for the three tested gelatin nanoparticle 
formulations is confirmed by the findings of Roser who worked with albumin 
nanoparticles and described comparable results [Roser et al., 1998]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.13 CLSM pictures of (A) liver, (B) spleen, (C) lung, (D) kidney, and (E) femoral 
muscle taken from organs resected 1 h after injection of P188-SLNC6 (green) into the jugular vein 
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The organ distribution of solid lipid nanoparticles is shown in Figure 3.3.13. In 
contrast to gelatin nanoparticle formulations a certain amount was detected in the 
spleen and only small amounts were detected in liver, lung, and interestingly as well 
in kidney. The lower extent accumulated in single organs and the appearance of SLN 
in the kidney reflect the differences already found during 2D-PAGE analysis for 
gelatin and solid lipid nanoparticle formulations. The main differences obtained from 
organ distribution studies are opposed in Figure 3.3.14. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.14 CLSM pictures of (A/D) liver, (B/E) spleen, and (C/F) kidney taken from organs 
resected 1 h after injection of G-NP488 pos (A/B/C) (green) and P188-SLNC6 (D/E/F) (green) 
respectively into the jugular vein 
 
The lack of opsonin adsorption on SLN seems to prevent an extensive 
phagocytosis by the MPS and presumably prolongs circulation. Though kinetic data 
from FACS analysis of P188-SLNC6 distribution studies revealed at first complete 
clearance from circulation as well after 15 min, which was contradictory considering 
the low organ accumulation demonstrated via CLSM. There were not any 
nanoparticles detectable in plasma or in association with blood monocytes and thus, 
with lacking fluorescence the histogram plots again look almost identical (Figure 
3.3.15). 
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Figure 3.3.15 Histogram plots of rat plasma (AP/BP) and whole blood (AL/BL) analyzed before 
(AP/AL) and 15 min after (BP/BL) the application of P188-SLNC6 
 
Increasing the applied SLN concentration by factor 20 suggested a dilution effect 
to be responsible for these findings. Monitoring the organ distribution pattern to be 
qualitatively and (semi-) quantitatively constant, SLN could be detected circulating 
with plasma (Figure 3.3.16) and associated with white blood cells (Figure 3.3.17). In 
both series of histogram plots a pronounced shift of counted events towards 
increased fluorescence intensity can be found for all three – after application of 
SLN – investigated sampling points. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.16 Histogram plots of rat plasma analyzed before (A) and 15 min (B), 30 min (C), and 
60 min (D) after application of a 20x increased amount of P188-SLNC6 
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It has to be mentioned that it can not be differentiated from these data between 
phagocytosis and adsorption to blood cells. But with respect to the low rate of 
phagocytosis reported for tissue macrophages an adsorptive process seems to be 
more likely. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.17 Histogram plots of rat whole blood analyzed before (A) and 15 min (B), 30 min (C), 
and 60 min (D) after application of a 20x increased amount of P188-SLNC6 
 
The increase in fluorescence intensity determined in plasma is summarized in 
Figure 3.3.18. Interestingly comparable intensities were observed over the complete 
experiment duration, which denotes clearly prolonged circulation of solid lipid 
nanoparticles compared to gelatin nanoparticles. But it has to be confined, that the 
dramatic increase in SLN concentration causes live threatening conditions for the test 
animal and that data from these experiment mainly contributes to elucidating the 
dilution effect seen for SLN applied in standard concentrations. Thus data should not 
be overestimated in terms of interpreting biodistribution and circulation time. 
 
 
 
 
 
 
 
Figure 3.3.18 Histogram plots of rat plasma analyzed before (violet) and 15 min (pink), 30 min 
(light blue), and 60 min (orange) after application of a 20x increased amount of P188-SLNC6 
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3.3.4 Summary 
Plasma protein adsorption patterns of all investigated gelatin nanoparticle 
formulations were proven to be comparable. The introduction of the positively 
charged cholamin onto the surface of the nanoparticles caused thereby slight 
quantitative changes in the observed adsorption patterns compared to not surface-
modified gelatin nanoparticles. This was not further pronounced by loading the 
nanoparticles with a double-stranded DNA oligonucleotide. All plasma protein 
adsorption patterns are dominated by opsonic proteins, which is in strong contrast to 
solid lipid nanoparticles mainly adsorbing apolipoproteins. Species specific 
differences could be detected after incubating gelatin nanoparticles with human or rat 
plasma but still revealing an adsorption pattern dominated by opsonic proteins. 
In addition to 2D-PAGE data in vivo results showed a differentiated behavior for 
gelatin and solid lipid nanoparticles and confirmed the knowledge about the plasma 
protein adsorption pattern to be decisive for the in vivo fate of colloidal drug carrier 
systems. Slight formulation dependent differences in between gelatin nanoparticles 
revealed by 2-DE were leveled by the in vivo conditions, which is reflected by rapid 
clearance from circulation and almost identical biodistribution observed for all 
gelatin nanoparticle formulations. In contrast SLN exhibited a reduced and 
unspecific organ distribution accompanying with a prolonged plasma half life. 
Thus our data could contribute to the intended correlation of plasma protein 
adsorption patterns with the respective biodistribution data of nanoparticulate drug 
delivery systems in terms of a better understanding of in vivo findings. In this context 
it has to be stated that gelatin nanoparticles exhibit only poor circulating properties 
and are thus not applicable for effective drug delivery except macrophage targeting 
without further modifications extending their plasma half life like PEGylation (cp. 
chapter 1.5). 
Finally, the missing organ specific accumulation and the described dilution of 
solid lipid nanoparticles within the blood stream led - compared to gelatin 
nanoparticles - to a low recovery rate of the SLN in the sum of CLSM and FACS 
analysis.
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3.4 NF-κB Inhibition During Hepatic Ischemia Reperfusion Injury 
With respect to the proposed selective inhibition of NF-κB in Kupffer cells 
positively affecting hepatic I/R injury the exclusive Kupffer cell uptake of gelatin 
nanoparticles could be proven (chapter 3.2). In the second step it was thereafter the 
challenge to develop an NF-κB decoy oligonucleotide loaded gelatin nanoparticle 
formulation which is stable under physiological conditions and that delivers adequate 
amounts of the NF-κB decoy ODN for the inhibition of NF-κB in Kupffer cells and 
that does not further pronounce liver injury occurring from ischemia and reperfusion. 
 
3.4.1 Materials and methods 
Reagents 
Reagent Description Supplier 
Acetone p.a. VWR International GmbH (Ismaning, Germany) 
Cholaminechloride 
hydrochloride 
(2-aminoethyl)-trimethyl- 
ammoniumchloride hydrochloride 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine 
Avanti Polar Lipids, Inc. 
(Alabaster, AL, USA) 
DOTAP-Cl 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) 
Avanti Polar Lipids, Inc. 
(Alabaster, AL, USA) 
ds NF-κB decoy ODN 5´-AGT TGA GGG GAC TTT CCC AGG C-3´ phosphorothioate 
biomers.net GmbH 
(Ulm, Germany) 
ds scr decoy ODN 5´-CCT TGT ACC ATT GTT AGC C-3´ phosphorothioate 
biomers.net GmbH 
(Ulm, Germany) 
EDC 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
Ethanol 96 % Merck KGaA (Darmstadt, Germany) 
Gelatin type A 175 Bloom Sigma-Aldrich GmbH (Taufkirchen, Germany) 
Glutaraldehyde 25 % aqueous solution  Sigma-Aldrich GmbH (Taufkirchen, Germany) 
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Reagent Description Supplier 
HCl 2 N VWR International GmbH (Ismaning, Germany) 
PBS Dulbecco’s phosphate buffered saline pH 7.4 (1x concentrate) 
PAA Laboratories GmbH 
(Linz, Austria) 
Sucrose  Suedzucker AG (Mannheim, Germany) 
Tween® 80 Polysorbat 80, Ph. Eur. Merck KGaA (Darmstadt, Germany) 
Fluorescent staining 
Reagent Description Supplier 
Alexa Fluor® 633 goat-
anti-mouse IgG1 (γ1) 
λem 647 nm 
Invitrogen GmbH 
(Karlsruhe, Germany) 
BSA bovine serum albumin, Cohn Fraction V 
Sigma-Aldrich GmbH 
(Taufkirchen, Germany) 
ds NF-κB decoy ODN488  
5´-AGT TGA GGG GAC TTT CCC AGG C-3´ 
5’ Alexa Fluor® 488 labeled, 
λem 519 nm, phosphorothioate 
biomers.net GmbH 
(Ulm, Germany) 
Hoechst 33342  trihydrochloride, trihydrate, λem 461 nm 
Invitrogen GmbH 
(Karlsruhe, Germany) 
Mouse-anti-rat CD163 
IgG1 
 
AbD Serotec GmbH 
(Duesseldorf, Germany) 
 
Permafluor aqueous mounting medium Beckmann Coulter GmbH (Krefeld, Germany) 
Triton® X-100  Sigma-Aldrich GmbH (Taufkirchen, Germany) 
Electrophoretic Mobility Shift Assay (EMSA) 
Solution Components* Concentration 
Buffer A 
Hepes pH 7.9 
KCl 
EDTA 
EGTA 
DTT# 
PMSF# 
10 mM 
10 mM 
0.1 mM 
0.1 mM 
1 mM 
0.5 mM 
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Solution Components* Concentration 
Buffer B 
Hepes pH 7.9 
NaCl 
EDTA 
EGTA 
Glycerol 
DTT# 
PMSF# 
20 mM 
400 mM 
1 mM 
0.5 mM 
25 % 
1 mM 
1 mM 
STE buffer pH 7.5 
Tris-HCl 
NaCl 
EDTA 
10 mM 
100 mM 
1 mM 
5x binding buffer pH 7.5 
Glycerol 
MgCl2 
EDTA 
NaCl 
Tris-HCl 
20 % 
5 mM 
2.5 mM 
250 mM 
50 mM 
Gel loading buffer 
pH 7.5 
Tris-HCl 
Bromphenolblue 
Glycerol 
250 mM 
0.2 % 
40 % 
Reaction buffer 
DTT 
5x binding buffer 
Gel loading buffer 
2.6 mM 
90 % 
10 % 
10x TBE pH 8.3 
Tris 
Boric acid 
EDTA 
0.89 M 
0.89 M 
0.02 M 
Non-denaturating 
polyacrylamid gel 
(4.5 %) 
10x TBE 
PAA solution (30 %) 
Glycerol 
TEMED 
APS 
5.3 % 
15.8 % 
2.6 % 
0.05 % 
0.08 % 
 
*All buffer salts were purchased from Sigma-Aldrich GmbH (Taufkirchen, Germany) 
#DTT and PMSF were added to the buffer stock solution (A and B) directly before use 
Preparation and surface modification of gelatin nanoparticles 
Gelatin nanoparticles were manufactured by the two step desolvation method 
and surface modified (cationized) with cholamine as described in chapter 1.2. 
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Oligonucleotide-loading of gelatin nanoparticles 
80.9 µL of an aqueous nanoparticle dispersion containing 1.7 mg surface 
modified gelatin nanoparticles was incubated with 120 µL of an aqueous 
oligonucleotide solution containing 6 nmol NF-κB decoy ODN (i.e., 5 % [w/w] drug 
loading) in PBS adjusted to a final volume of 1,200 µL for 2 h at 22 °C and 800 rpm 
under constant shaking (Thermomixer Comfort, Eppendorf AG, Hamburg, 
Germany). 
Freeze dried formulation of empty and oligonucleotide loaded gelatin nanoparticles 
40.5 µL and 34.8 µL of aqueous nanoparticle dispersions containing 0.85 mg and 
0.73 mg surface modified gelatin nanoparticles were incubated with 120 µL aqueous 
oligonucleotide solution containing 6 nmol NF-κB decoy ODN and 6 nmol scr decoy 
ODN respectively (i.e., 10 % [w/w] drug loading) in 1,030.2 µL and 1,053.7 µL 
highly purified water for 2 h at 22 °C and 800 rpm under constant shaking 
(Thermomixer Comfort, Eppendorf AG, Hamburg, Germany). For the formulation of 
freeze dried empty nanoparticles 0.73 mg surface modified gelatin nanoparticles 
were diluted in highly purified water to a volume of 1,053.7 µL. Afterwards 
169.8 µL and 146.3 µL respectively of a sucrose solution (10 % [w/v] dissolved in 
highly purified water) were added to a total volume of 1,200 µL. The amount of 
sucrose added accounted for an excipient to oligonucleotide ratio of 200 (cp. chapter 
2.3.1). Subsequent suspensions were transferred to 2R glass vials (Schott AG, Mainz, 
Germany) and dried in an EPSILON 2- 6D pilot scale freeze dryer from Martin 
Christ Freeze Dryers GmbH, Osterode, Germany with the below stated freeze drying 
cycle (Figure 3.4.1). Upon completion of this cycle the chamber was vented with 
nitrogen, samples were stoppered under slight vacuum, and the sealed vials were 
stored at 20 °C. Rehydration was conducted directly before use in 169.8 µL and 
146.3 µL respectively of highly purified water under adding a Tween® 80 solution 
(100 µg/µL) in a 1:1 ratio to the mass of gelatin nanoparticles leading to a 
concentration of 10 % sucrose [w/v], which is almost isoosmotic. Finally, samples 
were completed with a 10 % [w/v] sucrose solution to a total volume of 300 µL. Four 
samples were combined per animal study, in sum containing 24 nmol of the 
respective oligonucleotide in 1.2 mL. For liver distribution studies the described 
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procedure was conducted with identical amounts of fluorescent-labeled NF-κB decoy 
ODN488. 
 
 
 
 
 
 
 
 
 
Figure 3.4.1 Freeze drying cycles with shelf temperature (□) and chamber pressure (○) 
Preparation of NF-κB decoy oligonucleotide loaded liposomes 
Drug loaded liposomes were prepared by ethanol injection with the 
oligonucleotide already present in the water phase. The drug loading is driven by 
opposing electrostatic attractive forces as they are as well utilized for the drug 
loading process of gelatin nanoparticles. Thereby the positively charged lipid 
headgroups interact with the negatively charged phosphodiester backbone of the 
oligonucleotide. The chosen ODN lipid ratio is geared to the work of Ogushi who 
applied an NF-κB decoy oligonucleotide in a fatal liver failure murine model 
[Ogushi et al., 2003]. 28.74 µL lipid ethanol stock solution (1.7932 g DOTAP-Cl and 
1.6961 g DOPC in 10.0 g EtOH), were dropwise added into 1.5 mL ice cooled 
aqueous oligonucleotide solution containing 15 nmol NF-κB decoy ODN (i.e., 2 % 
[w/w] drug loading) under constant stirring. The mixture was than 10x passed 
through a 0.22 µm sterile filter. Caused be the extrusion process there is a certain 
sample loss, thus leading to a final volume around 1.2 mL containing 12 nmol/mL 
NF-κB decoy ODN applicable for animal studies, equivalent to the sample volume of 
gelatin nanoparticle formulations. For liver distribution studies fluorescent-labeled 
NF-κB decoy ODN488 was incorporated into liposomes in reduced concentration, 
according to biodistribution studies conducted with ODN loaded gelatin 
nanoparticles. 150 µL of ODN stock solution were diluted with PBS to a final 
volume of 1.5 mL, which was utilized for liposome preparation. 
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Characterization of liposomes and nanoparticles 
Size and zetapotential of the applied liposome and gelatin nanoparticle batches 
were determined by dynamic light scattering (DLS) using a Nanosizer ZS (Malvern 
Instruments, Worcestershire, UK). Zetapotential measurements were conducted 
under standardized ionic conditions in 10 mM NaCl at pH 7.0. 
In vivo biodistribution experiments 
Experiments were conducted in male Sprague-Dawley rats. 1 mL of liposomal 
and gelatin nanoparticle formulations either loaded with fluorescent-labeled NF-κB 
decoy ODN were directly injected into the portal vein. Prior to injection rats were 
anesthetized by i.p. injection of 0.005 mg/kg Fentanyl and 2.0 mg/kg Midazolam. 
Anesthesia was maintained over the whole experiment with 1.5 % Isofluran 
continuously applied using a vaporizer with Carbogen (5 % CO2 / 95 % O2) as carrier 
gas. To monitor blood pressure and control anesthesia the jugular artery was 
cannulated with a 16 gauge PE catheter and connected to a blood-pressure gauge. 
The abdomen was opened by midline-laparotomy and the portal triad was prepared. 
The body temperature was kept between 36.0 °C and 37.0 °C with a warming lamp. 
After 15 min rats were sacrificed and blood was rinsed out. Liver was resected, 
frozen with liquid nitrogen and stored at -80 °C. The distribution of NF-κB decoy 
ODN within the liver was determined via confocal laser scanning microscopy 
(CLSM). 
CLSM imaging 
Preparation of tissue samples from biodistribution studies was conducted as 
described in chapter 3.2.1. Compared to those studies Alexa Fluor® 488 labeling was 
used for the NF-κB decoy ODN. Thus secondary antibody staining of Kupffer cells 
had to be achieved with an Alexa Fluor® 633 labeled IgG1, whereas the staining 
protocol itself remained unaltered. In addition a nuclear staining was conducted 
following the protocol for the Kupffer cell staining as well explained in chapter 
3.2.1. CLSM imaging was performed with a Zeiss LSM 510 Meta confocal laser 
scanning microscope (Carl Zeiss Microscope Systems, Jena, Germany). 
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In vivo Hepatic Ischemia Reperfusion rat model 
Experiments were conducted in male Sprague-Dawley rats. Rats were 
anesthetized, the abdomen opened, and the portal triad prepared as described above. 
Arterial and portal blood flow to the left lateral and median lobe of the liver was 
interrupted by applying an atraumatic clip, resulting in a 70 % liver ischemia. After 
60 min of ischemia blood supply was restored by removal of the clip. 
15 min prior to ischemia 1.0 mL of the accordingly prepared NF-κB decoy ODN 
loaded, scr decoy ODN loaded, and empty gelatin nanoparticle suspension 
respectively was injected into the portal vein with a 1.0 mL syringe over a period of 
5 min. Control experiments were conducted with nanoparticle free solvent. 
Subsequent to collection of blood samples into heparinized tubes, animals were 
sacrificed after 120 minutes of reperfusion by bleeding. Liver was rinsed from blood 
by perfusing with PBS through the portal vein via a peristaltic pump at a flow of 
55 mL/min for 2 min. The median lobe was excised and the remaining lobes were 
perfused with 3 % formalin in PBS for protein fixation. All tissues were cut in 3 mm 
cubes, immediately snap frozen in liquid nitrogen and kept at -80 °C until further 
examination. After centrifugation of blood samples at 5000 rpm for 8 min obtained 
plasma was stored in aliquots at -80 °C. 
All animal studies were conducted thrice for each nanoparticle formulation. 
In vivo hepatic LPS (sepsis) rat model 
Experiments were conducted in male Sprague-Dawley rats. Rats were 
anesthetized, the abdomen opened, and the portal triad prepared as described above. 
1.0 mL of the accordingly prepared NF-κB decoy ODN loaded, scr decoy ODN 
loaded, and empty gelatin nanoparticle suspension as well as the liposomal 
formulation was respectively injected into the portal vein with a 1.0 mL syringe over 
a period of 5 min. Control experiments were conducted with nanoparticle / liposome 
free solvent. 15 min thereafter 10 µg LPS (c = 50 µg/mL in PBS, E. coli serotype 
055:B05, Sigma-Aldrich GmbH, Taufkirchen, Germany) were injected into the 
portal vein, leading to sublethal sepsis. After waiting for another 30 min experiments 
were terminated and blood and tissue samples were collected as described above. 
All animal studies were conducted thrice for both nanoparticle and liposomal 
formulations. 
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Electrophoretic Mobility Shift Assay (EMSA) 
Extraction of nuclear protein 60 mg of liver tissue were homogenized in 
0.6 mL of ice cooled Buffer A till a homogenous suspension was obtained. Samples 
were centrifuged at 1,000 rpm at 4 °C for 10 min. The pellet was resuspended in 
300 µL Buffer A, followed by addition of 18 µL non ionic detergent (Nonidet) P-40 
(USB Corp., Cleveland, Ohio, USA) and careful mixing. After 10 min of incubation 
under ice cooling, samples were centrifuged for 1 min at 14,000 rpm and 4 °C and 
the pellet was resuspended in 40 µL Buffer B. Finally samples were incubated by 
shaking for 30 min at 4 °C. After centrifugation (14,000 rpm, 10 min, 4 °C) 
undiluted supernatants were transferred to EMSA, and a dilution of 1:20 was used 
for determination of protein concentrations. 
Measurement of protein concentration with Bradford-assay Protein 
concentration in isolated nuclear fractions was determined as described by Bradford 
[Bradford, 1976]. 
Radioactive labeling of consensus oligonucleotides Double stranded 
oligonucleotides, containing the NF-κB consensus sequence 
(5’-AGT TGA GGG GAC TTT CCC AGG C-3’, Promega GmbH, Mannheim, 
Germany), were labeled with [γ32P] adenosine triphosphate (3,000 Ci/mmol) by 
using the T4 polynucleotide kinase (PNK) (USB Corp., Cleveland, Ohio, USA), 
which catalyzes the transfer of the terminal phosphate of ATP to the 5’-hydroxyl 
terminus of the ODNs. Oligonucleotides were incubated with PNK for 10 min at 
37 °C. The reaction was stopped by adding a 0.5 M EDTA solution. Subsequent 
radioactive labeled ODN was separated from unlabeled ODN by using NucTrap 
probe purification columns (Stratagene Inc., La Jolla, California, USA), whereas 
radiolabeled DNA was eluted from the column with 70 µL of STE buffer and frozen 
at -20 °C until use for EMSA. 
Binding reaction and electrophoretic separation Equal amounts of nuclear 
protein (approximately 30 µg) were incubated in a total volume of 14 µL containing 
2 µg poly(dIdC) and 3 µL reaction buffer for 10 min at room temperature. 
Afterwards 1 µL of the labeled oligonucleotide solution (approximately 
300,000 cpm) was added and incubated with nuclear protein for 30 min at room 
temperature. The resulting nucleoprotein-oligonucleotide complexes were then 
separated by gel electrophoresis (Mini-Protean 3, Bio-Rad Laboratories GmbH, 
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Munich, Germany) at 110 V for 60 min on non-denaturating polyacrylamide gels 
(cp. table “EMSA”; Rotiphorese™ Gel 30, Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany). Bands were detected by exposure of the gels to Cyclone Storage 
Phosphor Screens (Canberra-Packard GmbH, Dreieich, Germany) for about 24 h 
(time of exposure depended on radioactivity of the labeled oligonucleotides), 
followed by analysis with a phosphorimager station (Cyclone Storage Phosphor 
System, Canberra-Packard GmbH, Dreieich, Germany). 
 
In vivo studies and electrophoretic mobility shift assays were conducted together 
with Florian Hoffmann at the department of pharmaceutical biology of the Ludwig-
Maximilians-University Munich, Germany. So, the present data are a result from the 
cooperation between the chairs of Pharmaceutical Technology and Pharmaceutical 
Biology of the Ludwig-Maximilians-University Munich described at the beginning 
of this chapter and will be discussed under further aspects in the thesis of Florian 
Hoffmann [Hoffmann, 2007]. 
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3.4.2 Results and discussion 
Characterization of gelatin nanoparticles and liposomes 
All applied nanoparticle and liposome formulations had similar sizes between 
230 and 280 nm. Compared to gelatin nanoparticles liposomes exhibit a higher 
polydispersity with a PDI above 0.200 typically seen for liposomes. During 
manufacturing of liposomes large fluidic structures are broken down; this degrading 
kind of manufacturing does not provide ideally i.e., homogenously distributed sizes, 
which is expressed in the depicted polydispersity. In addition due to the positively 
charged headgroups of the applied lipids, DOTAP/DOPC liposomes are 
characterized by a very high zetapotential around +45.0 mV (determined in 10 mM 
NaCl at pH 7.0). Thus the zetapotential after oligonucleotide-loading remains higher 
than for oligonucleotide loaded gelatin nanoparticles (cp. chapter 3.3.3). 
Table 3.4.1 Size, polydispersity, and surface charge of gelatin nanoparticle and liposome 
formulations applied for biodistribution and in vivo ischemia reperfusion and LPS models 
 
 
Gelatin 
nanoparticles (empty) 
(G-NP 06-028 pos) 
DOTAP/DOPC 
liposomes loaded with 
NF-κB decoy ODN488 
(Lip + O488) 
DOTAP/DOPC 
liposomes loaded with 
NF-κB decoy ODN 
(Lip + O) 
size [nm] 261.0 228.5 279.0 
PDI 0.069 0.244 0.269 
ZP [mV] +16.6 +11.3 +12.6 
 
Hepatic Ischemia Reperfusion model in rat 
Even though liver injury caused by hepatic I/R injury takes place 6-48 h after 
reperfusion [Teoh et al., 2003a] the described duration of the animal study with 1 h 
of ischemia and 2 h of reperfusion is adequate as IκB phosphorylation, initial step of 
the NF-κB activation, already starts after 30 min. After 1 h NF-κB activation reaches 
its maximum and both IκB phosphorylation and NF-κB activation approximate basal 
amounts after 3 h of reperfusion [Zwacka et al., 1998]. Thus targeting the NF-κB 
activation during the stated experimental period is feasible. In addition, considering 
the removed abdominal wall, keeping the test animal over a period of 6-48 h alive is 
even under anesthesia hardly possible. Partial ischemia was chosen to facilitate the 
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survival of the test animal until the end of the 2 h reperfusion period. Technical 
reasons led to adjusting the volume of nanoparticle and liposome formulations 
prepared for the animal studies to 1.2 mL. To guarantee a reproducible injection of 
1 mL i.e., a reproducible amount of NF-κB decoy oligonucleotide applied per 
attempt is only possible if not the whole formulation has to be injected and a certain 
excess volume remains within the infusion system. 
The first experiments were conducted with 5 nmol NF-κB decoy oligonucleotide 
applied per animal study. The amount of 5 nmol represents the maximum pay load of 
5 % [w/w] on gelatin nanoparticles achievable under PBS buffered conditions and 
was proven to be complete via UV-spectroscopy. By further increasing the amount of 
the NF-κB decoy ODN for a drug loading above 5 % [w/w] aggregation of the 
nanoparticles occurred. Similar findings were reported by Goetting who investigated 
the effect of a 16mer PTO oligonucleotide-loading on the stability of polystyrene 
nanoparticles investigated as model delivery system for antisense drugs [Goetting et 
al., 1999]. Presumably this is caused by missing electrostatic repulsion forces 
between nanoparticles, which are compensated by an elevated drug loading process 
and are in general necessary to stabilize nanoparticle suspensions [Mueller, 1996]. 
The, compared to empty surface-modified nanoparticles, reduced zetapotential 
already referred for 5 % [w/w] oligonucleotide loaded gelatin nanoparticles in 
chapter 3.3.3 demonstrates the influence of the loading process to the nanoparticles’ 
surface charge and strengthens this assumption. Furthermore, the ionic strength of 
the PBS buffered environment leads to diminished surface charges and therefore 
reduced zetapotential values of the nanoparticles. High concentrations of the 
nanoparticle suspensions may additionally foster interparticulate bridging of 
oligonucleotide molecules and are thus a possible explanation for the observed 
nanoparticle aggregation as well. In addition the total suspension volume injected per 
rat could not be further increased to avoid undesired side effects from a strongly 
expanded plasma volume. Therefore 5 nmol NF-κB decoy oligonucleotide were the 
maximum amount applicable under the chosen conditions. 
The presence of NF-κB within livers obtained from animal studies was followed 
by an electrophoretic mobility shift assay (EMSA). During this assay NF-κB 
extracted from liver tissue is visualized via coupling with a radioactive labeled 
oligonucleotide bearing the NF-κB consensus sequence. Built 
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Decoy ODN 
G-NP 5 nmol
I/R 1h/2h 
NF-κB 
I/R control 
protein-oligonucleotide complexes are separated from unbound oligonucleotide 
during gel electrophoresis and can be quantified by their radioactive intensity within 
the gel. Thus, if NF-κB amounts are lowered a reduced number of protein-
oligonucleotide complexes is formed, which results in fewer radiation intensities 
detectable. This in turn is expected for the assumed in vivo interaction between 
nanoparticulate delivered NF-κB decoy oligonucleotides and NF-κB. Figure 3.4.2 
displays the bands of protein-oligonucleotide complexes derived from hepatic I/R 
animal studies conducted with and without NF-κB decoy ODN treatment. As the 
intensities of all bands are almost identical an inhibitory effect of the NF-κB decoy 
oligonucleotide can not be stated. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.2 Hepatic NF-κB activation caused by 1 h of ischemia and 2 h of reperfusion of 
animals treated with 5 nmol NF-κB decoy oligonucleotide and of untreated animals; one band 
represents one animal study 
 
These results were verified several times and also changing the experimental 
setup towards a reduced reperfusion time of 1 h did not reveal any detectable NF-κB 
inhibition. As the amount of NF-κB decoy ODN applicable per animal study could 
not be increased for the above explained reasons, increasing the concentration of the 
stable 5 % [w/w] oligonucleotide loaded gelatin nanoparticle formulations became 
crucial. Addressing this need Anchordoquy described a freeze drying based 
procedure for the production of concentrated suspensions of polyethylenimine (PEI) 
DNA complexes possessing isoosmotic amounts of freeze drying excipients 
[Anchordoquy et al., 2005]. Based on their work an analog procedure could be 
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developed, which allows the preparation of stable 20 nmol NF-κB decoy 
oligonucleotide containing drug loaded gelatin nanoparticle suspensions (chapter 
2.3.1). The drug loading could thereby be increased to 10 % [w/w] so that the 
fourfold amount of oligonucleotide comes along with 2x higher amounts of gelatin 
nanoparticles. Exposure of these newly developed samples to blood plasma with its 
elevated ionic strength led to the same aggregation tendencies already reported for 
loading attempts with increased amounts of oligonucleotide and nanoparticles. 
According to Goetting who worked with poloxamer 388 to overcome this problem 
[Goetting et al., 1999], concentrated ODN-loaded nanoparticles were coated with 
Tween® 80 in a 1:1 [w/w] Tween® 80:nanoparticle ratio as described in chapter 
2.3.1. Empty nanoparticle formulations as well as NF-κB decoy or scr decoy 
oligonucleotide-loaded nanoparticle formulations were all treated the same way. 
To determine the influence of the nanoparticle formulations on the progression 
of liver injury after ischemia and reperfusion, transaminases were determined in rat 
plasma samples taken after terminating the animal studies. The plasma concentration 
of transaminases is the standard clinical parameter that is utilized for evaluating the 
current liver status as their release is enhanced from damaged hepatocytes, whereas 
alaninaminotransferase (ALT) and aspartataminotransferase (AST) are the routinely 
monitored enzymes. Their concentrations after I/R animal studies conducted with 
and without decoy ODN loaded and empty nanoparticles are summarized in Figure 
3.4.3.  
 
 
 
 
 
 
 
 
 
Figure 3.4.3 Transaminases determined in rat plasma after 1 h of ischemia and 2 h of reperfusion 
of animals treated with 20 nmol NF-κB decoy oligonucleotide loaded gelatin nanoparticles (D-NP) 
and empty nanoparticles (eNP) and of untreated animals (Control); each animal study was performed 
three times represented by the error bars 
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With respect to the great margins of deviation typically seen for animal studies 
nearly all displayed transaminase concentrations account for almost identical values. 
Despite the high concentration of nanoparticle suspensions injected there was no 
further statistical significant increase in transaminases concentration detectable, 
which underlines the exceptional physiological tolerability of gelatin nanoparticles 
already reported by Zwiorek during comparative in vitro studies with PEI polyplexes 
and liposomes [Zwiorek, 2006]. In addition, data indirectly show the successful 
stabilization of the nanoparticles by Tween® 80. 
In the following empty nanoparticles as well as scr decoy ODN and NF-κB 
decoy ODN loaded gelatin nanoparticles were investigated for their NF-κB inhibiting 
properties in hepatic I/R animal studies. Reference experiments were identically 
performed except the injection of any nanoparticle formulation. The resulting EMSA 
electrophoresis gel shows a clear attenuation of the NF-κB band for all three animal 
studies performed with NF-κB decoy ODN loaded gelatin nanoparticles (Figure 
3.4.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.4 Hepatic NF-κB activation caused by 1 h of ischemia and 2 h of reperfusion of 
animals treated with 20 nmol NF-κB decoy oligonucleotide and 20 nmol scr decoy oligonucleotide 
loaded gelatin nanoparticles as well as empty nanoparticles and of untreated animals; one band 
represents one animal study 
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Related to the former experiments conducted with 5 nmol NF-κB decoy ODN a 
concentration dependent mechanism can be assumed, which illustrates the 
quantitative principle of action of a decoy oligonucleotide. At the same time scr 
decoy ODN loaded and empty gelatin nanoparticles only slighty alter the appearance 
of the detected NF-κB bands. The exhibited respective radiation intensities are rather 
comparable to those of the reference (I/R control) experiments than to the 
experiments applying the NF-κB decoy ODN. The findings additionally prove the 
selectivity of the NF-κB decoy oligonucleotide for NF-κB especially in comparison 
to the chosen scr decoy oligonucleotide. 
However, phagocytotic uptake through Kupffer cells stands for their activation 
with its according signaling pathways [Aderem et al., 1999]. In addition to the 
outcome of I/R injury and the inhibition of NF-κB, this is a third factor influencing 
signal transduction and expression of involved proteins. Thus, investigations on the 
molecular stage might reveal differences for liver tissue derived from animals treated 
with empty gelatin nanoparticles and from control animals being only exposed to 
ischemia and reperfusion. These parameters and the outcome of the NF-κB inhibition 
within Kupffer cells are further discussed in the work of Florian Hoffmann 
[Hoffmann, 2007]. 
Lipopolysaccharide (LPS) induced hepatic NF-κB response in rat 
Subsequent to intraportal injection LPS induces NF-κB activation in liver. This 
activation can be as well used for evaluating the NF-κB inhibitory potential of 
NF-κB oligonucleotide loaded gelatin nanoparticles. Compared to the hepatic I/R 
model the LPS setup is less elaborative and thus provides a faster approach to gain 
insight into mechanisms attributed to NF-κB blockade in Kupffer cells. So, LPS was 
utilized in a second experimental setup to stimulate NF-κB activation. Interestingly 
the resulting strong activation of NF-κB could be as well completely inhibited by the 
application of 20 nmol nanoparticulate-bound NF-κB decoy oligonucleotide. In 
addition neither scr decoy ODN loaded nor empty gelatin nanoparticles had any 
diminishing influence on the detected NF-κB bands. Figure 3.4.5 exemplarily 
displays the described outcome of the shift assays for one series of animal studies. 
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Figure 3.4.5 Hepatic NF-κB activation after stimulation with 10 µg LPS of animals treated with 
20 nmol NF-κB decoy oligonucleotide and 20 nmol scr decoy oligonucleotide loaded gelatin 
nanoparticles as well as empty nanoparticles and of untreated animals; one band represents one animal 
study 
 
Again, downstream processes related to NF-κB activation and NF-κB inhibition 
respectively are investigated and discussed by Florian Hoffmann [Hoffmann, 2007]. 
Liposomal vs. gelatin nanoparticulate delivery of the NF-κB decoy oligonucleotide to 
Kupffer cells 
The so far presented results demonstrate the ability of gelatin nanoparticles to 
selectively address Kupffer cells and at the same time to deliver an oligonucleotide 
drug substance to its designated target where it finally could deploy its function. In a 
further step emphasis was laid on ranking these results. As the liposomal delivery of 
NF-κB decoy oligonucleotides to liver was just recently described in literature 
[Ogushi et al., 2003; Higuchi et al., 2006; Higuchi et al., 2007] liposomes were 
chosen for comparative studies. Therefore liposomal formulations loaded with the 
known NF-κB decoy oligonucleotide were prepared and applied in the established in 
vivo biodistribution and hepatic LPS animal test systems. At first biodistribution 
studies with liposomes as well as gelatin nanoparticles each loaded with fluorescent-
labeled NF-κB decoy ODN488 were conducted, whereas liver distribution after 
intraportal injection was focused on. The resulting distribution pattern of 
nanoparticulate delivered NF-κB decoy ODN488 corresponds to the biodistribution 
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data obtained from fluorescent-labeled gelatin nanoparticles (chapter 3.2.2). CLSM 
pictures exhibit a yellow combination color expressing the colocalization of 
fluorescent-labeled Kupffer cells (green) and NF-κB decoy ODN488 (red) (Figure 
3.4.6 B, C, and E). No oligonucleotide derived fluorescence could be detected in 
areas without the green fluorescence from Kupffer cell staining. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.6 CLSM pictures of liver tissue taken from liver resected 15 min after injection of 
gelatin nanoparticulate (G-NP 06-028 pos) loaded ds NF-κB decoy ODN488 into the portal vein; 
pictures show different fluorescent stained structures (A) nuclei (blue), (B) Kupffer cells (green), (C) 
decoy ODN (red), and the overlay of (D) nuclei and decoy ODN, (E) Kupffer cells and decoy ODN, 
and (F) nuclei, Kupffer cells and decoy ODN 
 
Looking at the according CLSM pictures from liposomal ODN delivery a 
comparable distribution pattern for the NF-κB decoy ODN488 is revealed on the first 
view (Figure 3.4.7). Again the overlay pictures E and F show the yellow combination 
color resulting from colocalization of fluorescent-labeled Kupffer cells (green) and 
NF-κB decoy ODN488 (red). In addition nuclear and ODN colocalization expressed 
in the pink combination color of picture D can be as well followed in picture F. It is 
indeed mainly superimposed by the described yellow combination color attributed to 
the same cells, but there are a couple of pink appearing nuclei (white arrows), which 
in contrast to nanoparticulate applied NF-κB decoy ODN488 clearly indicate a 
distribution beyond Kupffer cells. These findings of a preferable uptake into Kupffer 
cells accompanied by distinct extra Kupffer cell distribution are confirmed by the 
data of Higuchi. Despite a targeting ligand on the liposomal surface addressing the 
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fucose receptor uniquely expressed on Kupffer cells he describes liposomal uptake 
mainly into non parenchymal cells i.e., Kupffer cells but at the same time to certain 
extent into parenchymal cells i.e., hepatocytes [Higuchi et al., 2007]. According to 
Romero the uptake of liposomes into hepatocytes can be explained by the fluidic 
structure that enables their extrusion through the endothelial fenestrae of liver 
sinusoids despite exhibiting a bigger diameter than those [Romero et al., 1999]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.7  CLSM pictures of liver tissue taken from liver resected 15 min after injection of 
liposomal (Lip + O488) loaded ds NF-κB decoy ODN488 into the portal vein; pictures show different 
fluorescent stained structures (A) nuclei (blue), (B) Kupffer cells (green), (C) decoy ODN (red), and 
the overlay of (D) nuclei and decoy ODN, (E) Kupffer cells and decoy ODN, and (F) nuclei, Kupffer 
cells and decoy ODN 
 
Thus due to the colloidal nature of the applied drug delivery systems expected 
similarities in the distribution pattern could be observed, but a compared to 
liposomes higher Kupffer cell selectivity of gelatin nanoparticles potentially based 
on their solid nature could be highlighted.  
As this study was conducted with the newly developed freeze dried nanoparticle 
formulation some additional conclusions can be drawn from these data. The 
increased nanoparticle (2x) and decoy ODN (4x) amount and the stabilizing 
Tween® 80 coating did not negatively affect the biodistribution. A perfect 
colocalization of Kupffer cells and NF-κB decoy oligonucleotide could still be 
observed. To reduce nanoparticle load per test animal by increasing the drug loading 
up to 10 % [w/w] the freeze dried formulation was developed under reduced ionic 
strength in sucrose solution. Interestingly the transfer into the in vivo situation with 
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its increased ionic strength did not affect the drug loading in way that a diffusive 
ODN distribution over the whole organ could be seen which may have been caused 
by partial unloading of the nanoparticles as it is known for siRNA from former in 
vitro experiments conducted in PBS [Zillies et al., 2004]. 
In the following studies with 10 nmol NF-κB decoy oligonucleotide bound to 
liposomes were accomplished in the LPS rat model. When the liposome experiments 
were conducted the freeze dried gelatin nanoparticle formulation with its higher 
amounts of decoy ODN was not yet available. Thus the 10 nmol drug loading was 
chosen to investigate a compared to gelatin nanoparticles twofold ODN amount per 
animal study, which finally led to a partial inhibition of NF-κB (Figure 3.4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.8 Hepatic NF-κB activation after stimulation with 10 µg LPS of animals treated with 
10 nmol NF-κB decoy oligonucleotide loaded liposomes and of untreated animals; one band 
represents one animal study 
 
After completing experiments with the freeze dried nanoparticle formulation, 
samples from the different animal studies were combined in one EMSA to oppose 
results (Figure 2.3.23). The results substantiate the concentration dependent 
mechanism dicussed above. After the application of 10 nmol liposomal delivered 
NF-κB decoy ODN in two of three cases compared to LPS control animals decreased 
radiation intensity can be observed (Figure 2.3.23). 
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Figure 3.4.9 Hepatic NF-κB activation after stimulation with 10 µg LPS of animals treated with 
10 nmol NF-κB decoy oligonucleotide loaded liposomes and 20 nmol NF-κB decoy oligonucleotide 
loaded gelatin nanoparticles and of untreated animals; one band represents one animal study 
 
At the same time the difference to the – related to control animals – almost 
erased bands after application of 20 nmol gelatin nanoparticulate-bound NF-κB 
becomes obvious. However, most important in this context is the unspecific 
distribution of liposomal delivered decoy ODN beyond Kupffer cells, which restricts 
the correlation between the inhibition of NF-κB in Kupffer cells and the outcomes to 
be described in relation to this inhibition. 
3.4.3 Summary 
The hepatic NF-κB activation in rats either caused by hepatic ischemia and 
reperfusion or by LPS stimulation could be nearly completely inhibited with an NF-
κB decoy oligonucleotide selectively delivered to Kupffer cells by gelatin 
nanoparticles. Scrambled decoy oligonucleotides and empty nanoparticles did not 
interfere with the mechanisms behind and left the NF-κB activation unaffected. 
Based on the decoy mechanism of action a quantitative capture of all activated NF-
κB protein molecules is a prerequisite for the complete blockade of NF-κB. This 
concentration dependent relation could be verified by administering different 
amounts of the decoy oligonucleotide. As samples from liver tissue were transferred 
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to EMSA in total and not extracted for Kupffer cells prior to analysis the 
demonstrated NF-κB activation may possibly stated to be limited to Kupffer cells, 
which could explain the complete disappearing of NF-κB bands from electrophoresis 
gels. Furthermore transaminases data from test animals revealed hepatic I/R injury to 
be not pronounced by the application of gelatin nanoparticles. To further assess the 
obtained results comparative data were gained from studies with liposomal delivered 
NF-κB decoy oligonucleotide. These data confirmed the concentration dependent 
NF-κB inhibition and demonstrated gelatin nanoparticles to be superior compared to 
liposomes for a selective Kupffer cell targeted drug delivery. 
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3.5 Concluding Remarks 
In the beginning of the cooperate work of the chairs pharmaceutical biology and 
pharmaceutical technology of the Ludwig-Maximilians-University Munich there was 
an animal model combined with a drug targeting approach aimed at that enables the 
interruption of the inflammatory cascade during hepatic I/R injury on the stage of 
NF-κB by delivery of a gelatin nanoparticulate-bound NF-κB decoy oligonucleotide. 
Basic idea behind this project was to investigate the signaling pathways leading to 
hepatic ischemia reperfusion injury. 
At this point of time the hepatic ischemia reperfusion rat model is established 
and the proposed selective Kupffer cell delivery of the NF-κB decoy oligonucleotide, 
based on a gelatin nanoparticle drug delivery system, was proven. The adoption of 
2D-PAGE for the analysis of plasma protein adsorption patterns on gelatin 
nanoparticles could contribute to the explanation of the observed in vivo 
biodistribution data. Finally a successful inhibition of NF-κB followed from the 
administration of NF-κB decoy oligonucleotide loaded gelatin nanoparticles prior to 
ischemia and reperfusion could be demonstrated. Regarding the gelatin nanoparticles 
applied in the hepatic ischemia reperfusion rat model for NF-κB decoy 
oligonucleotide delivery modified plasma protein adsorption may occur due to the 
Tween® 80 stabilization of the nanoparticles. As the 2D-PAGE technique was no 
longer available after the completion of the thesis of Torsten Göppert this issue could 
not be investigated so far. 
The impact of the NF-κB blockade on the downstream processes of the 
inflammatory cascade is now particularly interesting and will be addressed in future 
studies. 
During the preparation of NF-κB decoy ODN loaded nanoparticles a convenient 
freeze dried formulation could be developed, which is now available and can be 
easily applied in the future of this cooperation project. 
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FINAL CONCLUSION 
The present work followed a course of analytical description, formulation 
development, and practical application of (NF-κB decoy oligonucleotide-loaded) 
gelatin nanoparticles. The introduction of asymmetrical flow field-flow fractionation 
(AF4) in the analysis of colloidal drug carrier systems was exemplarily described for 
gelatin nanoparticles (CHAPTER I), stable freeze-dried formulations of empty and 
oligonucleotide loaded gelatin nanoparticles were successfully developed 
(CHAPTER II), and gelatin nanoparticles were proven as effective tool for the 
targeted delivery of an NF-κB decoy oligonucleotide to Kupffer cells within a 
hepatic ischemia reperfusion rat model (CHAPTER III). 
Gelatin bulk material is characterized by inherent heterogeneity of its molecular 
weight distribution. Selective fractionation yet enables the production of 
homogenously size-distributed gelatin nanoparticles, at which asymmetrical flow 
field-flow fractionation (AF4) analysis revealed a mean molecular weight of the 
favorable gelatin fraction of ~2,000 kDa (CHAPTER I). This is about one order of 
magnitude higher than it was determined for the unfractionated gelatin. This two-step 
desolvation procedure could successfully be simplified towards a one-step 
desolvation by employing customized gelatin batches. This is remarkable as the 
mean molecular weight of these batches could be determined ranging in the middle 
between regularly applied gelatin bulk material and the above mentioned high 
molecular weight fraction obtained during two-step desolvation. In addition the 
specification of the customized batches stated a reduced portion of low molecular 
weight gelatin < 65 kDa below 20 % [w/w]. Thus, the restrictions that have to be 
made for gelatin bulk material in terms of successful one-step desolvation include a 
mean molecular weight around 500 kDa and a concurrently reduced portion of low 
molecular weight fractions. The necessity of reducing the peptide amount below 
20 % [w/w] could be proven to be even more decisive than the expanded presence of 
high molecular weight fractions. Subsequently, the resolving power of AF4 for 
particulate matter was exemplified. The separation of suspended gelatin 
nanoparticles from dissolved single- and double-stranded oligonucleotides was 
demonstrated and the drug loading of a single-stranded oligonucleotide onto the 
nanoparticles’ surface could be quantified via the AUCs of the respective UV 
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detection signals. A precedent sample preparation was thereby not necessary. The 
drug loading of a double-stranded oligonucleotide in turn highlighted the methodical 
limit of this analytical approach. The concept of adverse charged reaction partners 
enabling drug loading via electrostatic attraction requires in case of double-stranded 
oligonucleotides clearly stronger charges than for single-stranded oligonucleotides. 
With respect to reproducible AF4 sample runs these charges are in general 
compensated by increasing the ionic background within the running buffer. This 
avoids on the one hand adsorptive tendencies within capillaries and the separation 
channel but causes on the other hand the release of oligonucleotide from the surface 
of gelatin nanoparticles due to the weakened electrostatic attraction between the 
double-stranded oligonucleotide and the nanoparticles. Independent from these 
considerations the quantification of covalently bound PEG on gelatin nanoparticles 
could be completed. In an analogues attempt to the single-stranded drug loading the 
amount of unbound PEG was calculated from its RI detection signals obtained before 
and after PEGylation. RI detection was imperative due to the poor spectroscopic 
properties of PEG. 
The need for a gelatin nanoparticle formulation that is easy to ship, to store, and 
to handle especially with regard to future application in clinical studies was 
addressed during the development of a freeze-dried formulation of gelatin 
nanoparticles (CHAPTER II). Nanoparticles were at first successfully freeze-dried 
with various amounts of sucrose. Particle size and size distribution were preserved, 
pertaining residual moisture contents ranged below 1 % and the respective glass 
transition temperatures matched expectations. For convenient application freeze-
dried samples of already drug-loaded gelatin nanoparticles are required. Thus, 
freeze-drying properties of loaded gelatin nanoparticles were explored for double-
stranded DNA and siRNA oligonucleotides. Basically, data from empty 
nanoparticles could be verified and were supplemented with important results from 
experiments investigating reduced rehydration volumes. In order to obtain high 
concentrated suspensions of oligonucleotide-loaded gelatin nanoparticles, samples 
were rehydrated upon freeze-drying with reduced volumes, whereas sample integrity 
was not affected. Concomitantly, excipient amounts were adjusted to guarantee 
isotonicity of the rehydrated samples. By substituting sucrose for dextran 3000, low 
excipient masses could be circumvented while the osmotic activity was maintained. 
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Interestingly, dextran 3000 was able to sufficiently stabilize loaded gelatin 
nanoparticles at its own. Samples combined of four accordingly concentrated NF-κB 
decoy oligonucleotide-loaded gelatin nanoparticle preparations were transferred to 
the hepatic ischemia reperfusion rat model, established during the cooperation work 
described in chapter 3.4, where a selective NF-κB inhibition within Kupffer cells 
could be accomplished: Thus, the concept of concentrating ODN-loaded gelatin 
nanoparticles by freeze-drying was successfully proving. 
In the last part of this chapter the storage stability of empty and oligonucleotide-
loaded gelatin nanoparticles was investigated. Formulations containing sucrose, 
trehalose, mannitol, and mannitol-sucrose in the ratio 4:1 were prepared and held 
under four different storage conditions. The results revealed good stabilizing 
properties of sucrose and trehalose, whereas trehalose appears superior at increased 
storage temperatures due to its higher Tg. If the residual moisture content did not 
exceed a threshold of 3 %, particle size and size distribution were preserved. 
Complete sample loss was observed during storage at elevated relative humidity. 
Despite its crystalline nature even mannitol was able to stabilize empty and 
oligonucleotide-loaded gelatin nanoparticles at its own, whereas compared to sucrose 
and trehalose higher excipient amounts were required. The resistance of mannitol 
against water sorption was expressed in sufficient stabilizing of samples containing 
the highest amount of mannitol during open storage at 30 % RH. Mannitol-sucrose 
formulations in turn exhibited poor stabilizing properties. This could be related to 
amorphous mannitol resulting from freeze-drying that underwent conversion to its 
crystalline state during storage, which finally corrupted the sample quality. Finally in 
vivo data from stored oligonucleotide-loaded gelatin nanoparticles demonstrated that 
maintained sample quality at the same time provides maintained biological function 
of the bound oligonucleotide. 
Based on the rapid clearance of colloidal drug carrier systems by cells of the 
MPS, an exclusive targeting of gelatin nanoparticles within liver to Kupffer cells was 
proposed (CHAPTER III). Loaded with an NF-κB decoy oligonucleotide, gelatin 
nanoparticle delivery should enable the selective inhibition of NF-κB in Kupffer 
cells. NF-κB inhibition should in turn contribute to the elucidation of inflammation 
processes taking place after NF-κB activation upon hepatic ischemia reperfusion. In 
cooperation with the chair of Pharmaceutical Biology of the Ludwig-Maximilians-
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University Munich a rat model of warm hepatic ischemia reperfusion was 
established. Before the NF-κB inhibition could be therein evaluated, the selectivity of 
the Kupffer cell uptake was scrutinized. Independent from the route of 
administration, nanoparticles were found to be exclusively distributed within liver to 
Kupffer cells. Intraportal application thereby increased the portion of nanoparticles 
detectable within liver compared to other organs. Additionally investigated 
liposomes were in contrast to a small extent also detectable beyond Kupffer cells in 
hepatocytes. The biodistribution of gelatin nanoparticles was further investigated 
with respect to their plasma protein adsorption patterns and compared to solid lipid 
nanoparticles (SLN). After incubating empty, surface-modified, and oligonucleotide-
loaded gelatin nanoparticles with human or rat plasma, adsorbed proteins were 
qualified and quantified by 2D-PAGE analysis. Different from SLN, mainly 
adsorbing apolipoproteins, classical opsonins were adsorbed in a comparable manner 
on all gelatin nanoparticle formulations indicating a rapid clearance from circulation. 
Findings from 2D-PAGE were confirmed in vivo with short plasma half lives below 
15 min and an accumulation of gelatin nanoparticles in the organs of the MPS. SLN 
in turn showed longer circulation times in addition to unspecific organ distribution.  
After proving the selective Kupffer cell uptake, NF-κB decoy oligonucleotide-
loaded gelatin nanoparticles were applied in the hepatic ischemia reperfusion rat 
model. The amount of the delivered oligonucleotide was thereby determined to be 
decisive for a successful NF-κB inhibition. Only after applying the concentrated 
samples obtained from formulation development by freeze-drying, (complete) 
inhibition of NF-κB was achieved, suggesting a concentration dependent mechanism. 
NF-κB decoy oligonucleotide released from liposomes showed as well certain NF-
κB inhibition. But, with respect to their distribution beyond Kupffer cells the direct 
correlation between NF-κB inhibition within Kupffer cells and monitored changes of 
the downstream processes will be limited. After establishing the in vivo model and 
the targeted delivery of the NF-κB decoy oligonucleotide to Kupffer cells via gelatin 
nanoparticles the outcome of the NF-κB inhibition within Kupffer cells can now be 
addressed during future studies. 
In sum the technological basis of gelatin nanoparticles was further broadened. 
Besides the advancement in the implementation of AF4, the description of a freeze-
dried gelatin nanoparticle formulation provides convenient handling and application 
Final Conclusion 
229 
in future. And, the development of gelatin nanoparticles for selective oligonucleotide 
delivery to Kupffer cells offers a tool to further investigate Kupffer cell related signal 
transduction within liver, as well beyond hepatic ischemia reperfusion injury. 
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